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What is screening?
Screening refers to the systematic testing in asymptomatic individuals to identify disease or 
risk factors for disease. This enables the possibility to act earlier, e.g. by starting treatment of 
the disease earlier. Screening is especially valuable for diseases like cancer, where prognosis 
is better when treated in earlier stages.
In the Netherlands, organized screening programs exist for early detection of cervical 
cancer, breast cancer, and colorectal cancer. Target populations are invited systematically, 
and follow-up of those with a positive screening test is ensured. The quality of each step in 
the screening process is measured, reported, and evaluated. As opposed to such organized 
screening, opportunistic screening is delivered on an ad hoc basis, where uptake depends 
on requests from individuals or recommendations from health care providers. Due to lack of 
organization, opportunistic screening is at greater risk for overuse and underuse of screen-
ing resources.1
Screening for disease aims to identify individuals that will be diagnosed with that disease 
within the (near) future, and for whom earlier detection and treatment is expected to reduce 
morbidity and mortality from that disease. However, even if early detection and treatment is 
expected to decrease the burden of a specific disease, it is not necessarily suitable for mass 
screening. Although some may have an idealized view of screening, the effects are never 
solely positive. Any type of screening program comes with burden (e.g. primary testing and 
waiting for the result), harms (e.g. complications of treatment of pre-invasive lesions), and 
significant costs. Therefore, there are several criteria that should be met prior to implemen-
tation of mass screening.
criteria for screening
In 1968, the World Health Organization (WHO) commissioned the report “Principles of 
early disease detection”, in which Wilson and Jungner proposed a first set of requirements 
for population-based screening (Box 1).2 Although the authors merely hoped that their 
publication would stimulate discussion, their criteria are still regarded as gold standard for 
the evaluation of screening programs. Forty years later, after many screening programs had 
been implemented, the WHO criteria were updated.3
There is general consensus that prior to implementation of screening, all of the (revised) 
WHO criteria should be met. The section of Early Detection at the Department of Public 
Health at the Erasmus MC suggests the use of a two-step approach, starting with a more 
condensed set of criteria:
1. There should be scientific evidence of screening program effectiveness;
2. The overall benefits of screening should outweigh the harm;
3. There should be scientific evidence of screening program cost-effectiveness.
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In case screening does not satisfy one or more of these criteria, screening should not 
be considered and further evaluation of the WHO criteria is not necessary. Alternatively, 
if all three criteria are met, a country or organization can proceed with evaluating the full 
set of WHO criteria to determine whether screening is feasible given its specific needs and 
resources. The next sections describe the aforementioned three criteria for screening in 
more detail.
1. Proof of effectiveness
Scientific evidence should show that screening is effective in reducing the disease burden. 
Ideally, the effectiveness of screening is shown in a randomized controlled trial (RCT) with 
two (or more) study arms: one with screening (intervention arm), and one without screen-
ing (control arm). Primary outcome of such a trial should be disease-specific incidence or 
mortality. If, in the intervention arm, significantly fewer individuals are diagnosed with the 
disease or die from the disease, then screening reduces the morbidity or mortality from that 
disease, and it can be considered effective.
Compared to other study designs, the major benefit of an RCT is the fact that individuals 
are randomly allocated to either the intervention or the control arm. This randomization en-
sures that the  distribution of baseline risk is similar in both arms. Drawbacks of RCTs include 
that they are expensive and time-consuming. Alternatively, non-randomized studies can 
be used to estimate the effectiveness of screening. In these studies, however, differences in 
Box 1. WHO criteria for screening.
Criteria proposed by Wilson and Jungner (1968)
–  The condition sought should be an important health problem.
–  There should be an accepted treatment for patients with recognized disease.
–  Facilities for diagnosis and treatment should be available.
–  There should be a recognizable latent or early symptomatic stage.
–  There should be a suitable test or examination.
–  The test should be acceptable to the population.
–  The natural history of the condition, including development from latent to declared disease, should be ad-
equately understood.
–  There should be an agreed policy on whom to treat as patients.
–  The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically bal-
anced in relation to possible expenditure on medical care as a whole.
–  Case-finding should be a continuing process and not a “once and for all” project.
Revised criteria proposed by Andermann et al. (2008)
–  The screening program should respond to a recognized need.
–  The objectives of screening should be defined at the outset.
–  There should be a defined target population.
–  There should be scientific evidence of screening program effectiveness.
–  The program should integrate education, testing, clinical services and program management.
–  There should be quality assurance, with mechanisms to minimize potential risks of screening.
–  The program should ensure informed choice, confidentiality and respect for autonomy.
–  The program should promote equity and access to screening for the entire target population.
–  Program evaluation should be planned from the outset.
–  The overall benefits of screening should outweigh the harm.
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health outcomes between attendees and non-attendees of screening may be the result of 
differences in disease risk at baseline. It is difficult to measure the effectiveness of screening 
if such a selection bias is present.
The disease-specific incidence or mortality as a primary outcome of an RCT is very 
important. Another outcome that is often reported is the difference in survival between 
screen-detected and clinically diagnosed cases.  This comparison, however, is prone to two 
other forms of bias, i.e. lead-time and length-time bias.
Lead time refers to the time frame from the moment of cancer detection by screening 
until the moment that the cancer would have been clinically diagnosed in the absence of 
screening. Lead-time bias occurs when this time frame is regarded as prolonged survival for 
screen-detected cancers, whereas in fact it only concerns a shift from healthy life years to life 
years lived with clinical disease (Figure 1).
Length-time bias refers to the phenomenon that cancers with a long preclinical duration 
are more likely to be detected with screening than those with a short preclinical duration. 
For slow progressive disease (i.e. cancers with a long preclinical duration), the time from the 
onset of disease until the death from disease is longer than for more rapidly progressive 
disease (i.e. cancers with a short preclinical duration). Even if early detection of cancer does 
not improve survival probabilities, screen-detected cancers have a longer survival time 
because screening is more likely to detect slow-growing disease (Figure 2).
Figure 1. Visualization of lead-time bias.4
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Due to lead-time and length-time bias, screen-detected cancers (seem to) have a more 
favorable survival, and screening may seem very effective. To ensure that the effect of 
screening is not being overestimated, the survival found in RCTs should therefore be cor-
rected for these two types of bias.
2. Benefits should outweigh the harm
Once the effectiveness of a program has been proven, one should determine whether the 
overall benefits outweigh the harm. Often, many individuals have to be screened to prevent 
one individual from being diagnosed with (or dying from) the disease. In general, it is difficult 
to judge whether this benefit of screening for one person is worth the burden of screening 
for all the others. It requires an estimate of the impact on quality of life of the screening itself, 
and of the different screening outcomes, both of which may differ substantially from one 
person to the other.
Screening
Screening itself can be experienced as burdensome. Receiving an invitation, and being 
aware of the fact that you might have (a pre-stadium of ) the disease, for some individu-
als already has a negative impact on their quality of life. They are forced to think about 
the possibility of them having the disease, and about whether they should participate in 
screening. For some types of screening, the test itself can be experienced as burdensome 
or even painful, like a mammogram in breast cancer screening. After testing, participants 
Figure 2. Visualization of length-time bias.4
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have to wait for the result, and during this period participants might suffer from feelings of 
anxiety and stress. Individuals with a positive test result are either treated directly (as with 
colonoscopy screening) or, in most cases, are referred for follow-up testing. Higher levels of 
anxiety and stress will be experienced towards this second, diagnostic test.
Screening outcomes
Screening tests can be either positive or negative, and this may either be correctly identify-
ing the absence or presence of disease, or it may be misclassifying someone as healthy or ill. 
Table 1 provides an overview of the benefits and harms related to those different screening 
outcomes.
True positive test result
Clearly, the major benefit of screening for disease is the early detection of progressive 
disease, thereby enabling early treatment. This requires a true positive test result at screen-
ing. However, the detected preclinical disease might have never developed into clinical 
disease in the absence of screening. An individual only benefits from early detection if the 
earlier initiation of treatment prevents morbidity or mortality from the disease. By detect-
ing preclinical disease that would never have progressed to clinical cancer, individuals are 
being overdiagnosed and potentially also overtreated. Although the severity of overtreat-
ment hugely depends on (the stage of ) the disease, it will surely have a negative impact on 
someone’s quality of life.
False positive test result
A screening test might also produce a positive test result in individuals without (a precursor 
of ) the disease. In such case, individuals will face unnecessary worry, stress and follow-up 
testing, which potentially reduces their quality of life. Although the negative test result at 
follow-up will show that any increased concerns were unnecessary, individuals might not 
be entirely reassured.
Table 1. Harms and benefits of screening outcomes.
Test result
Positive Negative
(Precursor 
of ) disease
Present True positive
Benefits: Early detection of progressive disease, 
thereby enabling early treatment and reducing 
morbidity or mortality from disease
Harms: Detection and treatment of non-
progressive disease, i.e. overdiagnosis and 
overtreatment
False negative
Benefits: --
Harms: False 
reassurance, potentially 
leading to a later clinical 
diagnosis
Absent False positive
Benefits: --
Harms: Unnecessary follow-up testing, and 
(additional) anxiety and stress
True negative
Benefits: Justified 
reassurance
Harms: --
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True negative test result
A negative test result at baseline is more likely to reassure individuals. Those who test nega-
tive and do not have (a precursor of ) the disease, may benefit from justified reassurance.
False negative test result
With any type of screening, some prevalent disease will be missed. Individuals with a nega-
tive test result, but with (a precursor of ) the disease, are falsely reassured by the screening. 
This may lead to a delayed clinical diagnosis, as symptoms may be recognized in a later 
stage.
3. Proof of cost-effectiveness
If studies have unequivocally demonstrated that the benefits of screening outweigh the 
harms, then the costs of the screening program should be evaluated. Screening programs 
are expensive, and health care budgets can only be spent once. If the same budget can save 
more life years in preventing or treating another disease, then, from a cost-effectiveness 
perspective, budgets should be directed to that disease first.
The cost-effectiveness of interventions can be evaluated in cost-effectiveness analyses 
(CEAs), which can be performed using mathematical models. In screening CEAs, strategies 
are compared in terms of their costs and (quality-adjusted) life years. Strategies are deemed 
cost-effective if they are considered to be good value for money, given alternative options. 
More formally, the additional cost per additional (quality-adjusted) life year gained of one 
strategy versus another is computed, and compared with the amount that society is willing 
to pay for one (quality-adjusted) life year. Although it seems straightforward that in order 
to make such a comparison, all relevant alternatives should be included in an analysis, it is 
not always straightforward what exactly comprises a relevant strategy. This is one of the 
issues we aim to address in Chapter 2 of this thesis, where we have reviewed the choice of 
strategies included in CEAs of HPV-based cervical cancer screening.
cervical cancer and colorectal cancer
This thesis includes studies on both cervical and colorectal cancer screening. The natural 
history of these diseases is similar in the sense that a long preclinical phase precedes cancer 
development. During this preclinical phase, benign lesions can be detected by screening. 
Although any treatment is associated with risk of complications, most precursor lesions of 
cervical and colorectal cancer can be removed relatively easy, thereby preventing cancer 
development. Alternatively, screening can detect cancer while it is still asymptomatic. For 
both cervical and colorectal cancer, prognosis steeply increases when detected in an earlier 
stage. For cases diagnosed in 2005-2011 in the United States, five-year survival of distant 
cancer was only 17% for cervical and 12% for colorectal cancer, whereas five-year survival of 
localized cancer was 92% for cervical and 90% for colorectal cancer.4 On the one hand, this 
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makes both diseases extremely suitable for screening. On the other hand, benign lesions in 
the cervix and colon are common, and screening can result in overdiagnosis and overtreat-
ment of such lesions. In order to minimize this potential harm of screening, over-screening 
(i.e. screening more often than recommended) should be kept to a minimum. Per-treatment 
complication risks might be low, but together with psychological distress, the harms of 
screening can outweigh the benefits for individuals who are intensively screened.
The epidemiology, natural history, risk factors and current status of prevention of cervical 
and colorectal cancer are described in more detail below.
cervical cancer
Cervical cancer is the fourth most common cancer in women worldwide, with an estimated 
528,000 new cases and an estimated 266,000 deaths in 2012.5 The burden of cervical cancer 
concentrates in the developing world, where approximately 84% of all new cases are found.5
In countries with well-developed screening programs, cervical cancer incidence and 
mortality have reduced substantially over the past decades. This decline is mainly due to the 
early detection and treatment of (precursors of ) squamous cell carcinomas, which comprise 
~90% of incident cases worldwide.6 The effectiveness of cytological screening in reducing 
the incidence and mortality of adenocarcinoma (i.e., the other ~10% of incident cases) is 
less evident.
Natural history
Infection with the human papillomavirus (HPV) is a necessary, but not a sufficient cause of 
cervical cancer.7 HPV infections are common sexual transmitted infections (STIs), that are 
transmitted via skin-to-skin contact. Although most HPV infections clear naturally, some are 
persistent and precursor lesions may develop. These lesions, so-called cervical intraepithelial 
neoplasia (CIN), may transition from grade 1 to grade 2, and from grade 2 to grade 3. Data on 
the progression of CIN to cancer are limited, because once detected, it is considered unethi-
cal to leave the lesions untreated. To date, there has been one study in which CIN 3 was left 
untreated though. The clinician involved in this study did not believe CIN to be a precursor 
of cancer. The results have shown that if left untreated for 30 years, 31-50% of CIN 3 lesions 
develop into clinical cancer.8 The entire process from acquiring an HPV infection to being 
diagnosed with cervical cancer is depicted in Figure 3, and takes on average approximately 
15-20 years.
Although nearly half of CIN 3 lesions are true precursors of cervical cancer, CIN 1 and 
CIN 2 often regress naturally. Especially for CIN 1, progression to cervical cancer is rare. 
Several guidelines therefore state that women with CIN 1 should not be treated (directly), 
but should be offered follow-up testing instead.9,10 If the lesion has not regressed after 1-3 
years, then treatment can still be offered.
16 | Chapter 1
Risk factors of cervical cancer
Risk factors of cervical cancer can be subdivided into those that increase the probability of 
acquiring HPV, and those that increase the probability of progression to CIN and cervical 
cancer.
Probability of acquiring HPV
Just as for all STIs, sexual behavior influences the probability of acquiring an HPV infection. 
Indeed, age at first sexual intercourse11 and number of new and recent sexual partners12 
were found to be associated with the risk of acquiring the virus. HPV is presumably transmit-
ted by skin-to-skin contact,12 and is found in male genital areas not covered by a condom.13 
Although inconsistent data have been published on the protective effect of condoms,14 the 
consistent use of condoms appears to be associated with lower rates of acquiring HPV.15
Probability of progression to (pre-)invasive disease
In addition to a lower probability of acquiring HPV, women who consistently use condoms 
have a higher probability of clearing an HPV infection and regressing any present CIN.15 Al-
though progression to high-grade CIN was found to be positively correlated with cigarette 
smoking16,17, long-term oral contraceptive use17,18, and multiparity17, there is insufficient 
evidence as to whether these risk factors are also associated with an increased risk of cancer 
development.16,17 To date, there have been no indications that, apart from behavioral dif-
ferences, ethnic background is associated with cervical cancer risk.19 Women infected with 
human immunodeficiency virus (HIV) are at an increased risk of developing both CIN20,21 
and invasive cervical cancer22. In addition, compared to women without HIV, the prognosis 
of HIV-infected women is worse after invasive cervical cancer has been diagnosed.23 Women 
carrying the BRCA1 mutation are also at an increased risk of developing cervical cancer.24
Current status of HPV vaccination
Since the discovery of HPV being a necessary cause of cervical cancer, HPV vaccines have 
been developed. Over the past decade, vaccination with either a bivalent or quadrivalent 
vaccine has been implemented in many developed countries.25 Both vaccines target the 
two highly oncogenic HPV-types 16 and 18, together causing roughly 80% of all cervical 
Figure 3. Natural history of cervical cancer.10
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cancer cases.26 Vaccination has shown to be highly effective in reducing the prevalence 
of HPV-16 and HPV-18.27,28 Nevertheless, coverage is still relatively low, with only ~40% of 
all targeted girls being vaccinated worldwide.25 Therefore, and because other oncogenic 
HPV-types may still cause cancer, birth cohorts that have been offered routine vaccination 
should still be invited for cervical cancer screening.
Current status of cervical cancer screening
In most developed countries, cytology-based screening has been in place for decades. With 
cytology, a smear is taken from the cervix, and is sent to the laboratory, where it is placed 
under a microscope and screened for abnormalities by a cytologist. Using a standardized 
scale, the degree of abnormalities is rated. In most settings, women with low-grade abnor-
malities are invited for triage testing, and women with high-grade abnormalities are referred 
for colposcopy.
Over the past 15 years, conventional cytology has been replaced by liquid-based cytology 
(LBC) in several countries, such as the UK, the US, Australia, and the Netherlands. Both con-
ventional cytology and LBC are performed on a cervical smear, which is collected by scraping 
off cells from the transformation zone of the cervix. The difference between the techniques 
is that with conventional cytology, the cells are directly smeared on a slide, whereas with 
LBC, the cells are rinsed in a vial with preservation solution and this vial is then transferred 
to the laboratory, where a uniform layer of cells is put on a slide. In most cases, the uniform 
layer does not require the inclusion of all collected cells, and the cells that are left in the vial 
can be used for HPV testing. This is a major advantage of LBC compared to conventional 
cytology. The use of LBC was also found to result in fewer smears of unsatisfactory quality.29 
Since the development of a wide range of HPV tests, they were gradually incorporated as a 
triage test in cytology-based screening programs. In 2017, the Netherlands and Australia will 
be the first countries to switch from a screening program with primary LBC testing, to one 
with primary HPV testing.30,31 In both countries, unscreened and underscreened women will 
be offered a self-sampling kit, which can be used to self-collect vaginal material at home.30,32 
Just as with the regular HPV test, the collected material can then be sent to the laboratory, 
where it is tested on the presence of HPV.
colorectal cancer
Globally, colorectal cancer is the third most common cancer in men, and the second in 
women, with an estimated 1,360,000 cases and nearly 700,000 deaths in 2012.5 Colorectal 
cancer risk increases with age, and is higher in men than in women.33 In contrast with cervi-
cal cancer, colorectal cancer is much more a disease of the developed world, where more 
than half of all cases are found.5 The Western lifestyle, including excessive alcohol and red 
meat consumption, smoking and obesity, significantly increases the probability of develop-
ing colorectal cancer.34
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Natural history
Colorectal cancer is believed to develop from non-malignant polyps in the colon. Until 
recently, all cancers were believed to develop through the type of non-malignant polyps 
called adenomas. These adenomas may grow in size, after which they might become ma-
lignant. This development is called the adenoma-carcinoma sequence (Figure 4). Whereas 
adenomas are thought to be present in 20-53% of the US population over age 50, the 
lifetime risk of developing an adenocarcinoma is only 5%.35 An early study suggested that it 
takes on average 10-15 years for an adenoma to progress to cancer.36
More recently, a new pathway to colorectal cancer has been identified, called the ser-
rated polyp pathway. This pathway also involves the development of non-malignant polyps, 
but other than adenomas they are non-neoplastic, but rather sessile serrated polyps. The 
magnitude of impact of this pathway is subject of debate and currently the most quoted 
number is that approximately 15% of cancers develop through this pathway.35 Data on the 
natural history of this pathway are scant.
Risk factors of colorectal cancer
It has been estimated that more than half of colorectal cancer cases are caused by lifestyle 
and environmental factors.37 The largest increase in risk is caused by alcohol consumption, 
with a 60% higher risk for heavy drinkers compared to non- or light drinkers.34 Smoking, 
diabetes, obesity and high meat intakes are independently associated with an increased 
colorectal cancer risk of 20%.34 Physical activity and the use of aspirin provide a protective 
effect.34,40 The increased risk of bleeding complications in individuals on high-dose aspirin 
may limit its usefulness in terms of primary prevention of colorectal cancer though.40
While most cases of colorectal cancer are sporadic, some can be linked to a specific in-
herited cancer syndrome, or to other less pronounced genetic factors. Approximately 5% of 
colorectal cancer diagnoses are found in individuals with a cancer syndrome, such as Lynch 
Syndrome or Familial Adenomatous Polyposis.38 As people with a positive family history, 
but without an identified cancer syndrome, are also at an increased risk for developing the 
Figure 4. Traditional adenoma-carcinoma sequence.
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disease, there must be other inherited factors that increase colorectal cancer risk. Currently 
a considerable amount of research is devoted to identification of single nucleotide poly-
morphisms (SNPs). These are mutations that are much more prevalent in the population 
than the genetic factors that have been linked to cancer syndromes. Although individually, 
their effect is much less pronounced, people with multiple SNPs can have a substantially 
increased risk.
Current status of colorectal cancer screening
The status of colorectal cancer screening varies widely across countries.39 Whereas in the 
United States, opportunistic screening was already introduced in the 1980s, most European 
countries have only recently introduced organized screening.39 This has been triggered by 
multiple RCTs showing the effectiveness of colorectal cancer screening.40-50
Colorectal cancer screening can be performed with a wide range of screening tests, 
which can be subdivided into stool-based, imaging and endoscopic tests. Stool-based tests 
include the guaiac fecal occult blood test (gFOBT) and fecal immunochemical test (FIT), 
which are both widely used in organized screening programs.39 Stool-based tests require 
the participant to collect stool and send it to the laboratory, where it is tested for the pres-
ence of blood by targeting heme (in case of gFOBT) or human globin (in case of FIT). In 
contrast with gFOBT, FIT is a quantitative test, meaning that the positivity cut-off level can 
be adjusted.39 Because of its limited sensitivity, stool-based testing is often recommended 
at an annual or biennial basis.39 One of the advantages of the more invasive imaging and 
endoscopic tests is that they are more sensitive, and therefore require less frequent testing. 
The drawback of imaging and endoscopic tests, however, is that they require a bowel prepa-
ration to clean out the colon. With imaging techniques, such as computed tomographic 
colonography (CTC), individuals are also exposed to low dose radiation, which is used 
to obtain an interior view of the colon. This technique is costlier and more invasive than 
stool-based testing and its use is much more limited. Most countries with opportunistic 
screening rely on the use of endoscopy, in particular colonoscopy.39 With endoscopy, a 
flexible tube with a fiber-optic camera is inserted into the anus, and pushed through the 
colon to visualize any adenomas or cancers. A major benefit of this technique is that, in 
most cases, detected adenomas can directly be removed. Whereas with colonoscopy the 
colon is fully visualized in ~95% of cases, sigmoidoscopy aims at visualization of the left 
colon only. Therefore, sigmoidoscopy is less sensitive than colonoscopy, but it is also less 
burdensome and it involves a lower risk of complications. As colonoscopy is regarded as the 
gold standard in terms of sensitivity, screening with tests other than colonoscopy require a 
diagnostic colonoscopy after a positive test result.
Despite the wide range of available screening tests in the US, adherence with colorectal 
cancer screening is relatively low. Whereas 81% of 21-65 year-old women had a cervical 
smear taken in the past 3 years, only 59% of 50-74 year-olds were up-to-date with colorectal 
cancer screening in 2013.51 Screening compliance varied widely by availability of health 
care, length of US residence, race, ethnicity and education.51
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imProving screening Programs
Any type of screening can be enhanced by reducing the harms and increasing the benefits 
from that type of screening. Even for cervical cancer screening, which has been ongoing for 
decades, possibilities for improvement keep arising. The development of new vaccines and 
tests constantly triggers the evaluation of new prevention strategies. Although colorectal 
cancer screening is relatively new in most countries, already a wide variety of tests exists, and 
new tests are constantly being developed. In this thesis, several suggestions for improve-
ment of the harm-benefit ratio of cervical and colorectal cancer screening are described, 
by either focusing on reducing the harms or increasing the benefits from screening, or on 
a combination of both.
reducing harms
It is important to keep track of the potential harms of screening. For cervical cancer 
screening, switching from cytology-based screening to HPV-based screening may lead to 
increased harms due to an increased number of (false-)positive screening tests. For women 
who are currently screened more often than recommended by international guidelines (e.g. 
the yearly check-ups in Germany), the expected increase in benefits with HPV screening 
may be outweighed by the increase in burden due to the increase in positive tests and un-
necessary follow-up examinations. In Chapter 3, the potential harms of primary HPV testing 
in over-screened women is discussed in further detail.
Another potential harm of cervical cancer screening is the increased risk of preterm birth 
after loop electrosurgical excision procedure (LEEP), i.e. the most commonly used CIN treat-
ment method.52,53 As especially at young age many CIN lesions regress naturally, the fact 
that treatment may be harmful emphasizes the importance of a restrained treatment policy 
in women of reproductive age. A cost-benefit analysis of screening in reproductive age, 
taking into account the increased risk of preterm birth after CIN treatment, is presented in 
Chapter 4.
increasing benefits
Two ways of enhancing the benefits from screening are by increasing participation rates, 
and by offering a test with better test characteristics.
Over the past 15 years, conventional cytology has been gradually replaced by the LBC 
tests SurePath and ThinPrep in, amongst others, the Dutch cervical cancer screening pro-
gram. As said, the use of LBC involves fewer samples of unsatisfactory quality and enables 
the possibility of also testing samples for the presence of HPV. As LBC test characteristics 
were thought to be non-inferior to those of conventional cytology,54,55 these two benefits 
led to the implementation of LBC in many countries. However, the systematic reviews on 
LBC versus conventional cytology did not consider a potential difference in test charac-
teristics between SurePath and ThinPrep. Using population-based data, we have shown 
that SurePath detects more CIN 2+ than conventional cytology, while ThinPrep does not.56 
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This suggests that the sensitivity of SurePath may be higher than that of conventional 
cytology and ThinPrep. However, the additionally detected CIN lesions might only include 
non-progressive lesions. Whether SurePath has a higher sensitivity for progressive lesions 
can only be evaluated by comparing cervical cancer rates. Therefore, in Chapter 5 of this 
thesis, we compare the cumulative cancer incidence after a normal conventional cytology, 
SurePath and ThinPrep screening sample.
In January 2017, the Dutch cervical cancer screening program has changed from 
cytology-based screening to HPV-based screening. This change is expected to lead to an 
increased program sensitivity, preventing over 100 additional cervical cancer cases and ~35 
additional cervical cancer deaths annually.57 Another advantage of HPV testing is that it can 
be performed on self-collected samples. This may trigger women who would not partici-
pate in screening otherwise, to take a sample and send it to the laboratory. In Chapter 6 of 
this thesis, the cost-effectiveness of offering a self-sampling test to non-attending women is 
evaluated, considering a range of different scenarios.
For colorectal cancer screening, a variety of different tests is available. The US Preven-
tive Services Task Force included 6 different tests in its 2016 recommendations.58 The large 
variety in tests stimulates individuals who do not want to be screened with test X, to still 
participate in screening with test Y. Although not all tests are equally effective and cost-
effective, offering an alternative test with slightly worse test characteristics may increase the 
expected benefits of screening if it entices previously unscreened individuals to participate 
in screening. Therefore, the Centers for Medicare and Medicaid Services (CMS) recently 
started covering the first multitarget Stool DNA (mtSDNA) test, Cologuard®, in the Medicare 
population. In addition to the ability of regular stool-based tests to identify the presence of 
occult hemoglobin in stool, the mtSDNA test can identify multiple human DNA biomarkers. 
The cost-effectiveness of three-yearly mtSDNA testing in the Medicare population, as is 
covered by CMS, is evaluated in Chapter 7 of this thesis.
reducing harms and increasing benefits: opportunities for risk-based 
screening
Current screening programs are often “one size fits all”, but there is an increasing demand 
for a more personalized approach. A personalized approach implies that individuals at 
increased risk are offered more intensive screening, while individuals at decreased risk are 
offered less intensive screening. By allocating screening resources based on disease risk, 
screening resources are used more efficiently. In theory, personalizing a screening program 
therefore always improves its harm-benefit ratio. However, it requires a more advanced 
organizational structure and the willingness of the screening eligible population to adhere 
to such guidelines.
For cervical cancer, the future screening eligible population can be divided into two main 
risk groups: vaccinated and unvaccinated women. Routine vaccination will not only reduce 
cervical cancer risk with roughly 80% in vaccinated women, but will also reduce HPV preva-
lence in the general population. This so-called herd immunity is likely to increase over time, 
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thereby gradually also reducing the cervical cancer risk in unvaccinated women. At first, vac-
cinated women will likely be at much lower risk of developing cervical cancer than unvac-
cinated women. However, they may not agree with being offered less intensive screening, 
just because they were willing to get vaccinated. In Chapter 8, we have investigated at 
what level of herd immunity it would be cost-effective to replace a screening program that 
is optimized to the risk level in a pre-vaccination cohort with one that is optimized to the 
risk level in a fully vaccinated cohort.
For colorectal cancer, risk groups can, among other things, be identified based on genet-
ics. For example, someone’s family history is indicative of someone’s genetic predisposition 
for the disease. Therefore, several guidelines recommend more intensive screening for those 
with a family history of colorectal cancer compared to the general population. We previously 
showed that it is more cost-effective to screen persons with multiple family members af-
fected by the disease more intensely than persons with only one affected family member.59 
In Chapter 9 of this thesis, we evaluate whether we could further optimize screening for 
different levels of family history by also taking age of the person at risk into consideration.
We also more directly considered genetic factors for personalized screening, i.e. by consider-
ing colorectal cancer screening based on polygenic risk. Polygenic testing can be used to 
reveal the presence or absence of single nucleotide polymorphisms (SNPs) that are associated 
with colorectal cancer risk. In Chapter 10, we investigated the potential benefit of offering all 
individuals a polygenic test at a certain age, with future colorectal cancer screening based on 
the results of that test. We compared the costs and effects of such individualized screening to 
current uniform screening.
microsimulation modeling
miscan model
The simulation studies described in this thesis were performed using the microsimulation 
screening analysis (MISCAN) model, which has been developed at the Department of Public 
Health of the Erasmus University Medical Center.60 This model can be used to assess the 
harms and benefits of different screening programs. Although different versions of the 
model have been developed for different cancer sites, the overall structure of the model is 
the same (Figure 5). The general idea behind the model is simple; we simulate a hypotheti-
cal cohort of individuals who are exposed to the disease. We let the model run twice; once 
with screening and once without screening. The effects of screening are then determined 
by the difference in results between those simulations.
Although demography inputs such as life expectancy can easily be derived from popula-
tion databases, assumptions for screening and natural history parameters might not be 
readily available. Even though much research has been done on the natural history of 
diseases, it is impossible to obtain the exact underlying disease process from clinical studies. 
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Model calibration is therefore needed to estimate most of the natural history parameters, 
such as the duration of preclinical disease stages.
MISCAN is an individual-based model, meaning that individual life histories are simulated 
one by one. First, a date of birth and a date of death is generated, resulting in a life his-
tory without disease (top line Figure 6). Second, the model simulates the development of 
precursor lesions. While most individuals will not develop any of those lesions, some might 
develop multiple. In this example, the individual develops one precursor lesion, at age 40. 
In the absence of screening, the precursor lesion will develop to clinical cancer and will 
lead to death from cancer at age 75. However, if a successful screening intervention takes 
place at age 50, the precursor lesion is detected and can be removed before it would have 
progressed to cancer. By avoiding death from cancer, the simulated individual will gain five 
life years (bottom line Figure 6).
Figure 5. Structure of the MISCAN model.
Life history without disease 0 80
Other-cause death
Birth
0
Cancer death
Birth
 
Life history with screening 0
Other-cause death
Birth
Screening (detecting the pre-invasive lesion) LYs gained by screening
Life history with development of 
cancer
Pre-invasive lesion    Preclinical cancer Clinical cancer
Pre-invasive lesion Lesion and cancer free
40 
40 
75 50 
Figure 6. Example of a life history as simulated in MISCAN.
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Why using a model helps to answer policy questions
Although RCTs are indispensable, they can only evaluate a few intervention strategies at a 
time, are expensive, and rely on the willingness of individuals to participate. Furthermore, 
the effectiveness of a cancer screening strategy in terms of incidence or mortality reduc-
tion can only be evaluated after several years of follow-up. In theory, screening strategies 
can alter in various ways, with differences in screening test, age range, screening interval, 
and in some instances also the referral threshold for follow-up testing. The options are so 
numerous, that it is impossible to compare them all in an RCT. This is one of the reasons 
why mathematical models have been developed for the evaluation of different screening 
strategies. In those models, any type of screening strategy can be simulated, and results 
can be generated within a reasonable amount of time (i.e. millions of individuals can be 
simulated within a few minutes). Models can be adjusted to other settings, and can be used 
to reproduce the results of trials. In summary, RCTs are needed to prove the effectiveness of 
screening, but microsimulation models are needed to evaluate a wide range of screening 
interventions.61
research questions and outline of this thesis
Current literature already includes a wide range of studies on cervical and colorectal cancer 
screening. The aim of this thesis is to provide insight into some of the gaps in literature on 
the possibilities to increase the harm-benefit ratio of both types of screening. The remainder 
of this thesis is subdivided into four parts. Whereas Part I elaborates on a methodological 
issue in cost-effectiveness analyses, the remainder includes studies on how to reduce harms 
(Part II), increase benefits (Part III), and improve the harm-benefit ratio by offering risk-
stratified screening (Part IV).
The research questions addressed in the respective parts are as follows.
Part I. Methodological issues in cost-effectiveness analyses
– To what extent do cost-effectiveness analyses of cervical cancer screening omit relevant 
strategies, and how does this affect their conclusions? (Chapter 2)
Part II. Reducing harms
– What are the potential harms of primary HPV screening in over-screened women? 
(Chapter 3)
– What is the impact of cervical screening on preterm birth? Is it of such importance 
that cervical screening at reproductive age should depend on a woman’s childwish? 
(Chapter 4)
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Part III. Increasing benefits
– Does cervical cancer incidence after a normal cytological sample differ between Sure-
Path, ThinPrep and conventional cytology? (Chapter 5)
– When do the harms of offering HPV self-sampling to non-attendees of organized pri-
mary HPV screening outweigh its benefits? (Chapter 6)
– Is colorectal cancer screening with the multitarget stool DNA test a cost-effective 
alternative for the Medicare population, and if not, under what conditions will it be? 
(Chapter 7)
Part IV. Reducing harms and increasing benefits: Opportunities for risk-based 
screening
– At what level of herd immunity can uniform cervical cancer screening be adjusted to the 
risk level in vaccinated women? (Chapter 8)
– Should colorectal cancer screening for people with a positive family history vary by age? 
(Chapter 9)
– What is the potential benefit of risk-stratified colorectal cancer screening based on com-
mon genetic variants? (Chapter 10)
This thesis ends with a general discussion (Chapter 11) in which the above research ques-
tions are answered, and suggestions for future research are made.
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aBstract
Objectives: To systematically review the choice of comparator strategies in cost-effective-
ness analyses (CEAs) of human papillomavirus testing in cervical screening.
Methods: The PubMed, Web of Knowledge, and Scopus databases were searched to iden-
tify eligible model-based CEAs of cervical screening programs using human papillomavirus 
testing. The eligible CEAs were reviewed to investigate what screening strategies were 
chosen for analysis and how this choice might have influenced estimates of the incremental 
cost-effectiveness ratio (ICER). Selected examples from the reviewed studies are presented 
to illustrate how the omission of relevant comparators might influence estimates of screen-
ing cost-effectiveness.
Results: The search identified 30 eligible CEAs. The omission of relevant comparator strate-
gies appears likely in 21 studies. The ICER estimates in these cases are probably lower than 
would be estimated had more comparators been included. Five of the 30 studies restricted 
relevant comparator strategies to sensitivity analyses or other sub-analyses not part of 
the principal base-case analysis. Such exclusion of relevant strategies from the base-case 
analysis can result in cost-ineffective strategies being identified as cost-effective.
Conclusions: Many of the CEAs reviewed appear to include insufficient comparator strate-
gies. In particular, they omit strategies with relatively long screening intervals. Omitting 
relevant comparators matters particularly if it leads to the underestimation of ICERs for 
strategies around the cost-effectiveness threshold because these strategies are the most 
policy relevant from the CEA perspective. Consequently, such CEAs may not be providing 
the best possible policy guidance and lead to the mistaken adoption of cost-ineffective 
screening strategies.
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introduction
This review considers the choice of screening strategies compared in cost-effectiveness 
analyses (CEAs) of cancer screening programs. It investigates how the choice of which 
strategies are compared can influence cost-effectiveness estimates and resulting policy 
advice. Specifically, this review addresses the choice of comparator strategies against which 
the cost-effectiveness of a given screening strategy is estimated. This issue is considered 
in the particular context of CEAs of cervical cancer screening using testing for the human 
papillomavirus (HPV).
The primary measure of cost-effectiveness is the incremental cost-effectiveness ratio 
(ICER), which is the ratio of additional costs to additional health effects of an intervention 
relative to its next best alternative (once strategies subject to simple and extended domi-
nance have been eliminated).1,2 Because the ICER is an incremental measure, it depends not 
only on the costs and effects of the strategy for which it is estimated but also on those of 
the comparator strategy.
Typically, decision makers use ICERs in conjunction with a cost-effectiveness threshold, 
which indicates the maximum willingness to pay for an additional (quality-adjusted) life 
year.3 The strategy with the highest ICER within the threshold is optimal from the cost-effec-
tiveness perspective because it is the most effective intervention that does not exceed the 
willingness-to-pay limit. More broadly, those strategies with ICERs closest to the threshold 
are defined here as the CEA-relevant strategies because they yield more net health benefit 
than do strategies with ICERs far above or below the threshold. It is the adequacy of the 
choice of comparators for these CEA-relevant strategies that is the focus of this review.
A particular characteristic of screening especially relevant to CEA modeling is that it can 
often be applied at a wide range of intensities, depending on the screening interval, screen-
ing age range, type of tests used, and the diagnostic criteria for follow-up. As a result, CEAs 
considering a wide range of screening intensities can yield a wide range of ICERs, varying 
from those well below the threshold through to those around the threshold and then on to 
well above the threshold.
What is already well appreciated in CEA theory is the importance of including relevant 
comparators for the reliable estimation of ICERs. Indeed, the Washington Panel on Cost-
Effectiveness in Health and Medicine uses a cancer screening example to illustrate the 
importance of including relevant comparators.4 It notes that to correctly estimate the ICER 
of annual screening, it must be compared with biennial screening rather than with no 
screening. The general principle is that to appraise the cost-effectiveness of a given screen-
ing strategy, the next best strategy should be included as a comparator against which to 
estimate the ICER. If less intense comparators are omitted, then the estimated ICER is likely 
to be lower than that in a more complete comparison, thereby giving an unrepresentatively 
favorable impression of the strategy’s cost-effectiveness.
The motivation for this review was an observation that although most models used in 
CEAs of HPV screening are carefully constructed and well described, many include relatively 
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few comparator screening strategies. Consequently, they may fail to adequately estimate 
the cost-effectiveness of certain strategies. This, in turn, could lead decision makers to 
mistakenly adopt cost-ineffective policies, thereby wasting health care resources. Therefore, 
the aim of this study was to systematically assess the adequacy of the choice of comparator 
strategies in CEAs of HPV testing in cervical screening. It seeks to demonstrate the impor-
tance of appropriately chosen comparators for the reliable estimation of ICERs. Although 
the review addresses the specific case of cervical screening, it is hoped that the example 
will illustrate the importance of including relevant comparators in CEAs in general to both 
analysts and decision makers alike.
the example of cervical screening
Cervical screening has proved highly successful in reducing cancer incidence and mortal-
ity.5 Cervical screening is widely practiced in developed countries, either through organized 
programs or on an ad-hoc basis.6,7 There is a wide variety of possible screening strategies 
because alternative screening intervals and start and stop ages can be used. Similarly, 
screening may use different tests, such as conventional Papanicolaou cytology or the more 
recent alternative of liquid-based cytology. Furthermore, there are alternative combinations 
of primary screening tests and triage testing for inconclusive primary screen results and 
alternative classifications of borderline results. In practice, there are large variations between 
countries in screening recommendations. For example, the German recommendations are 
for annual screening from age 20 years, whereas the Dutch screening program has used 
screening every 5 years from age 30 years.8,9
The range of possible strategies continues to expand, in part because of the recent ad-
vent of HPV DNA testing. HPV testing offers better sensitivity for the detection of high-grade 
lesions, but at the cost of lower specificity.10–12 HPV testing is typically used in conjunction 
with cytology, for example, using HPV and cytology as the primary test and the triage test, 
respectively. Some proposed strategies also involve a switch in the order the strategies are 
used,8 using cytology and HPV as the primary test and the triage test, respectively, in younger 
women in whom transient HPV infections are more prevalent. Importantly, for this review, 
HPV testing has been recognized as offering the potential for longer screening because a 
negative HPV test result is associated with a longer period of reduced risk of precancerous 
lesions than is negative cytology.13
Another relevant development is the HPV vaccine, which has been implemented in many 
countries recently. Although current vaccines are expected to reduce the incidence of 
cervical cancer, the level of protection is not anticipated to be sufficient to abandon screen-
ing.14 Reduced incidence will reduce the cost-effectiveness of current screening services, so 
screening intervals may need to lengthen for screening to be cost-effective.15
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methods
The PubMed, Web of Knowledge, and Scopus databases were searched for model-based 
CEAs of cervical screening using HPV testing. The search string is given in Box 1. Figure 1 
shows the search protocol. The search was restricted to English language academic articles 
published between January 1995 and September 2013. The search excluded conference 
proceedings, government reports, and gray literature. The search returned 382, 438, and 361 
titles from PubMed, Web of Knowledge, and Scopus, respectively. Combining and removing 
duplicates gave 646 unique studies, the titles and abstracts of which were then reviewed by 
one reviewer (J.F.O’M.).
Pubmed
382
Scopus
361
Web of Knowledge
438
Combined and 
duplicates removed
646
Exclusions following abstract review:
Irrelevant disease or intervention 326
Not a CEA 165
Not from a developed country 115
Not a model-based CEA 4
Review article 2
Methods study 2
Exclusions following hand search:
Other exclusions 3
Additional inclusion 1
CEAs for review
30
Figure 1. Composition of literature search and exclusions.
CEA = cost-effectiveness analysis.
Box 1. The PubMed version of the search string
Cervi*[tiab] OR pap[tiab] OR cytolog*[tiab] OR (cervi*[tiab] AND cancer[tiab])
AND (HPV[tiab] OR “Human Papillomavirus”[tiab])
AND (screen*[tiab] OR prevent*[tiab])
AND (cost-effect*[tiab] OR “cost effect*”[tiab] OR CEA[tiab] OR CUA[tiab] OR HTA[tiab]OR “health technology 
assessment”[tiab] OR “health economic”[tiab])
AND English[lang]
AND (“1995/01/01”[PDAT] : “2013/10/01”[PDAT])
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Studies were excluded if they did not relate to cervical cancer or cervical screening. 
Studies were included only if they concerned screening in countries classified as advanced 
economies by the International Monetary Fund.16 These studies were excluded for the 
two reasons that the screening services in such countries are very different from those in 
developed settings and it is markedly less clear what the appropriate cost-effectiveness 
thresholds are. Studies were excluded if they were trial-based CEAs because the intermedi-
ary outcome measures such as cases detected are not directly comparable with estimates 
of life years gained (LYG) or quality-adjusted life years (QALYs) from model-based CEAs.17–21 
Methodological studies and reviews were also excluded.22–25
The remaining studies were reviewed independently in detail by two reviewers (J.F.O’M. 
and S.K.N.). Discordance between reviewers regarding the inclusion of articles was resolved 
by reviewing the studies together. One analysis was published in two similar articles, one 
in an academic journal,26 the other in a government journal;27 the latter was excluded. In 
addition, the article by van Ballegooijen et al.28 was excluded because it is primarily an ex-
ploratory analysis of two alternative hypotheses regarding disease progression rather than 
a standard CEA. Another study was excluded because it did not report costs and effects 
estimates or a cost-effectiveness plane, but reported only ICERs, meaning that it was not 
possible to appraise the appropriateness of the comparisons made.29 The reference lists of 
the included studies were reviewed, and this yielded an additional article.30 The final number 
of CEAs reviewed was 30.8,14,15,26,30–55
The reported costs and effects estimates from the 30 studies were extracted by the two 
reviewers and compiled for analysis. The cost-effectiveness planes and ICERs were repro-
duced from the available results. Some studies reported ICERs that are at variance with the 
conventional interpretation as the ratio of incremental costs to incremental health effects 
relative to the next most effective strategy.38,52,54,55 In these cases, the ICERs were recalculated 
from the reported costs and effects. The reproduced cost-effectiveness planes were used to 
review the comparisons and interpretations made by the studies.
The selected studies were reviewed to assess the adequacy of the comparators included. 
This was informed by a previous CEA of cervical screening that assessed conventional cytol-
ogy over a broad range of screening ages and intervals.56 It estimated an efficient frontier 
without pronounced kinks, as the ICERs increased steadily from long intervals and short 
screening age ranges (low-intensity strategies) through to very high ICERs for short screen-
ing intervals and long screening ages ranges (high-intensity strategies). It was assumed that 
if the reviewed studies also simulated a broad range of screening intensities they would 
find similarly shaped frontiers, in which low-intensity strategies would be the comparators 
against which the ICERs of higher-intensity strategies were estimated. This assumption 
implies that if low-intensity comparators have been omitted from the analysis, then some of 
the resulting ICER is likely to be underestimated.
The primary objective was to assess the adequacy of the comparator against which the 
ICER of the optimal strategy was estimated in each study. The cost-effectiveness threshold 
used to identify the optimal strategy was retrieved from each study, or, if not explicitly stated, 
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from another included study for the same country. In one case this was not possible,26 so the 
gross domestic product per capita threshold suggested by the World Health Organization 
from the year of publication was used instead.57,58
The primary criterion used to identify the omission of a relevant comparator was the 
failure to include a screening interval longer than that found for the optimal strategy. Stud-
ies without such a longer interval strategy were considered likely to have omitted relevant 
comparators. The analysis also considered the ratio of the ICER of the optimal intervention 
relative to the next higher ICER on the efficient frontier. Larger ratios were considered more 
suggestive of the omission of relevant comparators. Finally, the analysis also considered 
other aspects of the strategies compared, including the screening age ranges, the alternative 
screening technologies, and the range of primary screening and triage protocols simulated.
This review is based on the assumption that all possible strategies are potential compara-
tors. Some CEAs, however, may be conducted with a specific research objective that (implic-
itly or explicitly) precludes some comparators. For example, the objective of Vijayaraghavan 
et al.54 to assess the cost-effectiveness of adding HPV triage testing to current screening 
services in the United States may preclude alternative screening intervals. Despite this, the 
criteria described above were applied to all studies irrespective of the stated research objec-
tives.
Some studies assessed more than one population; simulating either vaccinated and 
unvaccinated women or a number of countries or provinces. In such cases, the issue of 
comparator omission was sometimes apparent in some but not all populations. This analysis 
reports results for subgroups in which the issue of comparator omission is suspected.
The results are further illustrated by considering cost-effectiveness planes for four ex-
amples from the review. In three of these examples, additional points marking hypothetical 
costs and effects estimates for longer screening intervals show how the efficient frontier 
might change if additional comparators were included. The positions of these hypothetical 
comparators are informed by inference from other studies and the assumption of decreas-
ing marginal returns in terms of costs and effects as the screening interval is shortened.
results
First, an overview of the studies included in this review is presented, summarizing the 
simulated populations and strategies. The principal results of this review are then shown, 
detailing which studies have likely omitted relevant comparators. These results are then 
complemented with several specific examples to illustrate the issues in greater detail.
overview of eligible ceas
Details of the eligible studies are presented in Table 1. The 30 CEAs were published be-
tween 2002 and 2013. The most frequent countries of origin were the United States and The 
Netherlands with eight studies each, followed by Canada with five.
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The number of alternative screening strategies compared varies widely, ranging from 4 
to more than 1500. Four studies considered more than 100 strategies,8,14,42,46 and 21 studies 
considered fewer than 20 strategies.15,18,26,30–33,35,36,38,39,41,43,45,48–50,52–55
The intensity of screening varied widely. Of the 30 CEAs reviewed, all but 2 varied the 
screening interval.48,50 Fourteen studies considered only two or three alternative screening 
intervals.18,30–32,34,35,38–40,45,49,53–55 Furthermore, only eight studies considered intervals longer 
than 5 years, all of which were in European settings.8,15,33,36,37,41,46,52 Similarly, only 10 varied the 
screening age range.8,14,15,26,30,41,42,46,47,52 Some considered only small changes to the screening 
age range, whereas others considered much broader ranges of alternative start and stop 
ages. Among the studies with fixed screening age range, start ages between 18 and 30 years 
were typical, as were stop ages between 60 and 70 years.
Primary HPV screening was considered by all but four studies.34,44,48,52 Alternative triage 
strategies for borderline primary cytology or positive primary HPV test results were consid-
ered by 19 studies.8,14,31,32,34,35,40–48,52–55 Strategies featuring a switch from primary cytology 
screening with HPV triage to primary HPV with cytology triage partway through the screen-
ing program were considered by 12 studies.8,14,18,26,35,37, 40,42,43,45,48,53
The review also recorded which studies explained the rationale for the range of strategies 
compared, in particular the screening interval and the screening age range. Only two pro-
vided explicit justifications for the intervals considered.30,37 Both explained that the intervals 
compared were those of policy recommendations, although neither included any additional 
comparators with longer intervals to serve as comparators to the recommended strategies. 
Although the remaining studies did not explain the choice of strategies, many mentioned 
current guidelines, the status quo strategy, or the possibility of lengthening screening inter-
vals with HPV testing when describing what strategies were compared.8,14,15,26,31, 33–36,38–41,45–55
evidence of omission of relevant comparators
Table 2 presents the principal results of the review. It records the threshold and the associ-
ated optimal strategy including the optimal interval. Relevant comparators have likely been 
omitted in 18 of the 30 studies reviewed. These are recorded in the table as having “probably” 
omitting relevant comparators. In most cases, this conclusion is based on the observation 
that a longer screening interval than that found to be optimal was not included.
There are three exceptions to the general observation that studies without longer in-
tervals have omitted relevant comparators. Although Rogoza et al.52 does include longer 
intervals, the choice of screening age ranges is inconsistent between the alternative inter-
vals simulated. In particular, the annual interval found to be optimal has a relatively short 
screening age range of 25 to 60 years, whereas the triennial comparator modeled has an 
age range of 15 to 87 years. The inclusion of a triennial strategy with an age range closer to 
25 to 60 years would probably be relevant, as would a biennial comparator. Similarly, the 
choice of screening protocols is inconsistent between the intervals considered in Chen et 
al.38 because combined cytology and HPV testing is not simulated in all intervals considered. 
Furthermore, although annual cytology is found cost-effective relative to triennial cytology, 
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no biennial strategy is modeled; despite this, biennial screening is typically found to be 
a relevant comparator to annual screening in other studies. Finally, although Goldhaber-
Fiebert et al.42 do not include intervals longer than that identified as optimal for vaccinated 
women, the strategies found to be efficient at shorter intervals suggest that the broad range 
of screening age ranges and screening protocols simulated probably provide sufficient 
comparators to correctly estimate the ICER of the optimal strategy.
The likely omission of relevant comparators is quite distinct in some cases, such as Accetta 
et al.31 and Bidus et al.35 This is evidenced in part by a high ratio of the next efficient ICER to 
that of the optimal strategy. There are other cases in which the omission of comparators is 
much less certain. For example, although Burger et al.37, Kim et al.45, and Sherlaw-Johnson 
et al.53 all omit intervals longer than that found to be optimal, the ratio of adjacent ICERs 
in these cases is much lower and it is less certain whether the ICER of the optimal interval 
would change with the inclusion of additional comparators.
illustrative examples of omissions
Four examples are now presented to further illustrate the omission of relevant comparators. 
The first is one of the distinct examples of comparator omission provided by Accetta et 
al.31 It assessed four combinations of primary and triage testing at screening intervals of 3 
and 5 years. Note that although the original analysis considered vaccinated and vaccinated 
women together, we consider them separately. Figure 2A shows the estimates for unvac-
cinated women. There is a notably sharp kink in the frontier around the second efficient 
strategy as the ICER increases from €5,700/QALY to €68,400/QALY. This corresponds to the 
highest ratio of adjacent ICERs observed in this review of 11.8. Similarly kinked frontiers 
are also found in other analyses with few alternative intervals.32,49,53 Such kinked frontiers 
contrast with the gently curved frontiers found in analyses with a broader range of screen-
ing strategies.8,42
It is possible to anticipate how the frontier from Accetta et al.31 might appear if additional 
strategies with longer intervals of 6, 7, and 8 years were modeled. Figure 2B includes three 
markers showing hypothetical costs and effects estimates for such intervals. The frontier 
over these supposed points is marked with the dotted line. In such a case, the frontier 
would not be sharply kinked, but be more gently curved. Furthermore, it can reasonably 
be assumed that the ICER estimate of €5,700/QALY for the 5-year interval would be revised 
upward, meaning that the reported ICER is probably an underestimate.
The lack of sufficient comparators in Accetta et al.31 is easily identified from the noticeably 
kinked frontier. The same problem of insufficient comparators, however, can also be found 
in studies considering a broader range of strategies without obviously kinked frontiers. For 
example, Goldie et al.43 considers four combinations of primary and triage testing at inter-
vals of 1, 2, 3, and 4 years. The corresponding cost-effectiveness plane in Figure 3 has been 
rescaled for clarity, and the points representing no screening and the four annual screening 
strategies are not shown. Although the frontier appears gently curved, the figure shows that 
it is certainly possible that a 5-year interval strategy could lie to the southwest of the 4-year 
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Table 2. Assessment of reviewed studies for omission of relevant comparator strategies.
Study
Example 
Subgroup
Threshold 
Stated 
Explicitly Threshold Optimal Strategy Comparator
Interval 
longer 
than 
optimal 
interval 
simulated
Optimal 
Strategy 
ICER
Next 
Efficient 
Strategy 
ICER
ICER 
ratio 
between 
optimal 
and next 
efficient 
strategy
Relevant 
Comparators 
Omitted
Accetta et al. 
(2010)
Unvaccinated Yes €50,000/QALY HPV with cytology triage every 5 years Cytology with HPV triage every 5 years No €5,800/
QALY
€68,400/
QALY
11.8 Probably
Balasubramanian 
et al. (2010)
- No $50,000/QALY HPV with cytology triage every 3 years No screening No $9,900/
QALY
$70,200/
QALY
7.1 Probably
Berkhof et al. 
(2006)
- No €20,000/QALY Cytology with combined triage of 
cytology & HPV at 6 months, every 5 
years
Cytology with HPV triage followed by 
combined cytology & HPV testing at 6 & 
18 months, every 5 years
No €8,700/
QALY
€22,000/
QALY
2.5 Probably
Berkhof et al. 
(2010)
- Yes €20,000/QALY HPV with cytology triage every 5 years HPV with cytology triage every 6 years Yes €18,800/
QALY
€67,100/
QALY
3.6 Probably not
Bidus et al. (2006) - Yes $50,000/LYG Cytology with HPV triage every 3 years No screening No $5,100/
LYG
$56,700/
LYG
11.1 Probably
Bistoletti et al. 
(2008)
- No NAa Combined cytology and HPV testing 
every 9 years
NAa No Cost 
saving
NA - Probably
Burger et al. 
(2012)
Vaccinated Yes $83,000/LYG HPV with cytology triage every 6 years No screening, vaccination only No $80,000/
LYG
$92,000/
LYG
1.2 Probably not
Chen et al. (2011) - Yes $40,000/LYG Cytology alone annually Cytology alone every 3 years Yes $31,700/
LYG
NA Probably
Chow et al. 
(2010)
- Yes $1,620,000/
QALYe
HPV with cytology triage every 3 years HPV with cytology triage every 5 years Yes $1,357,700/
QALYe
$3,891,300/
QALYe
3.1 Probably not
Chuck (2010) - Yes $50,000/
QALYd
Cytology with cytology triage with HPV 
testing for women over 30 with ASCUS 
every 3 years
Cytology with cytology triage annually No Cost 
saving
$58,500/
QALYd
- Probably
Coupé et al. 
(2009)
- Yes €20,000/QALY HPV with cytology triage every 7.5 years HPV with cytology triage every 6 years Yes €11,100/
QALY
€26,700/
QALY
2.4 Probably not
Coupé et al. 
(2012)
- Yes €20,000/QALY HPV with cytology triage every 10 years Cytology with cytology triage every 10 
years
No €6,700/
QALY
€22,300/
QALY
3.3 Probably
Diaz et al. (2010) Vaccinated Yes €30,000/QALY Cytology with HPV triage every 5 years No screening €24,400/
QALY
€97,000/
QALY
4.0 Probably
Goldhaber-
Fiebert et al. 
(2008)
Vaccinated Yes $50,000-
$100,000/
QALY
Cytology with HPV triage switching 
to HPV with cytology triage at age 35 
every 5 years
Cytology with HPV triage switching to 
HPV every 5 years
No $41,100/
QALY
$126,100/
QALY
3.1 Probably not
Goldie et al. 
(2004)
- Yes $50,000/QALY Cytology with HPV triage every 4 years Cytology with cytology triage every 4 
years
No $20,600/
QALY
$95,300/
QALY
4.6 Probably
Kim et al. (2002) - No $50,000/LYG Cytology with reflex HPV triage every 
5 years
Cytology with co-collected HPV triage 
every 5 years
No $20,300/
LYG
$59,600/
LYG
2.9 Probably
Kim et al. (2005) UK Yes $30,200/LYG HPV and cytology combined testing 
every 5 years
Cytology with HPV triage every 5 years No $13,800/
LYG
$33,200/
LYG
2.4 Probably not
de Kok et al. 
(2012)
- Yes €20,000/QALY HPV with cytology triage every 6 yearsa HPV with cytology triage every 7 yearsa Yes €10,300/
QALYa
€21,130/
QALYa
2.1 Probably not
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Table 2. Assessment of reviewed studies for omission of relevant comparator strategies.
Study
Example 
Subgroup
Threshold 
Stated 
Explicitly Threshold Optimal Strategy Comparator
Interval 
longer 
than 
optimal 
interval 
simulated
Optimal 
Strategy 
ICER
Next 
Efficient 
Strategy 
ICER
ICER 
ratio 
between 
optimal 
and next 
efficient 
strategy
Relevant 
Comparators 
Omitted
Accetta et al. 
(2010)
Unvaccinated Yes €50,000/QALY HPV with cytology triage every 5 years Cytology with HPV triage every 5 years No €5,800/
QALY
€68,400/
QALY
11.8 Probably
Balasubramanian 
et al. (2010)
- No $50,000/QALY HPV with cytology triage every 3 years No screening No $9,900/
QALY
$70,200/
QALY
7.1 Probably
Berkhof et al. 
(2006)
- No €20,000/QALY Cytology with combined triage of 
cytology & HPV at 6 months, every 5 
years
Cytology with HPV triage followed by 
combined cytology & HPV testing at 6 & 
18 months, every 5 years
No €8,700/
QALY
€22,000/
QALY
2.5 Probably
Berkhof et al. 
(2010)
- Yes €20,000/QALY HPV with cytology triage every 5 years HPV with cytology triage every 6 years Yes €18,800/
QALY
€67,100/
QALY
3.6 Probably not
Bidus et al. (2006) - Yes $50,000/LYG Cytology with HPV triage every 3 years No screening No $5,100/
LYG
$56,700/
LYG
11.1 Probably
Bistoletti et al. 
(2008)
- No NAa Combined cytology and HPV testing 
every 9 years
NAa No Cost 
saving
NA - Probably
Burger et al. 
(2012)
Vaccinated Yes $83,000/LYG HPV with cytology triage every 6 years No screening, vaccination only No $80,000/
LYG
$92,000/
LYG
1.2 Probably not
Chen et al. (2011) - Yes $40,000/LYG Cytology alone annually Cytology alone every 3 years Yes $31,700/
LYG
NA Probably
Chow et al. 
(2010)
- Yes $1,620,000/
QALYe
HPV with cytology triage every 3 years HPV with cytology triage every 5 years Yes $1,357,700/
QALYe
$3,891,300/
QALYe
3.1 Probably not
Chuck (2010) - Yes $50,000/
QALYd
Cytology with cytology triage with HPV 
testing for women over 30 with ASCUS 
every 3 years
Cytology with cytology triage annually No Cost 
saving
$58,500/
QALYd
- Probably
Coupé et al. 
(2009)
- Yes €20,000/QALY HPV with cytology triage every 7.5 years HPV with cytology triage every 6 years Yes €11,100/
QALY
€26,700/
QALY
2.4 Probably not
Coupé et al. 
(2012)
- Yes €20,000/QALY HPV with cytology triage every 10 years Cytology with cytology triage every 10 
years
No €6,700/
QALY
€22,300/
QALY
3.3 Probably
Diaz et al. (2010) Vaccinated Yes €30,000/QALY Cytology with HPV triage every 5 years No screening €24,400/
QALY
€97,000/
QALY
4.0 Probably
Goldhaber-
Fiebert et al. 
(2008)
Vaccinated Yes $50,000-
$100,000/
QALY
Cytology with HPV triage switching 
to HPV with cytology triage at age 35 
every 5 years
Cytology with HPV triage switching to 
HPV every 5 years
No $41,100/
QALY
$126,100/
QALY
3.1 Probably not
Goldie et al. 
(2004)
- Yes $50,000/QALY Cytology with HPV triage every 4 years Cytology with cytology triage every 4 
years
No $20,600/
QALY
$95,300/
QALY
4.6 Probably
Kim et al. (2002) - No $50,000/LYG Cytology with reflex HPV triage every 
5 years
Cytology with co-collected HPV triage 
every 5 years
No $20,300/
LYG
$59,600/
LYG
2.9 Probably
Kim et al. (2005) UK Yes $30,200/LYG HPV and cytology combined testing 
every 5 years
Cytology with HPV triage every 5 years No $13,800/
LYG
$33,200/
LYG
2.4 Probably not
de Kok et al. 
(2012)
- Yes €20,000/QALY HPV with cytology triage every 6 yearsa HPV with cytology triage every 7 yearsa Yes €10,300/
QALYa
€21,130/
QALYa
2.1 Probably not
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Table 2 (continued). Assessment of reviewed studies for omission of relevant comparator strategies.
Study
Example 
Subgroup
Threshold 
Stated 
Explicitly Threshold Optimal Strategy Comparator
Interval 
longer 
than 
optimal 
interval 
simulated
Optimal 
Strategy 
ICER
Next 
Efficient 
Strategy 
ICER
ICER ratio 
between 
optimal 
and next 
efficient 
strategy
Relevant 
Comparators 
Omitted
Kulasingham et 
al. (2006)
Canada No $50,000/
QALYd
HPV with cytology triage every 3 years 
from age 18
HPV with cytology triage every 3 years 
from age 25
Yes $47,300/
QALYd
$72,000/
QALYd
1.5 Probably not
Legood et al. 
(2006)
- No £20,000-
30,000/
QALY
Cytology with combined triage 
of cytology & HPV & combined 
surveillance of cytology & HPV every 3 
to 5 years
Cytology with combined triage of 
cytology & HPV & surveillance of 
cytology alone every 3 to 5 years
No £18,600
/LYG
NA - Probably
Mandelblatt et al. 
(2002)
- No $50,000/QALY Cytology alone every 2 years Cytology alone every 3 years Yes $29,800/
QALY
$56,400
/QALY
1.9 Probably not
Maxwell et al. 
(2002)
- Yes $50,000/QALY Cytology with HPV triage every 3 years Cytology alone every 3 years No $14,300/
LYG
$65,500/
LYG
4.6 Probably
Mittendorf et al. 
(2003)
- No NA Combined cytology and HPV annually HPV alone annually No €298/
LYG
NA - Probably
Östensson et al. 
(2010)
- Yes €80,000/LYG HPV with HPV triage every 5 years No screening No €43,000/
LYG
€84,000/
LYG
2.0 Probably
Rogoza et al. 
(2008)
US Yes $50,000-
$100,000/
QALY
Cytology with cytology triage annually 
between ages 30-60
Cytology with cytology triage every 
5years between ages 15 and 85
Yes $47,700/
QALY
$178,100/
QALY
3.7 Probably
van Rosmalen et 
al. (2012)
- Yes €20,000/QALY HPV with cytology triage every 6 years HPV with cytology triage every 7 years Yes €10,300/
QALY
€21,130/
QALY
2.1 Probably not
Sherlaw-Johnson 
et al. (2004)
- No £20,000-
30,000/
QALY
Combined cytology & HPV with 
combined cytology & HPV triage every 
5 years
HPV with cytology triage every 5 years No £22,600/
LYG
£37,900/
LYG
1.7 Probably not
Sroczynski et al. 
(2011)
- No €33,000/QALY HPV alone every 2 years HPV alone every 3 years Yes €28,400/
LYG
€93,700/
LYG
3.3 Probably not
Vijayaraghavan et 
al. (2010)b
- No $50,000/
QALYd
HPV alone every 3 years Cytology alone every 3 years No $11,400/
QALYd
NA - Probably
Vijayaraghavan et 
al. (2010) c
- No $50,000/QALY Combined cytology & HPV with triage 
of HPV genotyping every 3 years
Combined cytology & HPV every 3 years No $33,500/
QALY
NA - Probably
Unless marked otherwise currencies are Euro, UK Pounds or US Dollars.
a Personal Communication
b  Vijayaraghavan at al (2010) Cost-effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screen-
ing in Québec, Canada; Can J Public Health
c  Vijayaraghavan at al (2010) Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical 
cancer screening. Gynecologic Oncology
d Canadian Dollars
e New Taiwan Dollar
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Table 2 (continued). Assessment of reviewed studies for omission of relevant comparator strategies.
Study
Example 
Subgroup
Threshold 
Stated 
Explicitly Threshold Optimal Strategy Comparator
Interval 
longer 
than 
optimal 
interval 
simulated
Optimal 
Strategy 
ICER
Next 
Efficient 
Strategy 
ICER
ICER ratio 
between 
optimal 
and next 
efficient 
strategy
Relevant 
Comparators 
Omitted
Kulasingham et 
al. (2006)
Canada No $50,000/
QALYd
HPV with cytology triage every 3 years 
from age 18
HPV with cytology triage every 3 years 
from age 25
Yes $47,300/
QALYd
$72,000/
QALYd
1.5 Probably not
Legood et al. 
(2006)
- No £20,000-
30,000/
QALY
Cytology with combined triage 
of cytology & HPV & combined 
surveillance of cytology & HPV every 3 
to 5 years
Cytology with combined triage of 
cytology & HPV & surveillance of 
cytology alone every 3 to 5 years
No £18,600
/LYG
NA - Probably
Mandelblatt et al. 
(2002)
- No $50,000/QALY Cytology alone every 2 years Cytology alone every 3 years Yes $29,800/
QALY
$56,400
/QALY
1.9 Probably not
Maxwell et al. 
(2002)
- Yes $50,000/QALY Cytology with HPV triage every 3 years Cytology alone every 3 years No $14,300/
LYG
$65,500/
LYG
4.6 Probably
Mittendorf et al. 
(2003)
- No NA Combined cytology and HPV annually HPV alone annually No €298/
LYG
NA - Probably
Östensson et al. 
(2010)
- Yes €80,000/LYG HPV with HPV triage every 5 years No screening No €43,000/
LYG
€84,000/
LYG
2.0 Probably
Rogoza et al. 
(2008)
US Yes $50,000-
$100,000/
QALY
Cytology with cytology triage annually 
between ages 30-60
Cytology with cytology triage every 
5years between ages 15 and 85
Yes $47,700/
QALY
$178,100/
QALY
3.7 Probably
van Rosmalen et 
al. (2012)
- Yes €20,000/QALY HPV with cytology triage every 6 years HPV with cytology triage every 7 years Yes €10,300/
QALY
€21,130/
QALY
2.1 Probably not
Sherlaw-Johnson 
et al. (2004)
- No £20,000-
30,000/
QALY
Combined cytology & HPV with 
combined cytology & HPV triage every 
5 years
HPV with cytology triage every 5 years No £22,600/
LYG
£37,900/
LYG
1.7 Probably not
Sroczynski et al. 
(2011)
- No €33,000/QALY HPV alone every 2 years HPV alone every 3 years Yes €28,400/
LYG
€93,700/
LYG
3.3 Probably not
Vijayaraghavan et 
al. (2010)b
- No $50,000/
QALYd
HPV alone every 3 years Cytology alone every 3 years No $11,400/
QALYd
NA - Probably
Vijayaraghavan et 
al. (2010) c
- No $50,000/QALY Combined cytology & HPV with triage 
of HPV genotyping every 3 years
Combined cytology & HPV every 3 years No $33,500/
QALY
NA - Probably
Unless marked otherwise currencies are Euro, UK Pounds or US Dollars.
a Personal Communication
b  Vijayaraghavan at al (2010) Cost-effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screen-
ing in Québec, Canada; Can J Public Health
c  Vijayaraghavan at al (2010) Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical 
cancer screening. Gynecologic Oncology
d Canadian Dollars
e New Taiwan Dollar
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interval strategy, which has an ICER of $20,600/QALY. If a 5-year interval strategy lay at the 
point marked with the pentagon, this would result in a higher ICER than $20,600/QALY for 
the 4-year interval strategy.
The omission of 5-year interval comparators in Goldie et al.43 is particularly relevant be-
cause the omitted strategies would likely form the most CEA-relevant part of the effi  cient 
frontier. As Goldie et al.43 note, although there is no established threshold in the United 
States, a value of $50,000/QALY is commonly used. The strategies with ICERs of $95,300/
QALY and above are not CEA-relevant because they exceed the threshold, whereas the 
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Figure 2A & B. Cost-eff ectiveness plane for unvaccinated women reinterpreted from Accetta et al. with 
the triangle and pentagons marking 3 and 5 year interval strategies respectively and panel B including 
hypothetical estimates for longer intervals of 6, 7 and 8 years and the possible change in the effi  ciency 
frontier.
QALY = quality-adjusted life year.
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$20,600/QALY strategy is optimal. Therefore, it is signifi cant that the inclusion of a 5-year 
interval comparator would probably infl ate this strategy’s ICER.
It is not possible to know how much greater the ICER of a 4-year strategy would be if a 
5-year interval was included. Had 4-year screening intervals been omitted, however, the 
ICER of the effi  cient 3-yearly strategy would be $23,500/QALY rather than $95,300/QALY. This 
large diff erence indicates how important the omission of comparators can be.
The importance of the CEA-relevant portion of the frontier is further illustrated by con-
trasting Goldie et al.43 with an example in which additional comparators would change the 
frontier, but not within the CEA-relevant range. Figure 4 graphs estimates for combinations 
of cytology and HPV testing at 2- and 3-year intervals from Mandelblatt et al.30 The 2-year 
strategy is optimal because it has the highest ICER within the threshold. The inclusion of a 
4-year interval comparator, represented here as a hypothetical estimate marked with the 
square, would probably increase the ICER of 3-yearly screening but not aff ect that of 2-yearly 
screening. So although the inclusion of additional comparators with longer intervals would 
likely change the frontier, the change is below the CEA-relevant portion and is therefore of 
little signifi cance.
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Figure 3. Cost-eff ectiveness plane from Goldie et al. showing the policy-relevant section of the effi  cient 
frontier with various screening strategies with dashes, triangles and squares representing intervals of 2, 
3 and 4 years respectively and the inclusion of a hypothetical strategy with an interval of 5 years marked 
with a pentagon.
QALY = quality-adjusted life year.
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The influence of the choice of comparator strategies can be further illustrated by showing 
how an analysis simulating a large range of screening alternatives differs when restricted to 
relatively in gray line in Figure 5 show the costs and effects estimates and efficient frontier 
for all strategies assessed in van Rosmalen et al.8 The costs and effects estimates for the 
dominated strategies were sourced through personal communication. The estimates have 
been rescaled to per-woman estimates from the original source for consistency with the 
other figures presented. This analysis includes a much wider range of screening intervals 
and age ranges than considered in most of the reviewed studies. The ICERs are included 
at three points on the frontier to illustrate the broad range of ratios estimated in this case. 
The analysis can be constrained to higher-intensity strategies typical of many of the studies 
included in this review. The black points and the black line show the estimates and frontier 
for strategies with intervals no longer than 5 years and screening age ranges that start no 
later and finish no earlier than ages 25 and 60 years, respectively.
Such a restriction omits very many of the efficient strategies from the complete analysis 
and finds strategies that are dominated in the complete analysis to be efficient. The opti-
mal strategies given the Dutch threshold of €20,000/QALY in the complete and restricted 
analyses are circled. The restricted analysis would lead to the selection of a program with 
eight rather than three lifetime screens that costs approximately 2.5 times more. Finally, 
the only efficient strategy common to both analyses is the most costly and most effective 
strategy. The restricted analysis estimates an ICER of €68,700/QALY for this strategy, whereas 
the unrestricted analysis finds a considerably higher ICER of €122,500/QALY.
excluding relevant comparators from the Base case
A secondary issue with the choice of comparators identified by this review is the exclusion of 
strategies from the base case that are simulated elsewhere in the analysis. This issue occurs 
in 5 of the 30 studies reviewed. Three studies featured additional strategies in secondary 
analyses that were not included in the base case.8,26,37 Importantly, some of these additional 
strategies dominate strategies found to be efficient in the base case. For example, Figure 5 
shows the cost-effectiveness estimates from van Rosmalen et al.8, including two strategies 
marked with the hollow squares considered in a sensitivity analysis in which the order of 
cytology and HPV testing between primary screening and triage is reversed at age 33 years.
Two other studies estimated costs and effects for a range of screening strategies, but 
excluded strategies that were less effective than the status quo when estimating ICERs, 
instead using the status quo as the comparator.33,40 Consequently, in both studies, the ICER 
estimate for one strategy is underestimated and the ICER estimates for some efficient strate-
gies are omitted.
These examples of exclusions of alternative strategies from the base case are analogous to 
the examples of comparator omission identified in Table 2. Relevant strategies or compara-
tors are omitted from the base-case analysis, meaning that what strategy is identified as 
optimal may be contingent on what analysts chose to compare.
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Figure 4. Cost-effectiveness plane from Mandelblatt et al. showing efficient frontier with dashes and 
triangles marking screening intervals of 2 and 3 years respectively and the inclusion of a hypothetical 
strategy with an interval of 4 years marked with a square.
QALY = quality-adjusted life year.
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Figure 5. Cost-effectiveness plane from van Rosmalen et al. for all strategies in the original analysis 
shown in grey and for a restricted set of strategies with shorter screening intervals and longer screening 
ages shown in black, with the optimal strategies for a given of threshold of €20,000/QALY circled in each 
case and two switching strategies considered in a sensitivity analysis marked by the hollow squares.
QALY = quality-adjusted life year.
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discussion
To date, there has been no systematic consideration of how cervical screening CEAs have 
addressed the expanded range of screening possibilities offered by HPV testing. This review 
adds to the literature by appraising the choice of comparator strategies in HPV screening 
CEAs with respect to the adequacy of ICER estimates. It has shown that many of these CEAs 
probably include insufficient comparator strategies to reliably estimate ICERs along the 
CEA-relevant portion of the efficient frontier. In particular, it is likely that many of the studies 
reviewed have not included strategies with sufficiently long screening intervals.
The omission of relevant comparators can lead to large errors in the ICER. The example 
from Goldie et al.43 shows that a fourfold difference in the ICER can result from the omission 
of a longer interval. Such differences are not trivial and could lead to the mistaken adoption 
of cost-ineffective strategies. Similarly, the example of van Rosmalen et al.8 shows that a 
restriction of the choice set could lead to the misidentification of an inefficient strategy as 
optimal and a 2.5-fold increase in screening costs.
Another problem identified in this review is that some CEAs exclude strategies from the 
base case, despite being shown to be relevant in secondary analyses. This could justifiably 
be considered a presentational issue rather than an analytical error. It should be acknowl-
edged, however, that such reporting creates scope for misinterpretation and may confuse 
decision makers regarding which strategies are cost-effective and which are not.
That many of the studies reviewed appear to include insufficient comparators is clearly a 
critical finding. It is however important to acknowledge a number of important caveats. The 
first is that subjective judgment is involved when deciding whether sufficient comparators 
have been simulated or not. Although the methods and evidence supporting this review’s 
conclusions have been documented, much relies on inference from previous studies re-
garding how the shape of the efficient frontier varies with screening intensity.
A second important caveat is that the conclusion of comparator omission depends in part 
on the cost-effectiveness threshold. The findings of this review would differ in particular 
cases if the threshold was different. For example, in the case of Goldie et al.43 if a threshold 
of $100,000/QALY was used instead of the $50,000/QALY, then the $95,300/QALY strategy 
would be optimal. Because this strategy is supported by sufficient comparators, this would 
reverse the conclusion that Goldie et al.43 probably includes insufficient comparators. Be-
cause very few countries have explicit thresholds, it is often unclear what the CEA-relevant 
portion of the efficient frontier is. In turn, this also means that the conclusion of comparator 
omission is less certain. An alternative perspective on this issue, however, is that if it is un-
clear what threshold applies, then it is arguably more incumbent on modelers to simulate a 
broad range of comparators because they should estimate the efficient frontier throughout 
the range of ICER values that might include the threshold.
A third important caveat concerns how policy relevance is defined and how this de-
termines modeling choices. This analysis explicitly considers policy relevance from the 
perspective of CEA and assumes that all technically feasible strategies are candidates for 
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simulation. What decision makers consider policy relevant, however, may of course depend 
on other factors and not all strategies may be judged feasible. Certain strategies may be 
considered infeasible if they represent a large reduction in screening intensity relative 
to current guidelines or what screened populations are accustomed to, especially if the 
expected health gains are less than those of current practice.
Indeed, differences in the screening status quo may help explain the omission of longer 
screening intervals in many studies. No North American study considered intervals longer 
than 5 years, whereas 8 of 17 European CEAs did. US and Canadian screening guidelines 
recommend cytology every 3 years,59,60 whereas the screening programs in the United 
Kingdom and The Netherlands feature 5-years intervals.9 It seems plausible that analysts are 
reluctant to simulate strategies with intervals much longer than current services.
Although alternative policy perspectives are certainly valid, it is less clear to what extent 
they should determine what comparators can and cannot be assessed. Indeed, if there are 
constraints on what policies are deemed feasible, then it seems important that CEA should 
be free to assess the implied incremental cost of these restrictions. For instance, even if 5 
years is the longest interval a decision maker judges feasible, it is probably still necessary to 
include a 6-year interval comparator against which to estimate its ICER. Without a 6-yearly 
comparator, the ICER of 5-yearly screening will likely be determined relative to no screening. 
Although this will probably yield a more favorable ICER, this seems unsatisfactory because 
no screening appears an even less feasible policy option than a 6-yearly interval. Allowing 
comparators to be excluded according to what is considered feasible means that ICERs may 
be arbitrarily determined by policymaker’s preferences rather than incremental differences 
in costs and effects.
A limitation of this review is that it has primarily addressed the omission of comparators 
with longer screening intervals that can often be readily identified from kinked frontiers. The 
omission of other relevant comparators may not always be obvious. For example, the results 
of van Rosmalen et al.8 indicate that shorter screening age ranges are also an important 
determinant of relevant screening intensity when specifying comparator strategies. This in-
sight, however, could not be discerned from a CEA that does not include shorter screening 
age ranges. The same applies to the finding that strategies in which the order of cytology 
and HPV testing is switched around age 30 years perform better than do strategies without 
switching. These other aspects of comparator choice that have not been addressed in such 
detail here are also relevant.
The concerns raised here about the validity of ICERs based on limited comparisons are not 
novel.4,61 As has been noted in the literature previously, however, the concern is not with the 
adequacy of CEA methods in principle, but their correct application in practice.62 The role of 
comparator strategies is particularly important in the case of screening, because unlike in 
the case of drug interventions in which the number of comparator interventions is typically 
finite, the variety of possible screening strategies means the choice of comparators is at the 
modeler’s discretion. It is notable that few of the analyses gave a justification for the range 
of strategies compared, possibly indicating that analysts are not explicitly aware of its sig-
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nificance in determining estimates. The issues raised here regarding comparator omission 
apply equally to CEAs of other interventions with multiple possible comparators, including 
breast and colorectal screening, within which kinked frontiers can also be found.63–65
The observations of this review can be distilled into a simple three-item checklist to avoid 
some of the problems described above. First, check whether the efficient frontier features 
marked kinks rather than being gently curved because this may indicate the omission 
of relevant comparators. Second, ensure that the analysis includes sufficient comparator 
strategies against which to reliably estimate the ICERs of the CEA-relevant strategies; ideally, 
the screening interval should be progressively increased in annual increments so a range 
of ICERs is achieved that extends from well below the cost-effectiveness threshold to well 
above it. Finally, verify that all the relevant strategies simulated are included in the base-case 
analysis.
conclusions
The importance of including relevant comparators has long been recognized, both in 
CEA in general and in the particular context of screening. Nevertheless, this review found 
that many CEAs of HPV screening would probably benefit from modeling more screening 
strategies, especially those of longer intervals. Hopefully, by drawing attention to specific 
examples within the literature, this review will refresh the attention of CEA analysts to the 
need to choose comparators carefully. Similarly, this analysis will hopefully help decision 
makers critically interpret CEA results an d to be aware of the implications of the choice 
of comparator strategies for ICER estimates. Doing so will bring easy-to-achieve enhance-
ments to the reliability of cost-effectiveness evidence, which, in turn, will support better, 
more efficient screening policies for cervical cancer and other diseases.
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aBstract
Background: It is well acknowledged that HPV testing should not be performed at young 
age and at short intervals. Cytological screening practices have shown that over-screening, 
i.e. from a younger age and at shorter intervals than recommended, is hard to avoid. We 
quantified the consequences of a switch to primary HPV screening for over-screened 
women, taking into account its higher sensitivity but lower specificity than cytology.
Methods: The health effects of using the HPV test instead of cytology as the primary screen-
ing method were determined with the MISCAN-Cervix model. We varied the age women 
start screening and the interval between screens. In the sensitivity analyses, we varied the 
background risk for cervical cancer, the HPV prevalence, the discount rate, the triage strat-
egy after cytology and the test characteristics of both cytology and the HPV test.
Results: For women screened 5-yearly from age 30, 32 extra deaths per 100,000 simulated 
women were prevented when switching from primary cytology to primary HPV testing. For 
annual screening from age 20, such a switch resulted in 6 extra deaths prevented. It was 
associated with 9,044 more positive primary screens in the former scenario versus 76,480 in 
the latter. Under all conditions, for women screened annually, switching to HPV screening 
resulted in a net loss of quality-adjusted life years.
Conclusion: For over-screened women, the harms associated with a lower test specific-
ity outweigh the life years gained when switching from primary cytology to primary HPV 
testing. The extent of over-screening should be considered when deciding on inclusion of 
primary HPV screening in cervical cancer screening guidelines.
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introduction
In several Western countries, cytological screening has considerably reduced the cervical 
cancer incidence and mortality over the past four decades.1 Nevertheless, even in countries 
with a nationwide screening program, women still die from cervical cancer. Although most 
deaths occur after age 30 and in women who did not adequately participate in screen-
ing, some deaths occur at young age and in women who recently received a negative test 
result (which suggests it was false negative).2-4 Therefore, clinicians may tend to screen more 
frequently than recommended.5
Ever since infection with the human papillomavirus (HPV) was found to be a necessary 
condition for developing cervical cancer,6,7 testing for the presence of high-risk HPV types 
(i.e., carcinogenic types) has received much attention. A summary of meta-analyses esti-
mated that the HPV test has a 23% (95% CI: 13 to 33%) higher sensitivity, but a 6% (95% 
CI: 4 to 8%) lower specificity than cytology for detecting high-grade lesions and cervical 
cancer.8 Cost-effectiveness analyses based on these findings have shown that in well-
controlled screening situations primary HPV screening is likely to be more effective, as well 
as more cost-effective than primary cytology.9,10 Therefore, many countries are considering 
a switch from primary cytology to primary HPV screening. In the US, co-testing (i.e. cytology 
combined with HPV testing) is already recommended, and Australia and the Netherlands 
are preparing a switch from primary cytology to primary HPV screening.11-13
For primary cytology it is known that over-screening, here defined as screening from 
a younger age or at shorter intervals than recommended, is neither required to detect 
progressive lesions in an early phase nor desired as it detects many regressive lesions. Un-
avoidably, it also involves more false-positive test results, adding to the psychological stress 
women may experience from having a positive test and being referred for colposcopy.14 
In addition, the costs of over-screening are substantial; amounting to approximately 0.5-1 
billion USD per year for the US healthcare system, while yielding little or no health gains.15
Because of its lower specificity to detect clinically relevant lesions, avoiding over-screening 
is even more essential for HPV screening than for cytology screening. The vast majority of 
HPV infections clear spontaneously, especially at young age.16 Detecting these infections 
leads to unnecessary triage situations or referrals to colposcopy. For over-screened women, 
switching to HPV (co-)testing may therefore do more harm than good.
Guidelines driven by rational decision making tend to restrict cytology screening–and 
HPV screening even more so. The US guidelines currently recommend cervical screening 
in women aged 21 to 65 years with an interval of 3 or 5 years (dependent on both age 
and test).17 In European guidelines, primary HPV screening is recommended for women 
aged ≥35 and discouraged for those below the age of 30.18 In the Netherlands, primary HPV 
screening will be offered from age 30 to 65 every 5-10 years, and in Australia from age 25 to 
69 every 5 years.11,13 Unfortunately, also for HPV screening, having well-considered screening 
policy recommendations will not guarantee that women are screened accordingly.
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A recent US study showed that over 68% of physicians would recommend another 
cytological test in 1 or 2 years where the guidelines recommend a 3-year interval.19 After 
a negative co-test, 67-94% of clinicians recommended a shorter screening interval than 
suggested by US guidelines.20 Several European countries also have reported considerable 
over-screening.21 In summary, large proportions of women are being over-screened with 
cytology, and this is likely to continue when HPV screening is implemented.
Notwithstanding these facts, HPV testing is, for good reasons, increasingly often included 
in primary screening recommendations. However, despite its lower specificity, we are un-
aware of intensified efforts to minimize the level of over-screening. In this study, we aim 
to quantify the harms and benefits of introducing primary HPV screening for women with 
diverse screening behaviors, with age of first screen ranging from 20 to 30 years, and screen-
ing interval from 1 to 5 years. These scenarios cover both recommended schedules and 
observed levels of over-screening. The results of this study show the effects of introducing 
HPV screening for over-screened women, as well as for those who adhere to guidelines. 
Although the model was based on Dutch data, the resulting outcomes are important for 
all over-screened women, regardless of where they live. Since it seems too early to draw 
conclusions on the effect of switching to HPV screening in over-screened women who have 
been vaccinated, this analysis only considers unvaccinated cohorts.
methods
Health effects of different screening scenarios were estimated using the MISCAN-Cervix 
model, which is described in more detail in the Model appendix.22
miscan-cervix model
MISCAN-Cervix is a microsimulation model in which a large study population with individual 
life histories is generated. In all of the analyses presented here, we simulated a 20-year-
old cohort of 100 million women with life expectancy as observed in the Netherlands,23 
which was not affected by HPV vaccination (neither directly nor through herd immunity). A 
fraction of these women will acquire HPV infections and/or develop cervical intraepithelial 
neoplasia (CIN) lesions. If these precursors progress to cervical cancer, the result may be 
death. Screening can detect the disease, which can then be treated at an earlier stage. As a 
result, cervical cancer death may be prevented or postponed.
In the model, the disease development is in seven sequential stages: high-risk HPV in-
fection, three pre-invasive stages (CIN 1, 2, and 3), and three invasive stages (International 
Federation of Gynecology and Obstetrics (FIGO) stages IA, IB and II or worse). Whereas pre-
invasive and FIGO IA stages can only be diagnosed by screening, because at these stages 
women are assumed to be symptom-free, FIGO IB or worse can also be clinically diagnosed. 
As precursors are usually not progressive,24 over 90% of modeled HPV infections clear 
without ever resulting in neoplasia and most pre-invasive lesions regress spontaneously. In 
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the hypothetical situation without competing other-cause mortality, undetected preclinical 
invasive neoplasia will always progress to clinical cancer. CIN grades 1 and 2 can develop in 
the absence of a high-risk HPV infection; in that case the lesion will always regress. CIN grade 
3 or worse can only develop if a high-risk HPV infection is present.
triage strategies
For primary HPV screening and primary cytology we used a cost-effective triage strategy, as 
published previously.9 Primary cytological test results classified as atypical squamous cells 
of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion are 
immediately followed by an HPV test using the same material. A positive primary HPV test is 
immediately followed by cytology using the same material. If no cytological abnormalities 
are found, another cytological test is performed after 6 months.
Although the latter strategy will also be implemented in the Dutch screening program in 
2017, triage strategies were not selected based on guidelines or current practice. Instead, 
we decided to select strategies based on cost-effectiveness, such that inefficiencies in triage 
strategies would not dilute or exaggerate the effect of switching to HPV screening. The 
triage practices of over-screened women are unknown and might be very heterogeneous. 
It seems unlikely that women who do not follow primary screening guidelines, do follow 
the exact triage recommendations. We therefore chose to simulate a relatively simple triage 
strategy for both primary tests, and to focus on the number of positive primary tests (i.e., 
those that require follow-up) instead of on the number of triage tests.
screening scenarios
We simulated 12 cohorts with different screening behaviors, varying the age at which 
women start screening (20, 25, or 30 years) and the frequency with which they get tested 
(every 1, 2, 3, or 5 years). In all scenarios, screening was assumed to end at or before the 
age of 65.17,25 The resulting outcomes are only relevant for women having the screening 
behavior as modeled, and should not be translated to an entire population.
assumptions for screening and treatment
Table 1 presents the base-case assumptions for screening. We assumed the sensitivity 
of cytology (that is, the probability that the result is at least ASCUS) to be 40% for true 
stage CIN grade 1, 50% for CIN grade 2 and 75% for CIN grade 3 or cancer.26 In the model 
calibration, the sensitivity of testing for at least high-grade squamous intraepithelial lesion 
(HSIL), the cytological cut-off for referral to colposcopy, and therefore for detection, was 
estimated to be 4% for CIN grade 1, 18% for CIN grade 2, 56% for CIN grade 3 and 60% for 
cervical cancer. Furthermore, the specificity of cytology was estimated to be 97.6% based 
on Dutch data.27 Based on the observed difference in CIN grade 3 or cancer detection rates 
between cytology and the HPV test, we assumed the sensitivity of the HPV test to be 94% 
for a high-risk HPV infection.28 As we assumed that cervical cancer can only develop if an 
HPV infection is present, the sensitivity for cervical cancer is also 94%. The overall sensitivity 
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for CIN lesions is lower and depends on the age-specific prevalence of HPV infections in CIN 
lesions. In the model, the specificity for detecting high-risk HPV infections was assumed to 
be 100%. A probable (but unknown) lack of specificity was accounted for by the inclusion of 
fast-clearing infections, in concordance with HPV clearing studies.29,30
Table 1. Base-case model inputs and variations in the sensitivity analyses.
Parameter Base-case value Alternative 
value(s)
Background risk of cervical cancer mortality 5 per 100,000 life 
years
10 per 100,000 life 
years
HPV prevalence in women without CIN grade 2 or worsea Low Highb
Sensitivity of cytology
Probability of at least ASCUS (at least triage) for:
CIN grade 1 40%26 32%
CIN grade 2 50%26 40%
CIN grade 3 or worse 75%26 60%
Probability of at least HSIL (referral for colposcopy) for:
CIN grade 1 4%c 3%
CIN grade 2 18%c 14%
CIN grade 3 56%c 45%
Cervical cancer 60%c 48%
Specificity of cytologyd 97.6%c 95.2%
Sensitivity of HPV teste 94%28 85%8, 100%8
Specificity of HPV test 100%f Not varied as suchg
Discounting 3%31 0%, 5%
HPV = human papillomavirus; CIN = cervical intraepithelial neoplasia; ASCUS = atypical squamous cells of undeter-
mined significance; HSIL = high grade squamous intraepithelial lesion.
a Depends on age, age-dependency was not varied.
b The number of false-positive referrals to colposcopy and CIN 1 lesions was doubled.
c Value was determined in model calibration.
d Probability of a normal test result in women without CIN or cancer.
e Probability to detect an HPV infection, regardless of whether a CIN lesion or cancer is present.
f A possible lack of specificity was modeled by including fast-clearing HPV infections.
g  As a lower specificity of the HPV test corresponds with a higher prevalence of harmless HPV infections in the model, 
this parameter was not varied.
Detection and management of pre-invasive lesions, including treatment if necessary, 
was assumed to lead to a 100% cure rate. However, new HPV infections and recurring 
CIN lesions after CIN treatment cannot be excluded. For invasive cancer, we determined 
age-specific and stage-specific survival probabilities based on data from the Netherlands 
Cancer Registry.31 Since cancers detected by screening are usually at a less advanced stage 
than clinically diagnosed ones, women have a higher chance to survive them. If an invasive 
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cancer is screen-detected, the probability to die from cervical cancer is reduced by 89.4%, 
50% and 20% when detected in FIGO stages IA, IB and II or worse, respectively.
Table 2 presents the utility losses assumed in the base-case scenario. A small (psychologi-
cal) loss in quality of life is assumed for attending a screen (including waiting for the result) 
and for being in triage (including attending follow-up screenings). Larger losses in quality 
of life are assumed for being diagnosed and treated for CIN or cancer and for having a 
terminal stage of cervical cancer. We based the utility losses on nationally and internation-
ally published data.32-35
Table 2. Model inputs regarding the utility loss due to screening, treatment and terminal care.
Disutility Duration Quality-adjusted time 
lost
Screening34
Primary screening 0.005 2 weeks 2 hours
Being in triage 0.005 0.5 yeara 22 hours
False-positive referral 0.005 0.5 year 22 hours
Treatment of pre-invasive lesions33
CIN grade 1 0.03 0.5 year 6 days
CIN grade 2 or 3 0.07 1 year 26 days
Cancer treatment32,33 and terminal care35
FIGO stage I 0.062 5 years 4 months
FIGO stage II+ 0.280 5 years 17 months
Terminal care 0.740 1 year 9 months
CIN = cervical intraepithelial neoplasia; FIGO = International Federation of Gynecology and Obstetrics.
a Time between primary and triage test is 6 months.
Base-case analysis
For every scenario, we first estimated health effects of both primary cytology and primary 
HPV testing as compared to the situation without screening. Then, differences in health 
effects between these two interventions were explored. A first indication of the harm-
benefit balance of introducing primary HPV testing is given by the number of additional 
positive primary screens (i.e., at least ASCUS for cytology screening and HPV-positive for HPV 
screening) that is required to prevent one additional cervical cancer death. As women with 
a positive primary screen require follow-up in terms of triage or colposcopy, we refer to this 
outcome measure as ‘Number Needed to Follow-up’, or NNF.
Comparing the life years lost to cervical cancer between the two interventions yields 
the number of life years gained by switching to the more sensitive primary HPV testing. 
Similarly, the difference in total disutility due to screening and treatment caused by these 
interventions can be computed. As the number of quality-adjusted life years (QALYs) gained 
combines these positive and negative effects of screening, this outcome measure was used 
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to compare the total health effects of primary HPV screening with those of primary cytology. 
Health effects were discounted to the year in which all women are 20 years old, using an 
annual rate of 3%.36
sensitivity analyses
Some model parameters may have a non-negligible level of uncertainty, while others differ 
among countries or geographical regions. In one-way sensitivity analyses, we varied these 
types of parameters, covering for high-income countries, if they would influence the dif-
ference in health effects between primary HPV screening and primary cytology (Table 1).
Among Dutch women, the assumed background risk of dying from cervical cancer is 
relatively low (5 deaths per 100,000 life years). We have doubled this risk to determine the 
effects for countries with a higher risk.
To observe the effect of a higher prevalence of harmless HPV infections, we have doubled 
the number of referrals that did not result in the detection of a clinically relevant lesion 
(i.e., CIN 2+). Detecting more harmless HPV infections implicitly corresponds with a lower 
clinically relevant specificity of HPV testing.
Presumably, the high level of quality assurance in the Netherlands contributes to a rela-
tively high quality of cytology compared to less controlled situations. To explore the impact 
of switching to HPV testing for settings with a lower quality of cytology, the sensitivity of 
cytology in both primary and triage testing was reduced by 20% in one of the sensitivity 
analyses. In another sensitivity analysis, the lack of specificity of cytology in both primary 
and triage testing was doubled from 2.4% to 4.8%.
Some uncertainty exists about the sensitivity of the HPV test, which may also vary be-
tween tests and situations. A summary of meta-analyses found that the relative sensitivity of 
the HPV test as compared to cytology is 1.23 (95% CI: 1.13 to 1.33). Based on this confidence 
interval, the sensitivity of the HPV test was assumed to be 85% in one of the sensitivity 
analyses, and 100% in another.8 As these are assumed probabilities to detect an HPV infec-
tion, and women with a CIN lesion are not necessarily HPV infected, the sensitivity for CIN 
lesions is still lower than 100% in the latter scenario.
In another sensitivity analysis, the triage strategy after a positive cytological test was 
adjusted to reflect current Dutch screening guidelines. According to these guidelines, 
women with HSIL are directly referred for colposcopy and women with ASCUS or low-grade 
intraepithelial lesion (LSIL) are invited for cytology and HPV triage after 6 months. Women 
testing HSIL or ASCUS/LSIL and HPV-positive at this point in time will be referred for col-
poscopy, and women testing either ASCUS/LSIL or HPV-positive will be invited for another 
cytological test at 18 months.
Lastly, as reported discount rates vary from 0% to 5%, we also present the health effects 
when using an annual discount rate of 0% and of 5%.
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results
Base-case analysis
For the 12 different screening scenarios considered, Table 3 shows the impact of replacing 
primary cytology with primary HPV screening. The numbers are based on the undiscounted 
results of primary cytology and primary HPV screening compared to the situation without 
screening, as displayed in Appendix Tables 1 and 2, respectively. Although in practice it 
is very unlikely that the start age is well-controlled while the screening interval is not, we 
first discuss the effects of switching to HPV testing in women who start screening at age 30 
and have repeated testing at intervals that are either recommended or shorter than recom-
mended. Then, we discuss the effects of switching for women who are not only screened 
more frequent than recommended, but also from a younger age.
Frequent screening from age 30
For 5-yearly screening starting at age 30, replacing primary cytology with primary HPV 
screening reduced the number of cervical cancer deaths by 32 per 100,000 simulated 
women, which was a reduction of 27% (Figure 1, Table 3). This reduction was achieved 
at the expense of 9,044 more positive primary screens per 100,000 women (+34%), result-
ing in 2,572 more referrals to colposcopy (+29%). With annual screening in the same age 
range, switching to primary HPV screening would prevent only 7 extra deaths per 100,000 
women (-9%), while positive primary screens would increase by 14,271 (+14%), and referrals 
to colposcopy by 3,477 (+19%). The (discounted) NNF was 769 in the first scenario versus 
11,880 in the latter, more intensive one (Table 4).
Frequent screening from age 20
With annual screening starting at the age of 20 instead of 30, switching from primary cytol-
ogy to primary HPV screening resulted in similar benefits (i.e., 6 additional deaths prevented 
per 100,000 women (-9%)). However, the number of women with a positive screen test 
increased by 76,480 instead of by 14,271 per 100,000 women. The NNF equaled 60,133, 
which was more than 5 times the NNF of switching in case of annual screening from age 
30, and more than 78 times the NNF of switching in case of 5-yearly screening from age 30.
Changes in QALYs
Table 5 shows the QALYs gained (or lost) by switching from primary cytology to primary HPV 
screening for the diverse screening behaviors. Under base-case assumptions, a substantial 
number of QALYs were gained for women who were screened every 5 years from age 30. For 
more intensively screened women, the benefit of switching to HPV screening was uncertain. 
For women screened annually or biennially from any age, or triennially from age 20 or 25, 
replacing primary cytology with primary HPV testing even resulted in a net health loss.
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sensitivity analyses
In all sensitivity analyses, primary HPV screening prevented more cervical cancer deaths 
than did primary cytology. In most scenarios, this occurred at the expense of more positive 
screens, and the NNF increased quite rapidly with the intensity of the screening scenario 
(Table 4). Only when the specificity of cytology was assumed to be lower (95.2% instead 
of 97.6%), for some levels of over-screening the number of positive screens decreased with 
the shift to primary HPV testing. The discount rate appeared to have the largest impact on 
the NNF.
In the sensitivity analyses, switching to primary HPV testing resulted in fewer QALYs 
gained in the case of more intensive screening. Overall, for a given level of over-screening, 
whether QALYs were gained or lost did not vary substantially among the sensitivity analyses. 
Generally, switching was favorable for women screened every five years, and unfavorable for 
those screened annually or biennially. However, when cytology was triaged as is currently 
recommended in the Dutch screening program or when health effects were not discounted, 
switching to HPV screening also resulted in QALYs gained for women screened biennially 
from age 30. For women screened every 5 years from age 20-25, QALYs were lost when the 
HPV prevalence was increased and when results were discounted at an annual rate of 5%.
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Figure 1. Simulated increase in lifetime number of deaths from cervical cancer prevented (left axis) and 
positive primary screens (right axis) when primary cytology is replaced with primary HPV screening. The 
increase in positive primary tests is split up in referrals to colposcopy (dark grey) and non-referrals to 
colposcopy (light grey). Undiscounted results for different start ages and intervals of screening are given 
per 100,000 women.
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discussion
Even in countries with carefully constructed screening guidelines, women may be over-
screened. As for over-screened women the risk for cervical cancer is already strongly reduced 
with primary cytology, the gains of switching to primary HPV screening are expected to be 
relatively small. Indeed, our analysis predicted that while switching would prevent 32 deaths 
per 100,000 women who are screened every 5 years, only 6-7 deaths would be averted in 
those screened annually. In the latter group, the increase in positive tests and subsequent 
follow-up procedures even resulted in a net loss in health.
Because the same conclusion was reached in all of the sensitivity analyses, it is likely 
generalizable to other developed countries. The lower the ratio of HPV prevalence to cervi-
cal cancer mortality risk, the less harmful HPV testing will be for over-screened women. 
The sensitivity analysis in which we doubled the lifetime risk of dying from cervical cancer 
Table 4. Number of additional positive primary screens per additionally prevented cervical cancer death 
(NNF) when primary cytology is replaced with primary HPV screening, for the base case and eight sensi-
tivity analyses.a
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a  Numbers were discounted with an annual rate of 3%, unless stated otherwise.
b  The number of women with a false-positive result or CIN 1 was doubled to account for a higher HPV prevalence 
among these women.
c  The number of positive primary screens decreased with switching to HPV screening.
d  The current Dutch screening program involves triage testing at 18 months after the primary test, which, for annual 
screening, interferes with the next screening round.
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showed that it would still be harmful if this ratio would be twice as low as in the Nether-
lands though. In countries with an even lower HPV prevalence to cervical cancer mortality 
risk ratio, switching to HPV testing might be beneficial for over-screened women. In the 
US, however, both HPV prevalence and cervical cancer mortality are comparable to the 
Netherlands.37,38 In most European countries, cervical cancer mortality is higher,39 but HPV 
prevalence is also (up to) twice as high.38
Obviously, the goal of a cancer screening program is to decrease the disease’s incidence 
and mortality rate. Because in every simulated scenario switching from primary cytology 
to primary HPV screening reduced the number of cervical cancer cases and deaths, one 
could argue that primary HPV screening should always be preferred. This would indeed be 
true if being in triage, being referred to colposcopy, and being treated for CIN would not be 
associated with losses in quality of life. However, the health-related burden of these events 
is a drawback of screening that should not be overlooked.40,41
A number of randomized controlled trials (RCTs) have compared primary cytology screen-
ing to either HPV screening alone or to HPV screening combined with cytology.42-45 In these 
RCTs, HPV screening resulted in a higher detection rate of CIN lesions and an improved 
protection against cervical cancer.46 CEAs based on these findings showed that primary 
HPV screening with an interval of at least three years is cost-effective for women above age 
30.9,47 We showed that the effectiveness is questionable if this cannot be guaranteed. In 
this regard, data from a US population-based registry showed that recommending 3-yearly 
cytology screening resulted in a median time between two consecutive smears of 1.87 years 
in 2011.48 There is no reason to assume that guidelines regarding primary HPV screening 
would be followed more closely. In fact, a study from 2010 found a lower adherence to 
guidelines after a negative co-test as compared to after a negative cytological test.19 Al-
though co-testing is intended for women who want to extend their screening interval from 
3 to 5 years, many clinicians provide it on an annual basis.19
Switching to HPV screening could be considered more effective for women with that level 
of over-screening for which HPV screening was associated with a net health benefit, but 
this would not necessarily be more cost-effective. However, the decision to include primary 
HPV screening in national screening guidelines should take into account its population-
level cost-effectiveness. If only a relatively small number of women are over-screened, then 
switching to HPV screening may well be (very) cost-effective on a population level. In the 
Netherlands, given the small number of smears taken outside the screening program,49 it is 
expected to be cost-effective.
strengths and limitations
Even though earlier research showed that primary HPV screening is more cost-effective than 
primary cytology for women who adhere to screening guidelines,10,50 this is the first study 
to quantify its harms and benefits for over-screened women. As over-screening practices 
are likely to remain, these results are relevant to any country considering recommending 
primary HPV screening, either alone or as a co-test.
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Our study also has some limitations. First of all, our model is based on Dutch data. Al-
though it might have been better to adjust the model for every single country, we did vary 
those country-specific parameters that would influence the conclusion. For example, we 
increased the HPV prevalence level to estimate effects for high HPV prevalence countries 
such as Denmark.51 We did not modify the prevalence age distribution as the peak between 
the ages of 20 and 30 has also been observed in other European countries and in the United 
States.51,52
Although we varied test characteristics to explore the effect of switching to HPV 
screening for different settings, the ranges considered are not representative for low- and 
middle-income countries, where sustaining cytology programs of sufficient quality is often 
difficult.53,54 As the test characteristics are only one of many factors that may be different in 
those countries, separate analyses are needed for these situations.
Meta-analyses have shown that removal of CIN lesions carries an increased risk of having 
pre-term births.55,56 We did not include this potential harm because estimates of the impact 
on a woman’s quality of life are unavailable. If we would have accounted for this in our 
analyses, in over-screened women even more QALYs would have been lost by switching to 
primary HPV screening.
Although there are numerous possible triage strategies for cytology and HPV testing, in 
the base-case analysis we only considered two that were found to be cost-effective in a 
previous analysis.9 In a sensitivity analysis we did explore the impact of switching from the 
less efficient cytology screening strategy that is currently recommended in the Netherlands 
to the cost-effective HPV screening strategy that will be implemented in 2017. When these 
less efficient cytology practices were assumed, switching to HPV testing was obviously more 
beneficial. Nevertheless, it still resulted in a net health loss for women screened biennially 
from age 20-25 or triennially from age 20 (effects for annually screened women were not 
evaluated for this triage strategy). If future triage practices would be much more efficient 
than current ones, then switching to HPV testing might be considered beneficial for over-
screened women, but this would be due to more efficient triage procedures rather than to 
an improved performance of the primary test.
Lastly, we did not consider a co-testing strategy, which is already recommended in the 
US for women aged 30-65 years.12,17,57 Co-testing results in more screen positives than does 
primary HPV screening because HPV negative smears can still be cytology positive. From re-
sults of an RCT performed in the Netherlands, where women aged 30-60 years are screened 
every 5 years, we calculated that the number of screen positives would be 33% higher with 
co-testing than with primary HPV screening.28 As a consequence, the number of screen-
detected CIN 3 lesions or cancer would be 7% higher. In an RCT performed in the UK, in 
which women aged 20-64 years were screened with an interval of 2 to 4 years, the number 
of screen positives would have been 46% higher with co-testing as compared to primary 
HPV screening, while the number of screen-detected CIN 3 lesions would have been only 
3% higher.58 For intensively screened women, co-testing can potentially prevent slightly 
more cervical cancer cases than primary HPV screening, but the utility loss associated with 
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the additional positive screens probably outweighs these minor gains. Therefore, co-testing 
is expected to be even more harmful than primary HPV screening alone for over-screened 
women.
conclusion
We determined the pros and cons of replacing primary cytology with primary HPV screen-
ing for women who are over-screened: i.e., from a younger age and with a shorter screen-
ing interval than recommended. Although in all scenarios more deaths would be averted 
by screening primarily with the HPV test, the negative effects outweighed the benefits. 
We may conclude that irrespective of costs, it is disputable to recommend primary HPV 
screening, either alone or as a co-test, as long as a substantial part of the population is still 
over-screened. A well-organized and structurally monitored screening program, in which 
primary tests taken outside the program are not reimbursed by the government, could 
help minimizing the number of tests taken outside the program, thereby limiting the level 
of over-screening.21,59 One may consider to first further develop strategies to reduce over-
screening, or at least give it high priority when issuing guidelines including primary HPV 
screening.
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Appendix Table 1. Effects of primary cytology for 12 different screening scenarios; undiscounted num-
bers per 100,000 simulated women.
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5 years
30 739,525 26,923 8,868 742 2,819 2,015 3,174 398 121
25 840,937 32,721 12,139 988 3,980 2,893 4,177 358 116
20 941,786 37,492 14,305 1,148 5,144 3,451 4,465 352 115
3 years
30 1,118,531 38,434 11,168 1,108 4,106 2,609 3,268 332 114
25 1,315,382 47,706 15,619 1,540 5,868 3,778 4,377 269 100
20 1,511,580 56,297 19,192 1,838 7,934 4,722 4,658 244 91
2 years
30 1,674,942 54,320 13,581 1,609 5,634 3,110 3,172 272 96
25 1,971,111 66,941 19,192 2,259 8,003 4,489 4,238 209 82
20 2,183,094 76,854 23,484 2,703 10,818 5,618 4,321 215 90
1 year
30 3,346,636 99,553 18,556 3,116 9,033 3,658 2,708 222 79
25 3,858,503 118,972 25,785 4,380 12,625 5,236 3,530 176 75
20 4,368,263 138,478 32,507 5,377 17,425 6,540 3,159 166 75
CIN = cervical intraepithelial neoplasia.
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Appendix Table 2. Effects of primary HPV screening for 12 different screening scenarios; undiscounted 
numbers per 100,000 simulated women.
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30 740,539 35,968 11,440 1,050 4,470 2,737 3,103 283 89
25 842,392 50,462 15,881 1,485 6,290 3,933 4,113 242 84
20 943,593 59,784 19,052 1,730 8,223 4,733 4,312 234 84
3 years
30 1,119,883 49,809 14,100 1,550 6,353 3,261 2,883 265 95
25 1,317,518 72,465 19,951 2,294 9,053 4,729 3,847 204 82
20 1,514,489 88,945 24,890 2,769 12,327 5,907 3,866 179 74
2 years
30 1,676,921 66,962 16,802 2,218 8,391 3,546 2,605 231 83
25 1,974,315 98,656 23,801 3,330 11,894 5,121 3,440 170 71
20 2,187,117 122,053 29,800 4,075 16,185 6,351 3,179 176 79
1 year
30 3,350,355 113,824 22,033 4,209 12,146 3,519 2,124 205 72
25 3,864,616 170,288 31,145 6,426 16,955 5,036 2,719 158 68
20 4,376,474 214,958 39,766 8,052 23,521 6,140 2,051 149 68
CIN = cervical intraepithelial neoplasia.
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aBstract
Objective: To compare the cumulative incidence of cervical cancer diagnosed within 72 
months after a normal screening sample between conventional cytology and liquid-based 
cytology tests SurePath and ThinPrep.
Design: Retrospective population-based cohort study.
Setting: Nationwide network and registry of histo- and cytopathology in the Netherlands 
(PALGA), January 2000 to March 2013.
Population: Women with 5,924,474 normal screening samples (23,833,123 person years).
Exposure: Use of SurePath or ThinPrep versus conventional cytology as screening test.
Main outcome measure: The 72-month cumulative incidence of invasive cervical cancer 
after a normal screening sample for each screening test. Cox regression analyses assessed 
the hazard ratios (HRs), adjusted for calendar time, age, screening history, and socioeco-
nomic status and including laboratories as random effects.
Results: The 72-month cumulative cancer incidence was 58.5 (95% confidence interval (CI): 
54.6 to 62.7) per 100,000 normal conventional cytology samples, compared with 66.8 (95% 
CI: 56.7 to 78.7) for ThinPrep and 44.6 (95% CI: 37.8 to 52.6) for SurePath. Compared with 
conventional cytology, the hazard of invasive cancer was 19% lower [HR of 0.81 (95% CI: 0.66 
to 0.99)] for SurePath, mainly caused by a 27% lower hazard [HR of 0.73 (95% CI: 0.57 to 0.93)] 
of a clinically detected cancer. For ThinPrep, the hazard was on average 15% higher [HR of 
1.15 (95% CI: 0.95 to 1.38)], mainly caused by a 56% higher hazard of a screen-detected 
cancer [HR of 1.56 (95% CI: 1.17 to 2.08)].
Conclusions: These findings should provoke reconsideration of the assumed similarity in 
sensitivity to detect progressive cervical intraepithelial neoplasia between different types of 
LBC and conventional cytology.
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introduction
The use of conventional cytology as the primary test method has been replaced by the use 
of liquid-based cytology (LBC) in many countries with organized cervical cancer screen-
ing programs, such as the UK, the Netherlands, and Denmark.1,2 The main advantages of 
using LBC instead of primary conventional cytology are facilitation of reflex testing (i.e. 
the residual material can be tested for the presence of the human papillomavirus (HPV) in 
case of borderline/mildly dyskaryotic smears)3,4 and reduction in the number of slides of 
unsatisfactory quality.5-9 The sensitivity of LBC for detecting cervical intraepithelial neoplasia 
(CIN) 2+ lesions is believed to be similar to that of conventional cytology.10,11 However, the 
literature has been dominated by many studies comparing CIN detection between ThinPrep 
and conventional cytology.12-17 whereas only two studies have compared CIN detection 
between SurePath and conventional cytology.7,18 Therefore, we compared CIN 2+ detection 
rates between these three types of cytology tests in our previous study, including more than 
six million smears taken within the Dutch cervical cancer screening program.19 Whereas the 
use of SurePath led to an 8% increase in detection of CIN 2+ compared with conventional 
cytology, the use of ThinPrep did not affect CIN 2+ detection rates. These results were com-
patible with the results of other studies.12-16,20
Detecting more CIN as a result of an abnormal screening test is expected to deplete the 
pool of lesions that would have progressed to cancer. However, in the absence of screening 
(and associated treatment) only a fraction of screen-detected CIN would progress to cervical 
cancer (i.e. the progressive CIN lesions), so detecting more CIN lesions is not always equiva-
lent to preventing more cervical cancers. To assess whether the ability to detect progressive 
CIN lesions differs between the types of screening tests, the probability of a diagnosis of 
invasive cervical cancer in the period after a normal test result (i.e. the progressive CIN that 
screening has missed) has to be compared. As the incidence of invasive cervical cancer 
after a normal test result is low (6-year cumulative incidence rate: 48 per 100,000 normal 
smears (95% confidence interval (CI): 43 to 54)),21 such a comparison can be made only by 
using an observational population-based study in which a large number of samples can be 
evaluated.
In the Netherlands, organized cervical cancer screening has existed since the 1980s, and 
women aged 30 to 60 years have been invited every five years since 1996. Until 2016, the 
screening strategy consisted of primary cytology screening with cytology triage testing, 
the latter either alone or in combination with HPV testing. All cervix uteri cytological and 
histological tests taken inside and outside the Dutch screening program are registered 
in the nationwide network and registry of histo- and cytopathology in the Netherlands 
(PALGA).22 By using these data, we assessed the cumulative incidence of invasive cervical 
cancer detected within 72 months after a normal screening test result (i.e. diagnosed in the 
next screening round or outside the organized Dutch screening program). If this incidence 
varies among the three tests (SurePath, ThinPrep, and conventional cytology), the sensitivity 
for progressive CIN lesions probably differs between them. In addition, we stratified for the 
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reason for cervical examination that led to the detection of cervical cancer (screen-detected 
when program smear detected, or clinically detected in all other cases, which includes op-
portunistic screening as well as direct biopsies).
methods
Information on all cytological and histological examinations of the cervix uteri taken in the 
Netherlands between January 2000 and March 2013 were available and retrieved from the 
national PALGA database. Multiple quality checks ensured the reliability of the retrieved 
data.23,24 We identified women through their birth date and the first eight letters of their 
(maiden) family name. This identification code enables linkage of multiple tests belonging 
to the same woman, allowing us to follow individual screening histories.
We identified and selected episodes starting with a normal primary screening sample 
taken within the Dutch screening program between January 2000 and March 2012. We 
identified screening samples through the reason for taking the sample being participation in 
the program, which is routinely registered in PALGA. We also selected women with a primary 
sample of inadequate quality followed by a normal sample within the same episode. We 
defined an episode as starting with a primary test followed by one or more secondary tests 
in case the result was abnormal (at least borderline or mild dyskaryosis) or of inadequate 
quality. Unless the follow-up of a primary test had already been completed according to the 
guidelines (e.g. by two consecutive normal samples after a screening result with borderline 
dyskaryosis), we conidered tests taken within four years after a primary test to be secondary 
tests.25 We labeled all other tests as primary tests.
We stratified normal primary screening samples by the type of cytology test used (Sure-
Path, ThinPrep, or conventional cytology). As PALGA does not register this routinely, regional 
coordinating pathologists obtained conversion dates (fixed to the first date of the yearly 
quarter) from the individual laboratories located in their region. In the Netherlands, it is 
standard practice for laboratories to supply general practitioners with cytology kits and 
thereby determine the type of cytology test that is used. We linked these conversion dates 
to the laboratory involved and the examination date as a proxy for which type of primary 
cytology test was used.
Follow-up ended at the date of the primary test of the next episode, which resulted in a 
cervical cancer diagnosis (a case) or not, on 31 March 2013 (the end of the database), or on 
completion of the 72-month period, whichever came first. We censored the follow-up at 
72 months because it covers the invitation for the next screening round, which takes place 
60 months after a normal screening sample. By definition, after a normal primary screening 
test, all new tests give rise to a new episode regardless of the reason for taking the test and 
the type of test. We identified histologically confirmed cases of cervical cancer by selecting 
all PALGA records that included pathology codes describing invasive cancers originating in 
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the cervix uteri. These codes were manually checked to avoid over-counting both of non-
invasive lesions and primary cancers originating elsewhere.
As women in the Netherlands are invited for screening in the year they turn 30, 35, 40, 
45, 50, 55, and 60, we categorized age as: 29-33, 34-38, 39-43, 44-48, 49-53, 54-58, and 59-
63 years at the time of the normal primary cytological sample. We also defined calendar 
year at the time of the normal cytological sample. We defined socioeconomic status (SES), 
categorized as low, middle, or high, by the status score. This is an ecological variable based 
on the household characteristics of the four-digit postcode area where the woman was 
living at the time of the primary test.26 Status scores per four-digit postal code came from 
the Netherlands Institute for Social Research and were based on mean income, percentage 
of households with a low income, percentage of households with (on average) a low educa-
tion, and unemployment rate in 2010. Low SES corresponded to a status score lower than -1 
(i.e. average status score minus 1 standard deviation), intermediate SES to a score between 
-1 and 1, and high SES to a score higher than 1 (i.e. average status score plus 1 standard 
deviation). We categorized screening history as no history of cytological smears (inside or 
outside the screening program) before the normal screening sample, one cytological smear 
that was taken less than seven years before the normal screening sample, one cytological 
smear that was taken more than seven years before the normal screening sample, at least 
two cytological smears with the last being taken less than seven years before the normal 
screening sample, and at least two cytological smears with the last being taken more than 
seven years before the normal screening sample.
statistical analyses
Laboratories implemented LBC testing at different points in time. Therefore, we expected 
follow-upand calendar time to differ between the three types of cytology tests. As demo-
graphic characteristics of screened women (age, screening history, and SES) probably dif-
fered between laboratories, we expected them to differ between the types of cytology tests 
as well. As age, SES, screening history, and calendar time were all associated with CIN and/
or cervical cancer detection rates,27-30 they were all potential confounding factors. We used 
a Pearson’s chi-squared test to test whether their distributions differed between the types 
of cytological tests. We considered a p value of less than 0.05 to be statistically significant. 
Missing values were imputed with 10 imputation sets.
Cumulative incidence and hazard ratio
For each type of cytology test, we did a Kaplan-Meier analysis to calculate the cumulative 
incidence of invasive cervical cancer per 100,000 normal cytological screening samples. 
We took differences in follow-up time into account and estimated the 95% CIs by non-
parametric Kaplan-Meier product-limit estimator for log(hazard).21,31 We used the R package 
“coxme”32 to do multilevel Cox regression analyses to compare the hazard of cervical cancer 
between the types of cytology tests, taking differences in follow-up time into account and 
adjusting for the confounding factors calendar time, SES, age, and screening history. We 
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included the determinant laboratory as a random effect in the model to take account of 
clustering of the data at the laboratory level. In addition, we stratified for the reason for the 
cervical examination that led to the cervical cancer diagnosis (i.e. screen-detected when 
detected by a program smear, or clinically detected in all other cases, including oppor-
tunistic screening as well as direct biopsies). We tested time dependencies of the hazard 
ratios (HRs) statistically by splitting the total follow-up time into two periods with a roughly 
equal number of cases. Subsequently, we assessed HRs for each time period. If the sum of 
the deviance of both sub-models was significantly lower than the deviance of the original 
model, we considered the HR to be time dependent as it differed significantly between the 
time periods.
Sensitivity analyses
In the first sensitivity analysis, we restricted our Cox regression analysis to women with at least 
one previous smear. In the subsequent sensitivity analysis, we selected only women who at-
tended the next screening round (within six years after a normal screening test result) in order 
to examine the effect that possible differences in the attendance rates at next screening might 
have had on the comparisons between the cytology tests. We repeated the latter analysis 
in the third sensitvity analysis with the addition of an extra confounding factor, the type of 
cytology test used in the subsequent screening round. We did this to correct for the potential 
differences in the sensitivity of the subsequent screening test.
Difference in CIN detection rates per 100,000 screening samples and 72-month cumulative 
cervical cancer incidence after 100,000 normal screening samples
We assessed the difference in CIN detection rates per 100,000 SurePath and 100,000 Thin-
Prep samples (compared with the CIN detection rates per 100,000 conventional cytology 
samples) and compared it with the difference in the 72-month cumulative cervical cancer 
incidence after 100,000 SurePath and ThinPrep normal screening samples. Information on 
the calculation of the difference in detection rates per 100,000 primary screening samples 
can be found in the Appendix. We calculated the 72-month cumulative cancer incidence 
rates for SurePath and ThinPrep by multiplying the distribution of the 72-month cumulative 
cancer incidence rate for conventional cytology with the distribution of the adjusted HRs for 
SurePath and ThinPrep versus conventional cytology, as obtained by Cox regression.
results
Within the follow-up period, 1042 invasive cervical cancers were diagnosed after 3,028,865 
normal conventional cytology samples, 231 cancers were diagnosed after 1,303,817 normal 
SurePath samples, and 328 cancers were diagnosed after 1,591,792 normal ThinPrep samples 
(Table 1). This corresponds to 7.6, 4.8, and 6.3 cervical cancer diagnoses per 100,000 person 
years, respectively.
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crude cumulative incidence
Compared with conventional cytology, the 12-, 24-, 36-, 48-, 60- and 72-month cumulative 
incidences of invasive cervical cancer were significantly lower for SurePath (Figure 1). When 
we compared SurePath with ThinPrep, all but the 24-month cumulative incidences were sig-
nificantly lower for SurePath. No significant differences were apparent between ThinPrep and 
conventional cytology. The 72-month cumulative incidence was 44.6 (95% CI: 37.8 to 52.6) after 
100,000 normal SurePath samples, 58.5 (95% CI: 54.6 to 62.7) after 100,000 normal conventional 
cytology samples, and 66.8 (95% CI: 56.7 to 78.7) after 100,000 normal ThinPrep samples.
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Figure 1. Cumulative cervical cancer incidence after 100,000 normal conventional cytology, SurePath, 
and ThinPrep samples taken within the Dutch cervical cancer screening program.
Cumulative cervical cancer incidence was calculated by Kaplan-Meier analyses. The 95% confidence intervals are de-
picted by vertical lines. 
*  Significant difference (P<0.05) between SurePath and conventional cytology.
#  Significant difference between SurePath and ThinPrep.
No significant differences between ThinPrep and conventional cytology were detected.
distribution of potential confounding factors
The distribution of calendar time differed significantly between the methods of cytology 
testing (P<0.001). In 2000, 94% of the included normal screening samples consisted of 
conventional cytology, whereas by 2012 this percentage had dropped to 2% (Figure 2). 
We also observed a large significant difference for the distributions of follow-up time. For 
instance, almost 80% of the normal conventional cytology samples had a follow-up time of 
at least 48 months, whereas for SurePath and ThinPrep this was the case for slightly more 
than 50 and 35% of the normal samples, respectively. Small but significant differences were 
also present in the distributions of SES, screening history, and age (Table 1). Missing values 
were imputed for SES (1.4% of the primary normal samples had a missing value).
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Table 1. Characteristics of normal screening samples and their follow-up for conventional cytology, 
SurePath, and ThinPrep. Values are numbers (percentages) unless stated otherwise.
Conventional SurePath ThinPrep P value
Normal screening samples 3,028,865 1,303,817 1,591,792
Person years at risk 13,796,018 4,835,917 5,201,188
Normal screening samples followed by 
subsequent screeninga
1,931,397 (63.8) 445,726 (34.2) 370,519 (23.3) <0.001
Median (interquartile range) normal 
screening samples per woman
1 (1-2) 1 (1-1) 1 (1-1) <0.001
Invasive cervical cancers diagnosed after a 
normal screening sample
1,042 231 328 <0.001
Screen-detectedb 414 84 103 <0.001
Clinically detectedc 628 147 225 <0.001
Follow-up time: <0.001
0-12 months 208,668 (6.9) 73,905 (5.7) 95,563 (6.0)
12-24 months 105,945 (3.5) 191,027 (14.7) 321,784 (20.2)
24-36 months 129,165 (4.3) 187,410 (14.4) 311,295 (19.6)
36-48 months 203,768 (6.7) 189,063 (14.5) 284,262 (17.9)
48-60 months 920,825 (30.4) 334,677 (25.7) 339,590 (21.3)
60-72 months 1,460,494 (48.2) 327,735 (25.1) 239,298 (15.0)
Age: <0.001
29-33 411,873 (13.6) 167,015 (12.8) 193,998 (12.2)
34-38 503,889 (16.6) 187,179 (14.4) 217,213 (13.6)
39-43 516,728 (17.1) 218,559 (16.8) 267,194 (16.8)
44-48 482,822 (15.9) 218,476 (16.8) 267,585 (16.8)
49-53 434,620 (14.3) 192,594 (14.8) 240,801 (15.1)
54-58 381,312 (12.6) 173,572 (13.3) 219,277 (13.8)
59-63 297,621 (9.8) 146,422 (11.2) 185,724 (11.7)
Screening history: <0.001
No historyd 396,174 (13.1) 167,880 (12.9) 194,251 (12.2)
1 smear ≤7 yrse 446,673 (14.7) 156,727 (12.0) 183,294 (11.5)
1 smear >7 yrsf 35,164 (1.2) 15,388 (1.2) 20,003 (1.3)
≥2 smears ≤7 yrsg 2,095,417 (69.2) 941,575 (72.2) 1,164,713 (73.2)
≥2 smears >7 yrsh 55,437 (1.8) 22,247 (1.7) 29,531 (1.9)
Socioeconomic status: <0.001
Low 248,097 (8.2) 153,494 (11.8) 108,492 (6.8)
Middle 2,501,696 (82.6) 1,038,602 (79.7) 1,337,521 (84.0)
High 232,658 (7.7) 87,193 (6.7) 132,863 (8.3)
Unknown 46,414 (1.5) 24,528 (1.9) 12,916 (0.8)
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cox regression analyses of invasive cervical cancers
When we compared SurePath with conventional cytology, the hazard of an invasive cancer 
was significantly lower [HR of 0.81 (95% CI: 0.66 to 0.99)] (Table 2). This decreased hazard 
was mainly caused by a decreased hazard of a clinically detected cancer (i.e. not detected 
through program screening) [HR of 0.73 (95% CI: 0.57 to 0.93)]; the hazard of a screen-
detected cancer was similar to that of conventional cytology [HR of 0.95 (95% CI: 0.72 to 
1.27)].
When we compared ThinPrep with conventional cytology, the hazard of an invasive 
cancer was on average non-significantly higher [HR of 1.15 (95% CI: 0.95 to 1.38)]. This effect 
seemed to differ over time (P=0.063), with a HR of 0.95 (95% CI: 0.75 to 1.22) in the first 44 
a  These differences are mainly caused by differences in follow-up time (see also Figure 2). Differences in length of 
follow-up were accounted for in all analyses. Sensitivity analyses were restricted to women with subsequent atten-
dance at screening program.
b  Include all cancers detected in first screening round following normal screening sample of ThinPrep, SurePath, or 
conventional cytology.
c  Include all cancers detected outside screening program following normal screening sample of ThinPrep, SurePath, 
or conventional cytology.
d  No history of cytological smears (inside or outside screening program) before normal screening sample.
e  History of one cytological smear taken <7 years before normal screening sample.
f  History of one cytological smear taken >7 years before normal screening sample.
g  History of ≥2 cytological smears, last taken <7 years before normal screening sample.
h  History of ≥2 cytological smears, last taken >7 years before normal screening sample.
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Figure 2. Annual distribution of the type of cytology used in normal screening samples taken within the 
Dutch cervical cancer screening program.#
* Until 31 March 2012.
#  All normal screening samples taken within this time period (January 2000-March 2012) were included in the study, 
except if the type of cytology test was unknown.
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months after the normal screening smear and of 1.40 (95% CI: 1.07 to 1.83) thereafter. This 
overall increased hazard was caused by an increased hazard of a screen-detected cancer 
[HR of 1.56 (95% CI: 1.17 to 2.08)], whereas the hazard of a clinically detected cancer was 
unaffected [HR of 0.96 (95% CI: 0.76 to 1.20)].
When we compared SurePath with ThinPrep, the hazard of an invasive cancer was signifi-
cantly lower [HR of 0.71 (95% CI: 0.58 to 0.87)]. This decreased hazard was caused by both 
a decreased hazard of a clinically detected cancer [HR of 0.76 (95% CI: 0.59 to 0.97)] and a 
decreased hazard of a screen-detected cancer [HR of 0.61 (95% CI: 0.46 to 0.81)].
sensitivity analyses
When selecting only women with at least one smear before the normal screening sample, 
we found that the HRs were consistent with the main analyses (not restricted to women 
with a screening history), although the effect of ThinPrep versus conventional cytology 
seemed to be somewhat less pronounced (Table 2).
When selecting only women who attended program screening within 72 months after 
a normal screening test result, we found that the hazard of a screen-detected cancer in-
creased slightly for both SurePath and ThinPrep versus conventional cytology. The hazard of 
SurePath versus ThinPrep stayed similar as compared to the main analyses.
Of those women with conventional cytology at baseline followed by a subsequent 
screening round, 36% were re-screened with conventional cytology, 20% with SurePath, 
and 37% with ThinPrep. For the remaining 7%, the type of cytology test at re-screening was 
unknown. Of those with SurePath at baseline, 52% were re-screened with SurePath, 21% 
with ThinPrep, 4% with conventional cytology and 23% with an unknown type of test. Of 
those with ThinPrep at baseline, 55% were re-screened with ThinPrep, 6% with SurePath, 3% 
with conventional cytology, and 36% with an unknown type of test. The addition of the test 
method in the subsequent screening round as a confounding factor resulted in HRs similar 
to the ones in the second sensitivity analysis (without this extra confounder).
difference in cin detection rates and 72-month cumulative invasive cervical 
cancer incidence
The difference in the detection of CIN 2+ for SurePath and conventional cytology, as ob-
served previously,19 was consistent with the observed difference in cumulative incidence of 
cervical cancer after a normal screening sample. The use of SurePath as primary test method 
resulted in 94.4 (95% CI: 68.9 to 120.6) extra CIN diagnoses per 100,000 screening samples, 
whereas the 72-month cumulative incidence of cervical cancer decreased by 11.9 (95% CI: 
-15.6 to -4.2) (Table 3). The use of ThinPrep versus conventional cytology showed quite dif-
ferent results. Whereas the number of CIN diagnoses was similar to that with conventional 
cytology, the 72-month cumulative incidence of cervical cancer increased by 8.5 (95% CI: 
-0.7 to 18.8) after 100,000 normal screening test results.
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discussion
The risk of invasive cervical cancer was 19% lower after a normal SurePath sample than 
after a normal conventional cytological sample, which was mainly caused by a 27% lower 
risk of a clinically detected cancer (i.e. not detected through program screening). The use 
of SurePath resulted in 12 fewer cervical cancers per 100,000 normal screening samples, 
whereas the number of detected CIN lesions increased by 94. The risk of invasive cervical 
cancer seemed to be 15% higher for ThinPrep in comparison to conventional cytology, but 
the magnitude of the difference seemed to differ over time. Within the first 44 months after 
the normal screening sample, the risks were comparable; thereafter, the risk was 40% higher 
when using ThinPrep. Both the increased risk and the difference over time were mainly due 
to a 56% higher risk for a screen-detected cancer. The use of ThinPrep resulted in eight 
additional cervical cancers per 100,000 normal screening samples, whereas the number of 
detected CIN lesions was slightly but not statistically significantly lower.
strengths and limitations
This study is the first to compare rates of invasive cervical cancer detected after a normal 
screening sample between two different types of LBC tests and conventional cytology, a 
widely accepted proxy for examining differences in the sensitivity to detect progressive CIN 
lesions. In addition, we examined the drawbacks of implementation of LBC by comparing 
indicators of overdiagnosis.
Our study has some limitations. First, we were not able to correct for the use of automated 
reading, although the possible influence would be small given that automated reading has 
been introduced in relatively few Dutch laboratories. Moreover, multiple studies have shown 
Table 3. CIN detection rates per 100,000 screening samples and 72-month cumulative cervical cancer 
incidence after 100,000 normal screening samples for conventional cytology, and the difference in those 
measures for SurePath and ThinPrep compared with conventional cytology.
Conventional
 cytology
SurePath vs. 
conventional cytology
ThinPrep vs. 
conventional cytology
Number of CIN diagnoses per 100,000 screening samples
CIN 1 216.1 +30.1 (+18.1 to +42.8) -3.5 (-14.3 to +7.9)
CIN 2 220.0 +31.2 (+19.0 to +44.1) +9.4 (-2.1 to +21.5)
CIN 3 495.0 +30.3 (+12.0 to +49.3) -12.2 (-29.6 to +5.9)
Total CIN 931.0 +94.4 (+68.9 to +120.6) -6.8 (-30.6 to +17.6)
Number of cervical cancer diagnoses after 100,000 normal screening samplesa
Total cancers 58.5 (54.6 to 62.7) -11.9 (-15.6 to -4.2) +8.5 (-0.7 to +18.8)
Numbers were corrected for confounding factors. The 95% confidence intervals are given in parentheses.
CIN = cervical intraepithelial neoplasia.
a  Differences in the distribution of follow-up were taken into account, and laboratories were included as random ef-
fects in the model.
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that CIN 2+ detection was unaffected or slightly decreased by adding automated assisted 
reading to ThinPrep or SurePath.33-35 Second, as we did not have a unique identification code 
[the identification code was based on the first eight letters of the (maiden) family name and 
birth date], tests belonging to different women may have been allocated to a single woman 
(so-called fusions). However, we think it unlikely that these fusions would be correlated 
with the type of cytology test used. Third, we did not have individual data on which type 
of primary test was used. Therefore, we used the date of the primary cytological smear and 
laboratory’s conversion date fixed to the first date of the quarter to deduce which type of 
cytology test was used. This means that normal screening samples taken during this quarter 
may have been misclassified to some extent, leading to a slight underestimation of the 
effects. Fourth, we were not able to censor follow-up for death and migration. However, as 
both mortality and migration rates are relatively low at screening ages,36,37 we do not expect 
that this has biased our results. Fifth, restricting our analyses to squamouscell carcinomas, 
adenocarcinomas, and/or micro-invasive and macro-invasive carcinomas was not possible, 
as this information in PALGA is not accurate and many values are missing. Finally, we did not 
correct for possible learning curve effects, as the aim of our study was to examine the effect 
of using SurePath and ThinPrep in routine practice, which also includes a possible learning 
effect.
effect of confounding factors and sensitivity analyses
As only laboratory and calendar time were clearly correlated with the moment of imple-
mentation of LBC, their confounding effects were much more pronounced than those of 
age, screening history and SES. Although significantly different, their distribution differences 
were very small and, therefore, confounding effects were negligible. It is possible that we 
did not take into account the effect of other (unknown) potential confounders. The fact that 
no large differences in age, screening history, and SES is reassuring, however.
We found that the effect of ThinPrep compared with conventional cytology seemed to 
be somewhat less pronounced in women with a screening history compared with our main 
analysis (also including women without a screening history). This suggests that the risk of 
a cervical cancer after a normal Thinprep screening sample is perhaps increased more in 
women without versus with a screening history.
Restricting the analysis to women who attended the next screening round slightly in-
creased the risk of a screen-detected cancer for both SurePath and ThinPrep, although the 
difference between these two types of LBC tests remained similar. This may have resulted 
in a slight underestimation of the HRs between SurePath and conventional cytology and 
between ThinPrep andconventional cytology.
In an ideal situation, the type of cytology test used would differ between the groups 
only at baseline to ensure that results are not biased by differences in sensitivity to detect 
a cervical cancer in the episode following the normal screening sample. Our finding that 
the addition of the second type of test (in the subsequent episode) as confounder did not 
change our results was reassuring.
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explanation of the main results
In our previous study, using the same data as in this study, we showed that the detection 
of CIN 2+ was increased by using SurePath compared with conventional cytology, whereas 
it was unaffected by using ThinPrep.19 As the use of SurePath resulted in decreased rates of 
cervical cancer after a normal screening sample, this indicates that at least part of the extra 
detected CIN lesions were progressive. As the use of ThinPrep seemed to result in increased 
cancer rates, this suggests that fewer of the detected CIN lesions were progressive.
In addition, we showed that the use of SurePath was associated with lower rates ofcervi-
cal cancer after a normal screening sample compared with the use of ThinPrep, indicating 
that the sensitivity to detect progressive CIN lesions is higher for SurePath. These suggested 
differences in sensitivity are most likely caused by differences between the techniques of 
the LBC tests, such as the extent of fixation, the technique of taking a representative sample 
from the vial, and the retention of the brush (the collecting device) in the fluid.38,39 Studies 
have shown that retaining the brush, as is done when using SurePath, is associated with an 
increased cell yield compared with rinsing and discarding the brush, as is done when using 
ThinPrep.40,41
extrapolation of the results
The cumulative incidence of cancer after a normal sample seemed to be higher for ThinPrep 
than for conventional cytology mainly because the risk of a screen-detected cancer after 
a normal sample was higher. In general, screen-detected cancers are found at a lower 
stage than clinically diagnosed ones, so their survival is probably better.42 Therefore, the 
suggested negative effect of using ThinPrep is probably less pronounced for cervical cancer 
mortality than it is for incidence. The opposite is true for the positive effect of Surepath, as 
we found that SurePath was primarily protective for clinically detected cancers. As no data 
on mortality were available, we were not able to estimate the effects of implementation of 
LBC on cervical cancer mortality. Although our results may not seem very relevant for the 
future of the Dutch cervical cancer screening program, as primary cytology screening has 
recently been replaced by primary HPV screening, they certainly can be relevant to other 
countries with organized primary cytology screening programs that have switched to using 
SurePath and/or ThinPrep or will switch in the near future.
overdiagnosis
An important drawback of cervical cancer screening is the overdiagnosis and overtreatment 
of CIN lesions (i.e. of lesions that would never have progressed to clinical cervical cancer in 
the absence of screening). The possible increase in such overdiagnosis and overtreatment 
related to more sensitive screening should be taken into account when considering new 
screening options. With SurePath, the prevention of 12 extra cervical cancers within the first 
six years after screening was accompanied by the detection of 94 extra CIN lesions at that 
screening round. Most of these CIN lesions would never have become invasive cancer and 
could therefore be classified as overdiagnosis. Assuming that only CIN 2+ are treated, replac-
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ing conventional cytology with Surepath would have implied that roughly five more CIN 
treatments are performed to prevent one additional cervical cancer diagnosis. However, in 
a subsequent screening round for the same cohort, increased detection rates tend to wane, 
and so does overdiagnosis and overtreatment. This effect was also observed in randomized 
controlled trials in which cytology screening was replaced by highly sensitive HPV-based 
screening in the intervention arm. The detection of high-grade CIN was increased at the 
prevalence round but decreased at the subsequent incidence round, accompanied by a 
reduced risk of interval cancers.43,44 Therefore, in our study, the number of additional CIN 
treatments per additionally prevented cancer is, if anything, overestimated.
comparison with the literature
Whether one cytology test is preferred over another should depend not only on the sensi-
tivity to detect progressive CIN lesions and rates of overdiagnosis but also on factors such as 
the possibility to test for the presence of HPV in the residual material and the percentage of 
unsatisfactory smears. Fontaine et al. have shown that unsatisfactory rates are significantly 
lower when using SurePath instead of ThinPep.45 Although this was not shown in our previ-
ous study,19 we then found similar results (an odds ratio of 0.74 (95% CI: 0.72 to 0.75)) when 
comparing unsatisfactory rates between SurePath and ThinPrep.
conclusion
The six-year cumulative incidence of cervical cancer after a normal screening sample was 
significantly lower for Surepath than for conventional cytology and ThinPrep, strongly sug-
gesting that the sensitivity of Surepath to detect progressive CIN lesions is higher. The use 
of ThinPrep compared with the use of conventional cytology seemed to be associated with 
a higher cumulative cancer incidence, suggesting that the sensitivity to detect progressive 
CIN lesions is lower, although results were non-significant. Our findings should provoke 
reconsideration of the assumed similarity in the sensitivity for progressive CIN between the 
different types of LBC tests and conventional cytology.
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aPPendix: calculation of differences in detection rates
In this appendix, we describe the methods that were used to determine the difference in 
CIN detection rates per 100,000 primary screening samples.
selecting data from Palga: cin lesions 
We identified primary samples taken within the national cervical cancer screening program 
between January 2000 and December 2011. As data until March 2013 were available to us, 
a minimum duration of 15 months follow-up was ensured. Histologically confirmed CIN le-
sions were identified by selecting all PALGA records that included corresponding pathology 
codes. Subsequently, lesions were linked to the type of cytology test used. Age, screening 
region, SES, and calendar year at the time of the primary sample were assessed in similar 
ways as in the main analysis.
statistical analyses: cin lesions
We compared CIN detection rates per 100,000 SurePath and 100,000 ThinPrep samples with 
CIN detection rates per 100,000 conventional cytology samples. As confounding factors are 
present, comparing observed CIN detection rates was not sufficient. Therefore, we calcu-
lated CIN detection rates per 100,000 SurePath and ThinPrep samples by multiplying the 
observed CIN detection rates per 100,000 conventional cytology samples with the adjusted 
odds ratios for SurePath and ThinPrep versus conventional cytology, as obtained in our 
previous study (Table 1).1 These odds ratios were adjusted for differences in the distribution 
of age, screening region, SES, and calendar time between the three cytology tests.
Table 1. Factors to calculate the adjusted CIN detection rates for SurePath and ThinPrep. Given factors are 
odds ratios comparing SurePath and ThinPrep with conventional cytology, adjusted for age, screening 
region, SES, and calendar time.
SurePath vs. CC
(95% CI)
ThinPrep vs. CC
(95% CI)
CIN 1 1.14 (1.08 to 1.20) 0.98 (0.93 to 1.04)
CIN 2 1.14 (1.09 to 1.20) 1.04 (0.99 to 1.10)
CIN 3 1.06 (1.02 to 1.10) 0.98 (0.94 to 1.01)
Total CIN 1.10 (1.07 to 1.13) 0.99 (0.97 to 1.02)
CC = conventional cytology; CIN = cervical intraepithelial neoplasia.
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aBstract
Background: Human papillomavirus (HPV) self-sampling might be a promising tool to 
increase effectiveness of primary HPV screening programs when offered to non-attendees. 
However, effectiveness could decrease if regular attendees “switch” to self-sampling, because 
self-sampling test characteristics may be inferior. We examined under which conditions the 
harms would outweigh the benefits.
Methods: The MISCAN-Cervix model was used to estimate quality-adjusted life years (QALY) 
gained and costs of offering HPV self-sampling to non-attendees. We varied the relative CIN 
2+ sensitivity and specificity (self-sampling vs. regular sampling), extra attendance, risk of 
extra attendees, and the switching percentage.
Results: Without switching, offering self-sampling is (cost-)effective under every studied 
condition. If the attendance due to self-sampling increases by ≥6 percentage points, higher 
primary background risk women (unscreened women who will never attend regular screen-
ing) attend and the relative CIN 2+ sensitivity and specificity are ≥0.95; it is (cost-)effective 
to offer self-sampling to non-attendees, even if all regular attendees switch. If the relative 
sensitivity decreases to 0.90 combined with either a 3 percentage points extra attendance 
or the absence of higher primary background risk women, QALYs are lost when more than 
30% to 20% of the regular attendees switch.
Conclusions: Offering self-sampling will gain health effects if the relative CIN 2+ sensitiv-
ity is ≥0.95, unscreened attendees are recruited, and the total attendance increases by 
≥6 percentage points. Otherwise, switching of regular attendees may decrease the total 
effectiveness of the program.
Impact: Self-sampling needs to be implemented with great care and advantages of office-
based sampling need to be emphasized to prevent switching.
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introduction
In the Netherlands, cervical cancer incidence and mortality have decreased in the past 
decades to 6.5 and 1.3 per 100,000 woman years (age-adjusted to the World Population) in 
2012.1 The introduction and improvements of the screening program played a considerable 
role in this decrease,2 Since 1996, Dutch women of ages 30 to 60 years are invited to attend 
cervical cancer screening every five years. From 2016 onward, primary cytology will be 
replaced by primary high-risk human papillomavirus (HPV) testing,3 because the sensitivity 
for detecting CIN 2+ lesions is higher when using HPV testing4 and HPV testing can be 
performed on self-samples.5,6 Although the current screening participation rate ranges from 
65% to almost 70%,7 it has been estimated that more than half of the invasive cervical can-
cers occur in women who did not participate in the previous six years. Moreover, some of 
these women had never been screened at all.8 This shows that addressing non-attendance 
can increase the effectiveness of the program considerably.
Self-sampling devices, with which women can collect cervical cells themselves, have been 
developed recently. As self-sampling is more woman-friendly and less time consuming than 
letting a clinician, general practitioner, or midwife collect cervical cells, it probably increases 
participation in screening. Indeed, the Dutch PROHTECT study has shown that offering a 
self-sampling HPV test to non-attendees of the program increased the overall screening 
participation rate by about 6 percentage points.9,10 However, the gain in effectiveness of the 
program [i.e., gain in quality-adjusted life years (QALYs)] probably not only depends on the 
increase in attendance, but also on the test characteristics of HPV self-sampling and on the 
ability to target higher risk non-attendees. It is likely that unscreened women (who were invited 
at least once but were never screened) have higher risks on developing cervical cancer than 
one-time non-attendees (who missed the last screening round, but have been screened in the 
past). Nevertheless, including any non-attendee will probably increase the effectiveness of the 
program. However, “switching” of regular attendees from office-based to self-sampling could, 
given a loss in detection (i.e., more loss to follow-up, possible lower sensitivity), result in a 
decrease of the effectiveness of the program (i.e., losing QALYs). In other words, the QALYs 
gained by attracting non-attendees could be annulled by the QALYs lost by switching of 
regular attendees. It is unclear at which level of switching this will happen.
The aim of this study is to examine the effectiveness of offering HPV self-sampling to non-
attendees of a primary HPV screening program. We modeled effects of parameters such as 
the relative CIN 2+ sensitivity and specificity (self-sampling vs. regular sampling), the extra 
attendance via self-sampling, and the risk of extra attendees. Given that the percentage of 
women who will switch from office-based to self-sampling is unknown, we determined the 
percentage of switching that would result in a decrease of the total effectiveness of the 
program (i.e., harms outweigh the benefits, QALYs are lost). We also examined the circum-
stances (i.e., limits) under which it would not be cost-effective to offer HPV self-sampling to 
non-attendees.
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methods
We used the MISCAN-Cervix model to estimate benefits, harms, and costs of offering a self-
sampling HPV test to non-attendees.11 For detailed information on the model specifications, 
see the Model appendix.
assumptions for screening and triage
The screening policy considered is primary HPV screening with cytology triage, as will be 
implemented in the Netherlands (Figure 1).12 Women will be invited for screening at ages 
30, 35, 40, 50, and 60 years. In addition, women will be invited at ages 45, 55, and 65 years 
if they did not attend screening or had a positive HPV test in the previous screening round.
assumptions for attendance
For HPV office-based sampling, we assumed an age-dependent overall 65% attendance rate 
as currently observed within the Dutch cytological screening program.7 On the basis of the 
findings of the PROHTECT trial (offering self-sampling to non-attendees after an opting-out 
letter), we assumed that a self-sampling kit was sent to 85% of the non-attendees,13 which 
resulted in an extra overall attendance of 6 percentage points.9 We assumed that 29% of 
these extra-attendees are higher primary risk women (i.e., unscreened women who will 
never attend via office-based sampling and who have a 1.7 times higher primary back-
ground risk for developing cervical cancer than women who are willing to attend office-
based sampling), which is equal to the proportion in non-attendees (i.e., 10% / 35% = 29%) 
(Figure 2). In addition to their increased primary background risk, these women also have 
an increased cervical cancer risk due to never attending regular screening.
We assumed that the loss to follow-up after a positive self-sampling test was higher than 
after a positive office-based sampling test. On the basis of the observed data, we assumed 
that 92% of the women comply with the first triage invitation and 68% with the second.7 
With office-based sampling, the collected material can be used both for primary HPV and di-
rect cytology triage testing (co-collection). Therefore, the first and only triage invitation is six 
months after the positive screening test. This results in a compliance of 100% for immediate 
cytology triage testing and 92% for triage testing six months after the positive office-based 
sampling test. In case of self-sampling, co-collection is not possible and women receive 
their first and second triage invitation directly and six months after the positive screening 
test. This results in a compliance of 92% for immediate cytology triage testing and 68% for 
triage testing six months after the positive self-sampling test (Figure 1).
As no data were available, we considered the two most extreme “switching” scenarios in 
the base-case analyses: no regular attendees and all regular attendees switch from office-
based to self-sampling.
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Base-case assumptions for test characteristics
The test characteristics of self-sampling were based on the assumption that a validated 
PCR test was used, as for instance the GP5+/6+.4,14 According to the recent meta-analysis of 
Arbyn and colleagues,15 the point estimate for the relative sensitivity of CIN 2+ when com-
paring self-sampling with office-based sampling is approximately 0.95, whereas the point 
estimate for the relative specificity is probably higher than 1.00. Therefore, we assumed a 5 
percentage points lower sensitivity for high-risk HPV infections when self-sampling (i.e. 80 
vs. 85%), and an equal specificity of 100% (i.e. the true but uncertain value of specificity is 
probably somewhat lower than 100% due to cross-reactivity with low-risk HPV types and 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HPV positive 
Immediate cytology triage test 
*Compliance self-sampling users = 92% 
#Compliance office-based sampling users = 100%  
 
No cytological 
abnormalities 
Cytology triage test at 6 months 
*Compliance self-sampling users = 68% 
#Compliance office-based sampling users = 92% 
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Return to routine 
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Colposcopy 
*Compliance = 97% 
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*Compliance = 66% 
 
HPV test 
(self-sampling or office-based sampling) 
 
No cytological 
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Figure 1. Triage strategy and compliance assumptions after a positive self-sampling and office-based 
sampling HPV test. We assumed that the compliance (i.e., attendance for triage and colposcopy) behavior 
does not differ between self-sampling, future, and current office-based sampling users.
*  Compliance rates of the first triage test (i.e., immediate cytology triage test), second triage test (i.e., cytology triage 
test at 6 months), and of colposcopy are assumed equal to those observed within the current program.
#  First triage (i.e., immediate cytology triage) after a positive office-based sampling test will be performed using co-
collection, so the compliance will automatically be 100%. Compliance with the second triage test (i.e., cytology 
triage at 6 months) is assumed to be equal to the first triage test in the current program. 
HPV = human papillomavirus; BMD = borderline or mildly dyskaryosis.
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contamination). By including fast clearing high-risk HPV infections, we were able to model 
a lack of specificity.
As women in our model can have multiple lesions at the same time, the CIN 2+ sensitivity 
not only depends on the sensitivity for a high-risk HPV infection, but also on the specific-
ity. Therefore, a 5 percentage points lower sensitivity for high-risk HPV infections and an 
equal specificity corresponds with a 0.95 relative CIN 2+ sensitivity. On the other hand, the 
specificity for a CIN 2+ lesion depends on the specificity and sensitivity for a high-risk HPV 
infection. As the prevalence of high-risk HPV infections in women without CIN 2+ is higher 
in young women and relatively more young women use self-sampling, a 5 percentage 
points lower sensitivity for high-risk HPV infections and an equal specificity corresponds 
with a 0.99 relative CIN 2+ specificity.
assumptions for costs and utilities
Table 1 presents the inputs for utilities and costs used in the analyses. Utilities were based on 
(inter)nationally published data.16 The unit costs were estimated from a societal perspective. 
As compared to office-based sampling, self-sampling was assumed to be less expensive, but 
the costs of immediate cytology triage were higher. Diagnostic costs of women referred for 
colposcopy, treatment costs and costs of palliative care were equal between the two tests 
and were derived from previous cost studies performed in the Netherlands.17
65% 
6% 
29% 35% 
Extra attendees 
Final non-attendees 
 
Non-attendees 
29%  of the extra attendees 
and final non-attendees 
consist of higher primary risk 
women Regular 
attendees 
Figure 2. Distribution of regular attendees, non-attendees, and extra attendees within the screening 
population.
After receiving a screening invitation 65% of the invited women will attend via office-based sampling (i.e., regular 
attendees) and 35% will not attend (i.e., non-attendees). After an HPV self-sampling test has been offered to the non-
attendees, 17% of them will attend (i.e., extra attendees; = 6% of the screening population) and 83% will not (i.e., final 
non-attendees; = 29% of the screening population). 29% of the non-attendees consist of higher primary risk women 
(= 10% of the screening population). We assumed that the proportion of higher primary risk women in the extra at-
tendees and final non-attendees stayed equal to that in the non-attendees (= 1.7% of the screening population are 
higher primary risk women who attend via self-sampling, 8.3% are higher primary risk women who do not attend). 
Office-based sampling users consist of regular attendees, while self-sampling users consist of extra attendees and, in 
case of switching, of (part of the) regular attendees.
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cost-effectiveness analysis
We assumed that the evaluated alternative screening policies (i.e. primary HPV screening 
with and without offering HPV self-sampling to non-attendees) started in 2013 and contin-
ued until all women reached the final screening age. The costs and effects of the simulated 
screening programs were counted from 2013 onward until all simulated women (i.e. born 
between 1953 and 1992) had died. We also simulated the last three screening rounds before 
2013 (i.e. primary cytology screening with cytology triage), because they can influence the 
effectiveness of the screening program after 2013. We simulated ten million women for 
each strategy. Future costs and health effects [life years (LYs) lived and utility losses] were 
discounted towards the year 2013 at an annual rate of 3%. We computed the net costs 
and number of QALYs gained by screening as the differences between the simulations with 
and without screening. The incremental cost-effectiveness ratio (ICER) was defined as the 
increase in costs per additional (QA)LY gained when self-sampling would be offered to non-
attendees as compared to no such offer. The cost-effectiveness threshold was set to €20,000 
per QALY gained, based on decisions of the Dutch government,18 and to €50,000, which is 
often used in an international perspective.19
multivariate sensitivity analyses
The relative CIN 2+ sensitivity and specificity can differ from the estimates we used in our 
base-case analysis, as there is uncertainty about the true value [e.g. the 95% confidence 
interval (CI) for the pooled relative sensitivity and specificity when using the GP5+/6+ is 0.89 
to 1.01 and 0.95 to 1.29 respectively].15 In addition, they depend on the type of HPV DNA test 
used,15 meaning that the values could be different when another validated HPV DNA test is 
used. Therefore, we choose to set the sensitivity for a high-risk HPV infection equally, 5, and 
10 percentage points lower for self-sampling as compared to office-based sampling. The 
specificity was set equally, 5, and 15 percentage points lower.
As the CIN 2+ sensitivity and specificity depend on both the sensitivity and specificity 
for high-risk HPV infections, the CIN 2+ sensitivity and specificity varied slightly between 
different combinations of self-sampling test characteristics for high-risk HPV infections. This 
resulted in a relative CIN 2+ sensitivity that varied between 0.89 and 1.02, and a relative CIN 
2+ specificity that varied between 0.84 and 1.00.
The relative CIN 2+ sensitivity and specificity are expected to have a major influence on 
the effectiveness of the program, especially when women switch. Therefore, we determined 
the percentage of women switching (0%, 10%, …, 90%, 100%) for which offering self-
sampling is no longer effective (i.e. QALYs are lost) or cost-effective (i.e. ICER is larger than 
the cost-effectiveness threshold).
In addition, we varied the loss in quality of life associated with cytology triage, the costs of 
the self-sampling kit, the extra attendance via self-sampling, and the attendance of higher 
primary risk women women (i.e. unscreened women who will never attend office-based 
sampling) and their background risk for cervical cancer.
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Table 1. Model input: Costs and utilities under base-case assumptions.
Parameter Costs in €
Utility loss
Fraction Duration
Invitation 4.85
Primary office-based sampling test 0.006 2 weeks
Programa 2.68 / 2.95
Organisation 12.50
Office-based sampling 12.09
Laboratory 29.00
Time/travel 6.28
Total 62.55 / 62.82
Primary self-sampling test 0.006 2 weeks
Self-sampling kitb 6.00
Program 2.68
Organisation 12.50
Laboratory 29.00
Timec 2.76
Total 50.94
Immediate cytology triage test after positive office-based samplingd NA NA
Laboratorye 30.27
Total 30.27
Immediate cytology triage test after positive self-sampling 0.006 2 weeks
Organisation 10.00
Office-based sampling 12.09
Laboratory 32.27
Time/travel 6.28
Total 60.64
Cytology triage test at 6 months 0.006 0.5 year
Organisation 10.00
Office-based sampling 12.09
Laboratory 32.27
Time/travel 6.28
Total 60.64
Diagnosis and treatment of pre-invasive stages
False-positive referral 296 0.005 0.5 year
CIN grade 1 924 0.03 0.5 year
CIN grade 2 1,368 0.07 1 year
CIN grade 3 1,602 0.07 1 year
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Utility loss associated with cytology triage. True estimates of the utility loss due to having 
cytology triage are unavailable. Especially if self-sampling is associated with a lower specific-
ity, this may influence the effectiveness of offering self-sampling. Therefore, we studied the 
effect of assuming no utility loss to 0.012 per week for being in triage (base case: 0.006 per 
week).
Costs. The total price of a self-sampling kit depends on many factors (e.g. type of self-
sampling device, possibility to achieve economies of scale, and on-going innovations for 
the self-sampling test). Therefore, we varied unit self-sampling kit costs from €3.50 to €10.00 
(base case: €6.00).
Attendance via self-sampling. We varied the extra attendance rate due to self-sampling 
from 3 to 10 percentage points (base case: 6 percentage points). Furthermore, we varied the 
proportion of higher primary risk women in extra attendees from 0 to 50% (base case: 29%).
Background risk for cervical cancer of “higher primary risk” women. We assumed that all 
women have the same background risk for cervical cancer (base case: “higher primary risk” 
women have a 1.7 times higher background risk than regular attendees), although “higher 
primary risk” women still have an increased cervical cancer risk due to never attending 
regular screening.
Table 1 (continued). Model input: Costs and utilities under base-case assumptions.
Parameter Costs in €
Utility loss
Fraction Duration
Diagnosis and treatment of cancer
FIGO 1A 5,246 0.062 5 years
FIGO 1B 12,440 0.062 5 years
FIGO 2+ (screen detected) 12,261 0.28 5 years
FIGO 2+ (clinically detected) 11,451 0.28 5 years
Terminal care 27,859 0.712 1 month
Costs are in 2012 prices. NA = not applicable.
a  As the total program costs were fixed, the costs per test was dependent on the number of women participating in 
the screening program. As this number was higher with the inclusion of the self-sampling test, the costs per test 
were lower in the situation with versus without self-sampling.
b  We assumed that 85% of the non-attendees received the self-sampling kit of €6.00 at home, irrespective of whether 
they used it or not. This price was estimated based on personal communication with multiple developers of brush 
and lavage HPV self-sampling kits. The remaining costs (e.g. laboratory, organisation, etc.) were only taking into ac-
count among women who actually attended via self-sampling.
c  Given that it was not required to go to the general practitioner’s office, we assumed that women who attended via 
self-sampling spent half of the time to screening (€2.76 instead of €5.52) as compared to women who attended via 
office-based sampling, while travel costs (€0.76) were absent.
d  Co-collection based analysis was possible after positive office-based sampling and, therefore, women did not have 
to go to the general practitioner´s office for the immediate cytology triage test.
e  We assumed that part of the material costs (€2.00) were already included in the price of the office-based sampling 
test. Therefore, laboratory costs of immediate cytology triage after a positive office-based sampling test were lower 
than after a positive self-sampling test.
134 | Chapter 6
results
Base-case scenario
Table 2 presents the undiscounted effects and costs per 100,000 simulated women when 
offering HPV self-sampling to non-attendees of a primary HPV screening program. Without 
switching, offering self-sampling increased the number of triage tests and false-positive re-
ferrals for colposcopy (+7.5% and +5.7%, respectively) and decreased the number of cervical 
cancer cases and deaths by 7.0% and 9.2%, respectively. Because the costs increased by only 
5.5%, it was not only effective (+12.1% QALYs gained) but also cost-effective (ICER of €2,115 
per QALY gained) to add self-sampling to the program (Table 3).
As the sensitivity of self-sampling was lower than that of office-based sampling and 
because the probability of being lost to follow-up after a positive self-sampling test was 
higher than after a positive office-based sampling test, switching resulted in a decrease of 
the number of triage tests and subsequently false-positive referrals, an increase of the num-
ber of cervical cancers, and a decrease in the number of cervical cancer deaths prevented 
Table 2. Undiscounted simulated effects and costs, compared to no screening, of primary HPV screen-
ing with and without offering self-sampling to non-attendees under base-case assumptions, per 100,000 
simulated women.
Without self-
sampling
With self-sampling (difference with 
situation without self-sampling, in %)
No switching 100% switching
Effects, No.
Primary screens 219,953 234,171 (+6.5) 234,108 (+6.4)
Triage tests 12,983 13,952 (+7.5) 10,834 (-16.6)
False-positive referrals 163 173 (+5.7) 133 (-18.5)
CIN grade 1 diagnoses 786 842 (+7.2) 676 (-13.9)
CIN grade 2 diagnoses 523 565 (+8.1) 460 (-12.0)
CIN grade 3 diagnoses 844 924 (+9.5) 812 (-3.7)
CeCa cases 626 582 (-7.0) 631 (+0.8)
Screen-detected CeCa cases 77 86 (+12.2) 89 (+16.0)
Clinically-detected CeCa cases 549 496 (-9.6) 541 (-1.3)
CeCa deaths 250 227 (-9.2) 247 (-1.3)
LYs lost 5929 5388 (-9.1) 5833 (-0.8)
QALYs lost 772 735 (-4.8) 760 (-1.6)
Costs, €
Testing costs 16,022,798 17,134,705 (+6.9) 14,930,636 (-6.8)
Treatment costs 16,820,809 15,856,766 (-5.7) 16,485,808 (-2.0)
Total costs 32,843,608 32,991,471 (+0.5) 31,416,445 (-4.3)
CIN = cervical intraepithelial neoplasia; CeCa = cervical cancer; LYs = life years; QALYs = quality-adjusted life years.
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and QALYs gained. Still, when all women switched it was effective and cost-saving to offer 
self-sampling (Tables 2 and 3).
Table 3. Discounted simulated effects and costs (both 3% per year) of providing non-attendees with 
a self-sampling test in a primary HPV screening program under the base-case scenarios, per 100,000 
simulated women.
Base-case scenario,
no switching
(% vs. no self-sampling)
Base-case scenario,
100% switching
(% vs. no self-sampling)
LYs gained 1,746 (+12.1) 1,573 (+1.0)
QALYs gained 1,880 (+12.1) 1,701 (+1.4)
Costs in € 8,184,676 (+5.5) 6,687,767 (-13.8)
ICER: Costs in € per LY gained 2,276 Cost-saving
ICER: Costs in € per QALY gained 2,115 Cost-saving
Cost-saving = Cervical cancer screening was both more effective and less costly with versus without offering HPV self-
sampling test to non-attendees. LYs = life years; QALYs = quality-adjusted life years;
ICER = incremental cost-effectiveness ratio.
multivariate sensitivity analyses
Without switching, a decrease in the CIN 2+ sensitivity of self-sampling mainly resulted in 
fewer QALYs gained (Figure 3A), whereas a decrease in the CIN 2+ specificity mainly resulted 
in increased costs (Figure 3B). Both resulted in a higher ICER (Figure 3C). However, even 
when the relative sensitivity and specificity were inferior to that of office-based sampling 
(i.e. 0.89-0.91 and 0.84-0.85, respectively), QALYs were gained and the ICER was below the 
threshold of €20,000 per QALY gained, if no women switched.
In all scenarios, switching resulted in fewer QALYs gained (Figure 3A). This effect was larger 
in case the relative sensitivity was lower than 1.00. However, even when the test character-
istics of self-sampling were inferior to that of office-based sampling, QALYs were only lost 
when more than 60% of the women switched (Table 4). When they were slightly inferior (i.e. 
0.95-0.97 relative sensitivity and 0.94-0.95 relative specificity) or similar (i.e. 1.01-1.02 relative 
sensitivity and 0.99-1.00 relative specificity), it was effective under every switching scenario. 
If self-sampling specificity was inferior, the costs of offering HPV self-sampling increased 
with increasing percentages of switching (Figure 3B). Considering a cost-effectiveness 
threshold of 20,000 per QALY gained, the switching limit was up to 30 percentage points 
lower (Table 5). Therefore, offering self-sampling was not effective or cost-effective when 
more than 40% of the women switch and test characteristics of self-sampling were inferior 
to those of office-based sampling.
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Figure 3. The effect of switching and the relative CIN 2+ sensitivity and specificity on the number of QA-
LYs gained (A), extra costs (B), and ICER (C). Results are given per 100,000 simulated women (3% discount-
ing for costs and effects). The relative CIN 2+ sensitivity and specificity (self-sampling vs. office-based 
sampling) are indicated by the sensitivity and specificity in the legend.
(C), the combined effect of sensitivity, specificity, and switching on the ICER is only shown when adding a self-sampling 
test resulted in a gain of QALYs as compared with primary HPV screening alone. Therefore, a negative ICER (i.e., cost-
saving) is also dominating (i.e., primary HPV screening with offering a self-sampling test to non-attendees was both 
more effective and less costly than primary HPV screening alone).
*  Beyond this level of switching, offering a self-sampling test resulted in a loss of QALYs as compared with primary HPV 
screening alone.
Black dashed line = primary HPV screening without offering self-sampling to non-attendees.
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Table 4. For what switching percentage does offering self-sampling to non-attendees lead to a loss in 
QALYs?
Relative CIN2+ 
sensitivity and 
specificity (self 
versus office-based 
sampling)
Base
case
Utility loss due 
to cytology 
triage
Extra 
attendance 
(percentage 
points)
Background 
risk of higher 
primary risk 
womena
% Extra 
attendees 
consisting 
of higher 
primary risk 
women
Sensitivity Specificity 0·000b 0·0012 10 3 Averagec 50 0
1.01 0.99 Ind. Ind. Ind. Ind. Ind. Ind. Ind. >60
1.01 0.94 Ind. Ind. Ind. Ind. >90 Ind. Ind. >50
1.02 0.84 Ind. Ind. Ind. Ind. >70 >80 Ind. >40
0.95 0.99 Ind. Ind. Ind. Ind. >50 >60 Ind. >30
0.96 0.95 Ind. Ind. >90 Ind. >50 >50 Ind. >30
0.97 0.85 >80 Ind. >70 Ind. >40 >40 Ind. >20
0.89 1.00 >70 >70 >70 Ind. >40 >40 Ind. >20
0.90 0.95 >70 >70 >70 Ind. >30 >30 >90 >20
0.91 0.85 >60 >80 >50 >90 >30 >30 >80 >10
For every scenario the minimum switching percentage is given under which it is no longer effective (i.e. QALYs are 
lost) to offer self-sampling to non-attendees. The switching percentage varies between 0 (i.e. even when no women 
switch it is not effective to offer self-sampling), >90 (i.e. when more than 90% of the women switch it is not effective to 
offer self-sampling) to independent (ind.) (i.e. independent of how many women switch, it is always effective to offer 
self-sampling).
Base-case assumptions: Utility loss due to cytology triage = 0.006 per week, extra attendance = 6 percentage points, 
background risk of higher primary risk women as compared to the rest of the screen population = 1.7 times higher, 
% of higher primary risk women in extra attendees = 29%. These variables, if not varied, were held constant at their 
base-case level.
a Background risk for developing cervical cancer.
b  Since a higher utility loss for primary than triage testing does not seem realistic we also assume no utility loss for 
primary testing.
c Average = Equal to the rest of the screen population.
The effect of the level of utility loss associated with cytology triage was negligible (Table 
4). Varying the extra attendance or background risk of higher primary risk women had 
more influence. When the extra attendance was halved (from 6 to 3 percentage points) or 
if higher primary risk women did not have an elevated background risk, QALYs were lost 
when more than 50% of the women switched and test characteristics were slightly inferior. 
When they were inferior, it was no longer effective if more than 30% of the women switched. 
The most influential parameter was the attendance of higher primary risk women. When 
they did not attend, it was not effective to offer self-sampling when more than 60% of 
the women switched and test characteristics were equal. In case they were inferior, this 
threshold decreased to 10%. For offering self-sampling to be cost-effective, these switching 
thresholds were even lower (Table 5).
Offering self-sampling to non-attendees of primary HPV screening | 139
6
Table 5. For what switching percentage is offering self-sampling to non-attendees not (cost-)effective?
Relative CIN2+ 
sensitivity and 
specificity (self 
versus office-based 
sampling)
Base
case
Utility loss 
due to 
cytology 
triage
Costs of 
self-
sampling 
kit in €
Extra 
attendance 
(percentage 
points)
Background 
risk of higher 
primary risk 
womena
% Extra 
attendees 
consisting 
of higher 
primary risk 
women
Sensitivity Specificity 0.000b 0.012 3.50 10 10 3 Averagec 50 0
1.01 0.99 Ind. Ind. Ind. Ind. Ind. Ind. Ind. Ind. Ind. >60
1.01 0.94 Ind. Ind. Ind. Ind. Ind. Ind. >90 Ind. Ind. >20
1.02 0.84 >80 Ind. >60 >90 >60 Ind. >40 >30 Ind. >0
0.95 0.99 Ind. Ind. Ind. Ind. Ind. Ind. >50 >60 Ind. >20
0.96 0.95 Ind. Ind. >90 Ind. >80 Ind. >50 >40 Ind. >10
0.97 0.85 >50 >70 >40 >60 >40 >80 >20 >20 >80 >0
0.89 1.00 >70 >70 >70 >70 >70 Ind. >40 >30 Ind. >10
0.90 0.95 >70 >70 >60 >70 >50 Ind. >30 >20 >90 >0
0.91 0.85 >40 >50 >30 >40 >30 >60 >20 >10 >50 >0
For every scenario the minimum switching percentage is given under which it is no longer effective (i.e. QALYs are lost) 
and/or cost-effective (i.e. €20,000 per QALY gained) to offer self-sampling to non-attendees. The switching percentage 
varies between 0 (i.e. even when no women switch it is not effective nor cost-effective to offer self-sampling), >90 (i.e. 
when more than 90% of the women switch it is not effective nor cost-effective to offer self-sampling) to independent 
(ind.) (i.e. independent of how many women switch, it is always effective and cost-effective to offer self-sampling).
Base-case assumptions: Utility loss due to cytology triage = 0.006 per week, extra attendance = 6 percentage points, 
background risk of higher primary risk women as compared to the rest of the screen population = 1.7 times higher, 
% of higher primary risk women in extra attendees = 29%. These variables, if not varied, were held constant at their 
base-case level.
a Background risk for developing cervical cancer.
b  Since a higher utility loss for primary than triage testing does not seem realistic we also assume no utility loss for 
primary testing.
c Average = Equal to the rest of the screening population.
discussion
The number of QALYs gained by offering HPV self-sampling to non-attendees was influenced 
by self-sampling test characteristics, the extra attendance via self-sampling, and the risk of 
extra attendees. When none of the regular attendees switched to self-sampling, it was always 
effective to offer HPV self-sampling. Switching resulted in fewer QALYs gained because the 
probability of being lost to follow-up after a positive self-sampling test was higher than after 
a positive office-based sampling test. If in addition the sensitivity of self-sampling was lower 
than that of office-based sampling, the number of QALYs gained decreased even more. 
However, even when test characteristics were inferior, up to 60% of the regular attendees 
could switch before the QALYs gained by the 6 percentage points extra attendance were 
annulled by the QALYs lost by switching. This percentage dropped to 30% when the extra 
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attendance halved from 6 to 3 percentage points or when higher primary risk women did 
not have an elevated background risk. It dropped to 10% if higher primary risk women did 
not attend self-sampling. When also considering a cost-effectiveness threshold of €20,000 
per QALY gained, these switching thresholds were 10 to 20 percentage points lower.
Our base-case assumption of 6 percentage points extra attendance was based on the 
Dutch PROHTECT trial in which a self-sampling kit was sent to 85% of all non-attendees (i.e. 
the remaining 15% opted-out via a letter).9 Using another strategy will probably result in 
another extra attendance rate. If this rate will be lower than 3 percentage points (almost) no 
women can switch before more QALYs are lost than gained.
We assumed that a subset of the unscreened women have a 1.7 times higher background 
risk of cervical cancer (i.e. higher primary risk women) than the rest of the screening popula-
tion, which was based on model calibration. Dugué and colleagues’ results have shown 
that non-attendees of cervical cancer screening (i.e. no cervical smear taken in the past 
8 years) had a 3.8-fold increased risk of dying from non-cervical (i.e. non-screened) HPV-
associated cancers,20 which seems to confirm our assumption that at least part of the non-
attendees have an increased background risk. Although the PROHTECT study showed that 
unscreened women (i.e. invited for screening at least once but never attended) attended 
via self-sampling,21 it is uncertain whether this is the subset with an increased background 
risk. If these higher primary risk women do not attend via self-sampling, 10% to 60% of the 
women can switch before QALYs are lost by offering HPV self-sampling to non-attendees.
The relative sensitivity and specificity of self-sampling as compared with office-based 
sampling will depend on the type of HPV DNA test used.15,22 However, even when a validated 
PCR is used (e.g. GP5+/6+ or the real-time hrHPV Test), it is possible that the sensitivity and 
specificity of self-sampling are both inferior to that of office-based sampling. In fact, relative 
test characteristics of self-sampling might even be worse than we assumed in our sensitivity 
analyses.15 In that case, the maximum percentage of women that can switch before QALYs 
are lost is also lower.
Studies in Sweden23, Finland24, the United Kingdom25, and Italy26 have also shown that 
offering self-sampling to non-attendees increased screening participation rates. We expect 
that our conclusions to a large extent apply to other countries and regions with well-orga-
nized invitational screening programs with a high compliance and an optimal age range 
and screening frequency. Even if this would mean that HPV self-sampling would be offered 
to non-attendees of a primary cytology instead of a primary HPV program. For countries 
and regions with a lower background risk and/or a more intensive screening program as 
compared to the Netherlands, benefits of increased participation due to self-sampling are 
probably lower. In countries without a highly organized invitational program, it may not 
be feasible to offer a self-sampling test to unscreened women. Instead, it could be offered 
to the general population by selling it over the counter. However, when screening is not 
reimbursed by the government, it is questionable to what extent unscreened women will 
use self-sampling. Indeed, a discrete choice experiment in the US showed that vulnerable 
adults valued costs higher than the kind of screening offered or the travel distance to obtain 
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screening.27 When non-attendance is driven by other factors than feeling uncomfortable or 
having little time (i.e. factors that can be overcome by using self-sampling instead of going 
to the clinician,28 the success of offering self-sampling may be limited.
To our knowledge, this is the first study on the harms and benefits of providing a self-
sampling test to non-attendees of a cervical cancer screening program. One of our key 
assumptions (i.e. extra attendance via self-sampling) was based on observations from the 
PROHTECT trials.9,10,21 We extensively studied the effect of the level of switching in combina-
tion with the test characteristics of self-sampling and the background cervical cancer risk of 
its users, which were important and uncertain parameters for the effectiveness of offering 
self-sampling.
A limitation of our study is that we only focused on unvaccinated women. Screening 
programs will probably be adapted when vaccinated cohorts reach the start age of screen-
ing. A separate analysis for this future situation is beyond the scope of the present analysis. 
However, we expect that offering self-sampling to non-attendees will be less (cost-)effec-
tive, because we expect that fewer health effects can be gained by increasing attendance 
because of a lower background risk. Another drawback is the limited transposability to other 
health systems. We expect lower benefits of increased participation due to self-sampling in 
screening programs that are more intensive than the Dutch future program will be (i.e. 5 
lifetime screens at ages 30, 35, 40, 50, and 60 years). Moreover, we might have overestimated 
the colposcopy compliance after a positive self-sampling test, as this may be lower than 
after a positive office-based sampling test. This may have resulted in a slight overestimation 
of the effectiveness of self-sampling. In addition, the relative CIN 2+ specificity as described 
in our study will be somewhat higher when regular attendees switch, as the prevalence of 
high-risk HPV infections in women without CIN 2+ is slightly lower in regular attendees as 
compared with non-attendees attending self-sampling. Furthermore, we did not account 
for other healthcare that women may get while attending clinic-based screening. This may 
have underestimated health losses in regular attendees switching to self-sampling, as well 
as health gains in the small group of extra attendees with a positive self-sampling test 
complying with their triage invitation.
Offering self-sampling to non-attendees clearly offers an opportunity to increase health 
benefits in cervical cancer screening if health providers make sure that (1) the relative CIN 
2+ sensitivity is at least 0.95, (2) unscreened attendees are recruited with self-sampling, and 
(3) the total attendance increases by at least 6 percentage points. Otherwise, switching 
of regular attendees to self-sampling may annul the benefits of self-sampling and even 
decrease the effectiveness of a primary HPV screening program.
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aBstract
Background: Vaccination against the oncogenic human papillomavirus (HPV) types 16 and 
18 will reduce the prevalence of these types, thereby also reducing cervical cancer risk in 
unvaccinated women. This (measurable) herd effect will be limited at first, but is expected 
to increase over time. At a certain herd immunity level, tailoring screening to vaccination 
status may no longer be worth the additional effort. Moreover, uniform screening may be 
the only viable option. We therefore investigated at what level of herd immunity it is cost-
effective to also reduce screening intensity in unvaccinated women.
Methods: We used the MISCAN-Cervix model to determine the optimal screening strategy 
for a pre-vaccination population and for vaccinated women (~80% decreased risk), assum-
ing a willingness-to-pay of €50,000 per quality-adjusted life year gained. We considered HPV 
testing, cytology testing and co-testing and varied the start age of screening, the screening 
interval and the number of lifetime screens. We then calculated the incremental cost-
effectiveness ratio (ICER) of screening unvaccinated women with the strategy optimized to 
the pre-vaccination population as compared to with the strategy optimized to vaccinated 
women, assuming different herd immunity levels.
Results: Primary HPV screening with cytology triage was the optimal strategy, with 8 life-
time screens for the pre-vaccination population and 3 for vaccinated women. The ICER of 
screening unvaccinated women 8 times instead of 3 was €28,085 in the absence of herd 
immunity. At around 50% herd immunity, the ICER reached €50,000.
Conclusion: From a herd immunity level of 50% onwards, screening intensity based on the 
pre-vaccination risk level becomes cost-ineffective for unvaccinated women. Reducing the 
screening intensity of uniform screening may then be considered.
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introduction
Infection with the human papillomavirus (HPV) has been identified as a necessary cause for 
cervical cancer.1 Both the bivalent vaccine (targeting HPV-types 16/18), which is used in the 
Netherlands, and the quadrivalent vaccine (targeting HPV-types 6/11/16/18) are effective 
in preventing the two highly oncogenic types 16 and 18,2,3 that are found in roughly 80% 
of invasive cervical cancers.4 Recently, a nonavalent vaccine has been approved,5 targeting 
seven oncogenic (and two non-oncogenic) HPV-types and thereby potentially preventing 
almost 90% of cervical cancers worldwide.6
In the Netherlands, a catch-up campaign targeted all 13- to 16-year-old girls in 2009. Since 
2010, all 12-year-old girls are offered vaccination. The three-dose vaccination coverage has 
steadily increased from 49% in the 1993 birth cohort to 61% in the 2000 birth cohort.7,8 In 
these partly vaccinated cohorts, the prevalence of HPV-16/18 infections is lower than in 
the pre-vaccination population. Therefore, unvaccinated women in those cohorts will be at 
lower risk for developing cervical cancer. While this indirect protective effect of vaccination, 
so-called herd immunity, will be limited at first, it is expected to increase over time.9 It can 
be estimated by the percentage reduction in HPV-16/18 prevalence among unvaccinated 
women who were offered vaccination, as compared to totally unvaccinated cohorts. In the 
Netherlands, primary HPV screening will be implemented in 2016. From then, it could be 
relatively easy to monitor HPV-16/18 prevalence in unvaccinated women.
In many developed countries, vaccinated cohorts are approaching the start age of cervical 
cancer screening. Especially in settings where both vaccinated and unvaccinated women 
are well represented, it is unclear what screening strategy should be offered. In the youngest 
vaccinated cohorts (with limited herd immunity), vaccinated women are at much lower 
risk than unvaccinated women and screening based on vaccination status is likely more 
cost-effective than current uniform screening.10-13 However, vaccinated women may not 
accept being offered less screening, solely because they adhered to vaccination guidelines. 
Screening based on vaccination status also requires the linkage of the screening invitational 
system with vaccination registries, which may not be (fully) possible in all settings.
As long as the follow-up of HPV vaccinated women in trials and population-based set-
tings is not long enough to observe (statistical) differences in cervical cancer rates between 
vaccinated and unvaccinated cohorts, countries are reluctant to reduce the screening 
frequency. In the US, the same screening protocol is recommended for both vaccinated and 
unvaccinated women.14,15 European guidelines even state that HPV vaccines cannot replace 
or modify current routine cervical cancer screening protocols.16
What is merely realized, is that women at reduced risk (due to either vaccination or herd 
immunity) could also be harmed by too intensive screening. These women will be offered 
more screening tests than needed, which increases their probability of being referred to the 
gynecologist in the absence of clinically relevant lesions. Women with abnormal cytology or 
HPV positive test results commonly experience fear, self-blame, distress and anxiety about 
cervical cancer, which reduces their quality of life.17,18 The ethical justification of continuing 
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screening optimized to unvaccinated women instead of to those who adhered to vaccina-
tion guidelines, is therefore questionable. Moreover, it is probably very inefficient and cost-
ineffective to do so. To avoid this inefficiency, screening should be optimized to vaccinated 
women as soon as unvaccinated women are substantially protected via herd immunity. We 
investigated at what level of herd immunity this would be justified for unvaccinated women.
methods
Using the MISCAN-Cervix model, we determined two optimal screening strategies: one for 
a pre-vaccination cohort, and one for a vaccinated cohort. To determine the level of herd 
immunity for which it would be cost-effective to replace the first strategy by the second, both 
strategies were applied to an unvaccinated cohort, assuming different levels of herd immunity.
miscan-cervix model
The MISCAN-Cervix model, which is described in more detail in the Model appendix, was 
used to estimate costs and effects of different screening strategies.19 In all of the analyses 
presented here, we simulated a cohort of 1 million women. While none of these women were 
assumed to be affected by vaccination when determining the optimal screening strategy for 
the pre-vaccination population, all of them were assumed to be vaccinated when determin-
ing the optimal screening strategy for vaccinated women. Both these optimal strategies were 
then applied to unvaccinated women assuming various herd immunity levels.
A fraction of these women will acquire HPV infections and/or develop cervical intraepithe-
lial neoplasia (CIN) lesions. If these precursors progress to cervical cancer, women may die 
from the disease. If the population undergoes screening, the disease can be detected and 
treated in an earlier stage. As a result, cervical cancer death may be prevented or postponed.
The population at risk for cervical cancer was simulated based on demographic and 
hysterectomy data;20,21 mortality from other causes was estimated using the observed age-
specific mortality in the Netherlands in 2013.20 The age-specific incidence of HPV infections 
that progress to cervical cancer was calibrated to the age-specific incidence of cervical cancer, 
which was obtained from the Netherlands Cancer Registry (NCR).22 The age-specific incidence 
of pre-invasive lesions that do not progress to cervical cancer was calibrated so that the 
simulated detection rates of CIN lesions fit the observed detection rates in the Netherlands. 
These observed detection rates were obtained from the nationwide network and registry of 
histo- and cytopathology in the Netherlands (PALGA) for the period 2000-2007.23 The incidence 
of high-risk HPV infections that do not progress to CIN was calibrated so that the simulated 
prevalence of all high-risk HPV infections fits the observed high-risk HPV prevalence.24,25
In the model, disease is subdivided into seven sequential stages: high-risk HPV infection, 
three pre-invasive stages (CIN 1, 2, and 3), and three invasive stages (International Federa-
tion of Gynecology and Obstetrics (FIGO) stages IA, IB, and II+).26 Pre-invasive and FIGO IA 
stages can be diagnosed by screening only, because no symptoms will develop, whereas 
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stages IB and II+ can also be clinically diagnosed. As precursors are usually not progressive;27 
in the model, most HPV infections will clear without ever resulting in neoplasia, and lesions 
in pre-invasive stages can regress spontaneously. In the hypothetical situation without com-
peting other-cause mortality, undetected preclinical invasive neoplasia will always progress 
to clinical cancer. CIN 1 and CIN 2 can develop in the absence of a high-risk HPV infection; 
in that case the lesion will always regress. CIN 3 or worse can only develop if a high-risk HPV 
infection is present.28
screening policies
We simulated four different screening policies: (A) primary HPV screening with reflex cytol-
ogy triage and cytology triage after six months (future Dutch screening program), (B) primary 
cytology with reflex HPV triage, (C) combined primary HPV and cytology (i.e. co-testing) with 
HPV triage after 12 months, and (D) primary cytology with cytology and HPV triage after six 
months and cytology triage after 18 months (current Dutch screening program). Policies (A) 
and (B) were already found to be cost-effective in case of no herd immunity;29policies (C) 
and (D) are included because of their resemblance with current practice in the US and in the 
Netherlands, respectively.
screening schedules
Screening schedules differed by start age, screening interval and number of screens in a 
lifetime. Possible start ages were 25, 30, 35, 40, and 45 years. The screening interval varied 
from 5 to 20 years and the number of lifetime screens ranged from 1 to 12. Because screen-
ing women older than 80 years is not likely to be beneficial,30 all strategies ended at or 
before the age of 80. In this way, 354 screening schedules were created.
assumptions for screening and treatment
As we aimed to optimized screening for women who adhere to screening guidelines, we 
assumed full attendance in both primary screening and triage testing (Appendix Table 
1). The sensitivity of cytology (the probability that the result is at least atypical squamous 
cells of undetermined significance (ASCUS)) was assumed to be 40% for CIN 1, 50% for CIN 
2 and 75% for CIN 3 or cancer.31 In the model calibration, the sensitivity of detecting at 
least high-grade squamous intraepithelial lesion (HSIL) was estimated to be 4% for CIN 1, 
18% for CIN 2, 56% for CIN 3 and 60% for cervical cancer. The specificity of cytology was 
estimated at 97.6%. Based on the observed difference in CIN 3 or cancer detection rates 
between cytology and the HPV test, we assumed the sensitivity of the HPV test to be 85% 
for a high-risk HPV infection.32 Although contamination and cross-reactivity may cause HPV 
tests to produce positive results in the absence of high-risk HPV infections, we assumed the 
specificity for the presence of HPV to be 100% and modeled a possible lack in specificity by 
including fast-clearing infections.
Detection of pre-invasive lesions and their associated management, including treatment 
if necessary, were assumed to lead to a 100% cure rate. A woman can, however, acquire new 
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HPV infections and develop CIN lesions after CIN treatment. For invasive cancer, we deter-
mined age-specific and stage-specific survival probabilities based on data from the NCR.33 
Since cancers detected by screening are found in an earlier stage than clinically diagnosed 
ones, women have a higher chance of survival. Using the NCR data, we estimated that if an 
invasive cancer is screen-detected, the probability to die from cervical cancer is reduced by 
89.4%, 50% and 20% for FIGO stages IA, IB and II+, respectively.33
assumptions for costs and utility losses
The estimated costs are based on a societal perspective, and are reported in 2013 euros 
Appendix Table 2). Screening costs include the costs for the invitational system and quality 
assurance, time and travel costs of the woman being screened, costs of smear taking, costs 
of evaluating the smear, costs of repeat tests after an inadequate test result, and costs of 
registration in PALGA. Diagnosis costs for women referred for colposcopy, treatment costs 
for detected pre-invasive lesions, treatment costs for invasive cervical cancer and costs of 
palliative care were derived from previous cost studies performed in the Netherlands.34 A 
small (psychological) loss in quality of life was assumed for attending screening (including 
waiting for the result) and for being in triage (including attending follow-up screenings).35 
Larger losses in quality of life were assumed for being diagnosed and treated for CIN or 
cancer, and for having a terminal stage of cervical cancer.36,37 Both costs and health effects 
were discounted with an annual rate of 3%.
assumptions for vaccination
We assumed the efficacy of the bivalent vaccine as observed in the PATRICIA trial,42,43 which 
is 25.3% for HPV infections without cytological abnormalities,38 and 35.0%, 54.8%, and 93.2% 
for CIN 1, 2, and 3, respectively (Table 1).2 As vaccination trials have not showed any waning 
in vaccine efficacy until now,39 the protection from vaccination was assumed to be lifelong. 
Due to limited follow-up of the trials, a reduction in cervical cancer incidence has not been 
observed yet. However, studies do give estimates of the type-specific reduction in HPV 
prevalence.40,41 In combination with the HPV-type distribution observed in cervical cancer 
cases in western Europe,4 the vaccine efficacy for cervical cancer was estimated at 83.4%. 
In this calculation we assumed that all cervical cancers are caused by a single oncogenic 
HPV-type, thereby avoiding overestimating the effect of the vaccine. We further assumed 
that all oncogenic types are equally likely to be co-infected with other oncogenic types, and 
decreased all type-specific HPV-positivity rates with the same percentage (6.6%) to account 
for multiple infections.
In the absence of herd immunity, unvaccinated women were assumed to have the cervical 
cancer risk as is currently observed in the Netherlands.42 Full herd immunity was assumed 
to be equally effective as vaccination in preventing both HPV infections, CIN lesions and 
cervical cancer. When the herd immunity level was assumed to be e.g. 25%, then 25% of 
the infections, lesions and cancers that would have been prevented by vaccination, were 
averted in unvaccinated women.
Cervical cancer screening in partly HPV vaccinated cohorts | 179
8
analyses and outcomes
For a pre-vaccination and a vaccinated cohort, we simulated the screening strategies 
described earlier and determined their discounted costs and effects as compared to no 
screening. For both cohorts, the optimal screening strategy was determined as follows. We 
first excluded all dominated screening strategies, i.e. those strategies that were more costly 
and less effective than (combinations of ) other strategies. We then ranked the efficient 
strategies based on the number of quality-adjusted life years (QALYs) gained and calculated 
their incremental cost-effectiveness ratio (ICER), i.e. the additional costs per additional QALY 
gained compared to the next less effective, efficient strategy. For each cohort, the optimal 
screening strategy was then defined as the strategy with an ICER just below the willingness-
to-pay threshold of €50,000 per QALY gained, which is a commonly used threshold in cost-
effectiveness analyses for cervical cancer screening.29,43
The two optimal screening strategies were applied to unvaccinated women assuming 
herd immunity levels of 0%, 25%, 50%, 75%, and 100%. For all these levels, the ICER of 
screening optimized to the pre-vaccination cohort as compared to screening optimized to 
the vaccinated cohort was calculated. If the ICER reached above €50,000 per QALY gained, 
screening optimized to the pre-vaccination risk level was no longer considered cost-
effective for unvaccinated women.
Table 1. Vaccination assumptions for base-case analysis and sensitivity analyses.
Vaccine 
type
Vaccine 
durationb
Vaccine efficacy
HPV 
infections 
without 
CIN
CIN 
grade 1
CIN 
grade 2
CIN 
grade 3
Cervical 
cancer
Directly observed from 
PATRICIA trial (base 
case)
Bivalent Lifelong 25.3% 35.0% 54.8% 93.2% 83.4%c
Directly observed from 
FUTURE trial
Quadrivalent Lifelong 21.4%d 29.7% 42.9% 45.5% 77.8%c
Indirectly based on 
PATRICIA triala
Bivalent Lifelong 51.4% 33.5% 55.4% 62.2% 83.4%
Indirectly based on 
FUTURE triala
Quadrivalent Lifelong 38.2% 26.1% 47.5% 53.9% 77.8%
HPV = human papillomavirus; CIN = cervical intraepithelial neoplasia.
a  Vaccine efficacy is calculated by combining the reduction in type-specific HPV infections observed in the trial, with 
the HPV-type distribution observed in HPV infections without cytological abnormalities (in the Netherlands),43 and 
in CIN 1, 2, and 3, and cervical cancer (in western Europe).4
b Trials do not (yet) show that vaccine efficacy wanes; we assumed that if it would, vaccine boosters would be offered.
c  Because the follow-up of the trials is too short to give (meaningful) estimates for cervical cancer, we used the esti-
mates from the indirect approach.
d  Observed vaccine efficacy for high-risk HPV infections combined with ASCUS (atypical squamous cells of undeter-
mined significance), trial results do not include efficacy for high-risk HPV infections only.
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sensitivity analyses
In the sensitivity analyses, we varied the following parameters.
Vaccine efficacy
1. First, we used the vaccine efficacy from two randomized efficacy trials in which the 
quadrivalent vaccine was used (FUTURE I and II).44,45 The efficacy found in these trials 
was lower than for the bivalent vaccine, i.e. 29.7%, 42.9%, and 45.5% for CIN 1, 2, and 3, 
respectively.46 Because in these trials HPV testing was only used when cytological abnor-
malities were observed, the reduction in HPV infections in women without cytological 
abnormalities is not known. Instead, we used the reduction in HPV-positive women with 
ASCUS, which was 21.4%.46 Again, the efficacy for cervical cancer was estimated using 
the type-specific reduction in HPV prevalence41,47 and the HPV-type distribution in cervi-
cal cancer,4 which resulted in an estimate of 77.8%.
2. Second, we estimated the efficacy for all disease stages by using the type-specific re-
duction in HPV prevalence observed in the PATRICIA trial and the HPV-type distribution 
observed in the Netherlands (for HPV infections without cytological abnormalities)48 and 
in western Europe (for CIN lesions and cervical cancer).4 This resulted in an assumed 
vaccine efficacy of 51.4% for HPV infections, and of 33.5%, 55.4%, and 62.2% for CIN 1, 
2, and 3, respectively. For cervical cancer, the efficacy remained at its base-case value of 
83.4%.
3. Finally, this indirect approach of combining the type-specific reduction in HPV preva-
lence with the HPV-type distribution in HPV infections, CIN lesions and cervical cancer 
was also used to determine the vaccine efficacy for the quadrivalent vaccine. The as-
sumed vaccine efficacy was 42.6% for HPV infections, 28.6%, 50.6%, and 57.7% for CIN 1, 
2, and 3, respectively, and 80.2% for cervical cancer.
Background risk for cervical cancer in unvaccinated women
Instead of assuming an equal background risk for vaccinated and unvaccinated women, we 
included two sensitivity analyses in which the background risk in unvaccinated women was 
assumed 50% higher and 50% lower than in vaccinated women.
results
Base-case analysis
For a pre-vaccination cohort, 6-yearly primary HPV screening in the age range 30-72 years 
is most cost-effective (Appendix Table 3). This corresponds to 8 screens in a lifetime. The 
optimal strategy for vaccinated women is also primary HPV screening, but in a smaller age 
range (35-59 years) and with a longer interval (every 12 years), corresponding with 3 lifetime 
screens (Appendix Table 4).
Cervical cancer screening in partly HPV vaccinated cohorts | 181
8
Health effects
As compared to screening 3 times, screening 8 times reduces cervical cancer deaths with 
161 per 100,000 unvaccinated women in the absence of herd immunity, and with 28 in case 
of full herd immunity (Table 2). It thereby yields 388 and 34 more QALYs gained when as-
suming 0% and 100% herd immunity, respectively (Table 3). However, it also requires more 
screen tests, more referrals for colposcopy and more CIN treatments. For one additionally 
prevented death, the required additional number of referrals for colposcopy increased from 
34 for 0% herd immunity to 118 for 100%.
Table 2. Undiscounted health effects for unvaccinated women of primary HPV screening at ages 30-72 
every 6 years (optimal for unvaccinated women without herd immunity) and at ages 35-59 every 12 years 
(optimal for vaccinated women), as compared to no screening. For different levels of herd immunity, 
results are given per 100,000 unvaccinated women.
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0%
30-72, 6y 717,049 55,427 10,188 873 3,805 2,360 3,029 1,416 589
35-59, 12y 277,073 20,127 4,718 271 1,479 1,014 1,782 982 423
25%
30-72, 6y 716,804 51,324 8,969 823 3,630 2,080 2,340 1,123 471
35-59, 12y 277,153 18,450 4,085 257 1,421 889 1,383 776 338
50%
30-72, 6y 716,579 47,130 7,756 770 3,468 1,802 1,648 832 348
35-59, 12y 277,233 16,752 3,447 242 1,357 765 985 579 248
75%
30-72, 6y 716,354 42,929 6,535 723 3,286 1,528 953 537 225
35-59, 12y 277,308 15,054 2,803 229 1,290 632 589 372 161
100%a
30-72, 6y 716,113 38,739 5,472 678 3,121 1,254 252 230 98
35-59, 12y 277,386 13,352 2,156 213 1,228 511 176 158 70
CIN = cervical intraepithelial neoplasia.
a  We assume that with full herd immunity, unvaccinated women have the same cervical cancer risk as vaccinated 
women.
Costs and cost-effectiveness
Screening 8 times instead of 3 increases total costs with approximately €10.9 and €11.1 
million assuming no and full herd immunity, respectively. Consequently, the ICER of screen-
ing 8 times instead of 3 increased from €28,085 per QALY gained in the absence of herd 
immunity to €35,042, €47,530, €77,541, and €322,234 for 25%, 50%, 75%, and 100% herd im-
munity, respectively. From Figure 1, the estimated herd immunity level for which screening 
8 times would cost approximately €50,000 per QALY gained when compared with screening 
3 times, is 52%.
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Table 3. Base-case costs and QALYs gained as compared to no screening (both 3% discounted) of 
screening optimized to a pre-vaccinated cohort and of screening optimized to a vaccinated cohort, and 
incremental cost-effectiveness of the former strategy as compared to the latter. For different levels of herd 
immunity, results are given per 100,000 unvaccinated women.
Herd 
immunity 
level
Screening strategy
Costs (€)
Incremental 
costs (€)
QALYs 
gained
Incremental 
QALYs ICER (€)
Age 
range
Interval No. of 
screens
0%
35-59 12y 3 4,458,721 1,488
30-72 6y 8 15,357,002 10,898,282 1,876 +388 28,085
25%
35-59 12y 3 5,062,986 1,184
30-72 6y 8 15,991,074 10,928,088 1,495 +312 35,042
50%
35-59 12y 3 5,756,793 868
30-72 6y 8 16,731,153 10,974,359 1,098 +231 47,530
75%
35-59 12y 3 6,457,603 556
30-72 6y 8 17,474,531 11,016,928 698 +142 77,541
100%a
35-59 12y 3 7,181,587 231
30-72 6y 8 18,277,092 11,095,505 265 +34 322,234
QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio.
a  With full herd immunity, unvaccinated women have the same cervical cancer risk as vaccinated women.
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Figure 1. Incremental cost-effectiveness ratio (ICER) of screening optimized to a pre-vaccination cohort 
as compared to screening optimized to a vaccinated cohort, for unvaccinated women who benefit from 
different herd immunity levels, under both base-case assumptions and sensitivity analyses.
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sensitivity analyses
When vaccine efficacy was calculated indirectly from the FUTURE trial, the optimal screen-
ing strategy for vaccinated women involved an additional screening round at age 71 (Ap-
pendix Table 5). In all other sensitivity analyses, the optimal strategy for vaccinated women 
was unchanged (Appendix Tables 6 and 7).
Similar to the base-case analysis, the ICER of using the strategy optimized to the pre-
vaccination cohort instead of to the vaccinated cohort, increased with increasing level of 
herd immunity (Table 4). In sensitivity analyses with different efficacy assumptions, screen-
ing optimized to the pre-vaccination population can be considered cost-effective as long 
as the herd immunity level is below 50-52%. When unvaccinated women would have a 
50% lower background risk for cervical cancer, screening can be optimized to vaccinated 
women, regardless of the herd immunity level. If instead, unvaccinated women have a 50% 
higher background risk, screening optimized to the pre-vaccination population should be 
continued until the herd immunity reaches above ~68%.
Table 4. Results sensitivity analyses: Incremental cost-effectiveness ratio of screening optimized to a pre-
vaccination cohort, as compared to screening optimized to a vaccinated cohort.
Herd 
immunity 
level
Vaccine efficacya Background risk in 
unvaccinated women
Directly 
observed 
from FUTURE 
trial
Indirectly 
based on 
PATRICIA trial
Indirectly 
based on 
FUTURE trial
+50% -50%
0% €28,085 €28,085 €31,450 €17,828 €80,972
25% €35,050 €34,675 €38,631 €22,950 €114,122
50% €46,471 €48,097 €49,747 €31,998 €175,596
75% €77,153 €78,139 €80,122 €56,390 €301,129
100%b €195,881 €303,352 €191,000 €157,043 QALYs lostc
QALYs = quality-adjusted life years.
a For vaccine efficacy assumptions, see Table 1.
b  We assume that with full herd immunity, unvaccinated women have the same cervical cancer risk as vaccinated 
women.
c  For unvaccinated women at 50% reduced cervical cancer risk, QALYs were lost when screening was optimized to the 
pre-vaccination risk level instead of to the risk level in vaccinated women.
discussion
For both a pre-vaccination and a vaccinated cohort, primary HPV screening is more cost-
effective than primary cytology or co-testing. The optimal number of lifetime screens varied 
from 8 for the pre-vaccination cohort, to only 3 for the vaccinated cohort. For unvaccinated 
women, the adverse effects and costs of screening become more important as the herd 
immunity level increases. Offering these women 8 instead of 3 lifetime screens incremen-
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tally required 34 colposcopy referrals per prevented death for 0% herd immunity, which 
increased to 118 referrals for 100% herd immunity. The ICER of screening 8 times instead 
of 3 increased from €28,085 per QALY gained in the absence of herd immunity to €322,234 
at full herd immunity. Screening optimized to the risk level in vaccinated women becomes 
more cost-effective than screening optimized to the pre-vaccination risk level when the 
herd immunity reaches above 50-55%.
To foresee whether and when the herd immunity will reach this level, countries need to 
monitor the HPV-16/18 prevalence in unvaccinated women, starting with a reliable pre-
vaccination baseline measurement. A recent cross-sectional study among women aged 
18-24 years in Australia, in whom vaccination coverage was 55-74% for 1-3 doses,49 showed 
a reduction in HPV-16/18 prevalence of 93% and 35% in vaccinated and unvaccinated 
women, respectively, compared to the pre-vaccination prevalence.50 From these early data, 
the estimated herd immunity level would equal (0.35 / 0.93 ≈) 38%.
We have not incorporated vaccination coverage as a separate parameter in our analyses, 
the reason for which is as follows. Vaccination coverage plays a role in two ways: first, it 
determines how many unvaccinated women there are (which is important when evaluating 
how to screen them), and second, it is one of the main determinants of herd immunity. 
Mathematical models have been created to estimate the level of herd immunity given 
vaccination coverage.51-53 These models have been helpful in decision analyses concerning 
vaccination (also in boys), by estimating its indirect effect in the unvaccinated. However, 
when it comes to screening decisions that depend on current or near future herd immunity, 
it seems more appropriate to seek guidance from actual measurements (of HPV prevalence 
in the unvaccinated) than from model based predictions of herd immunity levels. Indeed, 
the exact relation between coverage and herd immunity will only become established 
based on such measurements.
The manuscript primarily focused on the effect of decreasing the screening frequency of 
uniform screening for unvaccinated women. For vaccinated women, this adjustment would be 
cost-effective by definition. Meanwhile, it is important to point out that the harms of screening 
the vaccinated 8 times instead of 3 were smaller than the life years gained (Table 3), meaning 
that unadjusted screening did not result in a net loss in health for vaccinated women.
We optimized the screening strategy to the pre-vaccination risk level and to the risk level 
in vaccinated women. For partly vaccinated cohorts, it could be beneficial to have a screen-
ing strategy that is a compromise of these two strategies. In fact, when ignoring the costs 
and efforts related to restructuring screening guidelines, it would likely be cost-effective to 
reduce the screening frequency gradually while the herd immunity level increases. Adjust-
ing national screening guidelines every few years is not a very workable solution though. 
Likewise, it could be cost-effective to tailor screening to vaccination status. Our results have 
shown that as soon as the herd immunity level reaches 50%, then it is beneficial (in terms 
of cost-effectiveness) for unvaccinated women to replace screening optimized to the pre-
vaccination risk level with screening optimized to the risk level in vaccinated women. If this 
already happens within a few years, then establishing tailored screening by e.g. develop-
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ing a vaccination registry that is linked to the screening invitational system, may not be 
worthwhile. The (lack of ) accumulation of herd immunity over time is crucial in deciding 
whether the establishment of tailored screening would be worth these additional efforts. 
We performed our analyses under the assumption that it is most realistic that countries will 
continue screening all women uniformly, and that a once-only adjustment is made as soon 
as this seems justified for unvaccinated women.
Notable limitations are the following. First, we assumed that the efficacy of the vaccine has a 
lifelong duration. Although until now, HPV vaccination trials have shown a sustained efficacy,2,3 
it is possible that the efficacy will wane in the future. If the protection would fade away and of-
fering vaccination boosters would not be an option, then screening optimized to vaccinated 
women would probably be more intensive than in the current analyses, and unvaccinated 
women could be screened accordingly from a lower herd immunity level onwards. Second, 
as the follow-up of the vaccination trials is too limited to give (meaningful) estimates of the 
vaccine efficacy for cervical cancer, we had to estimate this efficacy indirectly. The decrease in 
CIN 3 lesions does indicate that the vaccine is likely to prevent clinically relevant lesions, and 
therefore also cancer.2,46 If the decrease in cervical cancer risk would be smaller than estimated, 
vaccinated women would also require more intensive screening, again meaning that unvac-
cinated women could be screened accordingly from a lower herd immunity level. Third, we 
assumed an equal background risk for vaccinated and unvaccinated women. Because reasons 
for refusing vaccination may vary widely (e.g. lack of knowledge about HPV, low perceived risk 
of infection, concerns about safety, religious values),54 the background risk in unvaccinated 
women could both be higher or lower as compared to vaccinated women. In the sensitivity 
analyses we showed that even if the background risk in unvaccinated women would be 50% 
higher, then unvaccinated women could already be screened as vaccinated women from 
~68% herd immunity onwards. Finally, we have not modeled the effects of the nonavalent 
vaccine, because its use is still limited compared to the bivalent and quadrivalent vaccine. If 
vaccination with this more potent vaccine would lead to a less intensive optimal screening 
strategy for vaccinated women, the herd immunity level at which unvaccinated women could 
be screened accordingly would be higher.
To our knowledge, this is the first study evaluating at what herd immunity level a once-only 
uniform (equal for vaccinated and unvaccinated women) screening adaptation becomes, 
considering risks, benefits and costs, an option. Because vaccinated women are approach-
ing the age at which cervical cancer screening starts, the results of this study will be relevant 
in the near future. It shows, that as long as stepwise adjustment or dichotomized screening 
based on vaccination status are considered unfeasible, one may wait until the HPV-16/18 
prevalence amongst unvaccinated women drops below 50% of the pre-vaccination level, 
before considering adjusting screening. Meanwhile, also the necessary evidence for a de-
crease in cervical cancer risk in vaccinated women should become available.
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Appendix Table 1. Base-case assumptions for screening.
Parameter Value
Attendance 100%
Cytology
Probability of at least ASCUS for:
CIN grade 1 40%
CIN grade 2 50%
CIN grade 3 or worse 75%
Probability of at least HSIL for:
CIN grade 1 4%
CIN grade 2 18%
CIN grade 3 56%
Cervical cancer 60%
Specificitya 97.6%
HPV test
Sensitivity for high-risk HPV infection 85%
Specificity for high-risk HPV infection 100%b
ASCUS = atypical squamous cells of undetermined significance; CIN = cervical intraepithelial neoplasia; HSIL = high-
grade squamous intraepithelial lesion; HPV = human papillomavirus.
a Probability of a normal test result in women without CIN or cancer.
b Potential false-positive HPV test results were modeled as HPV infections with a short duration.
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Appendix Table 2. Base-case assumptions for costs and utilities.
Costs (€) Utilities
Disutility Duration Quality-adjusted 
time lost
Invitation
4.91 - - -
Primary screening
Cytology 66.95
HPV test 63.63 0.005 2 weeks 2 hours
Cytology + HPV test 96.32
Reflex triage
Cytology 32.69 - - -
HPV test 29.38
Triage after 6, 12 or 18 months
Cytology 64.41 0.005 Time since last 
test
Depends on 
intervalHPV test 61.10 0.005
Diagnosis and treatment of pre-invasive stages
False-positive referral 300 0.005 0.5 year 22 hours
CIN grade 1 936 0.03 0.5 year 6 days
CIN grade 2 1,386 0.07 1 year 26 days
CIN grade 3 1,623 0.07 1 year 26 days
Diagnosis and treatment of cancer
FIGO IA 5,314 0.062 5 years 4 months
FIGO IB 12,601 0.062 5 years 4 months
FIGO II+ (screen-detected) 12,420 0.28 5 years 17 months
FIGO II+ (clinically detected) 11,599 0.28 5 years 17 months
Terminal care
28,220 0.740 1 year 9 months
HPV = human papillomavirus; CIN = cervical intraepithelial neoplasia; FIGO = International Federation of Gynecology 
and Obstetrics.
Costs are in 2013 prices. €1.00 (£0.85; $1.37).
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Appendix Table 3. Cost-effective strategies for a pre-vaccination cohort under base-case assumptions.
Strategy Cost-effectivenessa
Policy Age 
range
Interval No. of 
screens
QALYs 
gained
Costs (€) ICER (€)
Primary HPV with cytology triage 45 - 1 817 3,656 -
Primary HPV with cytology triage 40 - 59 19 2 1,192 595,896 1,851
Primary HPV with cytology triage 40 - 57 17 2 1,210 654,022 3,093
Primary HPV with cytology triage 40 - 66 13 3 1,355 1,225,940 3,971
Primary HPV with cytology triage 35 - 71 12 4 1,545 2,777,862 8,138
Primary HPV with cytology triage 35 - 65 10 4 1,602 3,247,901 8,226
Primary HPV with cytology triage 35 - 71 9 5 1,662 4,013,836 12,866
Primary HPV with cytology triage 35 - 75 8 6 1,706 4,888,675 19,898
Primary HPV with cytology triage 35 - 70 7 6 1,726 5,505,034 30,264
Primary HPV with cytology triage 30 - 72 7 7 1,820 8,797,780 35,292
Primary HPV with cytology triage 30 - 72 6 8 1,857 10,423,560 43,175
Primary HPV with cytology triage 30 - 78 6 9 1,865 10,849,457 55,738
Primary HPV with cytology triage 30 - 75 5 10 1,890 13,024,210 85,673
Primary HPV with cytology triage 30 - 80 5 11 1,893 13,420,746 138,221
Primary HPV with cytology triage 30 - 74 4 12 1,897 16,495,407 865,290
QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio; HPV = human papillomavirus.
a Costs and QALYs were discounted at an annual rate of 3.
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Appendix Table 4. Cost-effective strategies for a vaccinated cohort under base-case assumptions.
Strategy Cost-effectivenessa
Policy Age 
range
Interval No. of 
screens
QALYs 
gained
Costs (€) ICER (€)
Primary HPV with cytology triage 45 - 1 115 1,618,507 -
Primary HPV with cytology triage 40 - 1 137 2,005,709 17,306
Primary HPV with cytology triage 40 - 57 17 2 178 3,057,518 25,930
Primary HPV with cytology triage 40 - 55 15 2 181 3,143,604 29,183
Primary HPV with cytology triage 35 - 50 15 2 198 3,855,345 39,937
Primary HPV with cytology triage 35 - 65 15 3 217 4,656,004 42,850
Primary HPV with cytology triage 35 - 59 12 3 226 5,081,409 45,286
Primary HPV with cytology triage 35 - 55 10 3 233 5,408,214 52,823
Primary HPV with cytology triage 35 - 65 10 4 242 6,238,514 88,735
Primary HPV with cytology triage 35 - 67 8 5 252 7,594,621 138,443
Primary HPV with cytology triage 35 - 75 8 6 254 8,139,809 257,058
Primary cytology with HPV triage 30 - 72 6 8 262 13,056,727 593,680
Primary cytology with HPV triage 30 - 78 6 9 263 13,534,997 862,056
Primary cytology with HPV triage 30 - 75 5 10 263 15,697,980 5,376,727
QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio; HPV = human papillomavirus.
a Costs and QALYs were discounted at an annual rate of 3%.
Appendix Table 5. Cost-effective strategies for a vaccinated cohort when vaccine efficacy is indirectly 
based on the FUTURE trial.
Strategy Cost-effectivenessa
Policy Age 
range
Interval No. of 
screens
QALYs 
gained
Costs (€) ICER (€)
Primary HPV with cytology triage 40 - 53 13 2 123 3,475,978 -
Primary HPV with cytology triage 40 - 66 13 3 147 4,199,297 29,996
Primary HPV with cytology triage 35 - 59 12 3 176 5,354,578 40,512
Primary HPV with cytology triage 35 - 71 12 4 189 5,955,460 47,493
Primary HPV with cytology triage 35 - 75 10 4 197 6,465,406 57,658
Primary HPV with cytology triage 35 - 71 9 5 209 7,359,065 74,476
Primary HPV with cytology triage 35 - 75 8 6 216 8,312,103 149,656
Primary HPV with cytology triage 30 - 78 8 7 229 10,955,327 203,002
Primary HPV with cytology triage 30 - 72 6 8 234 13,466,715 457,539
Primary HPV with cytology triage 30 - 78 6 9 235 13,922,136 639,319
Primary cytology with HPV triage 30 - 75 5 10 236 16,060,457 1,680,746
QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio; HPV = human papillomavirus.
a Costs and QALYs were discounted at an annual rate of 3%.
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Appendix Table 6. Cost-effective strategies for a vaccinated cohort when vaccine efficacy is directly 
observed from the FUTURE trial.
Strategy Cost-effectivenessa
Policy Age 
range
Interval No. of 
screens
QALYs 
gained
Costs (€) ICER (€)
Primary HPV with cytology triage 45 - 1 178 1,448,046 -
Primary HPV with cytology triage 40 - 1 216 1,850,074 10,678
Primary HPV with cytology triage 40 - 58 18 2 273 2,776,309 16,067
Primary HPV with cytology triage 40 - 54 14 2 280 2,946,291 25,127
Primary HPV with cytology triage 35 - 65 15 3 334 4,455,547 27,861
Primary HPV with cytology triage 35 - 61 13 3 341 4,728,923 44,804
Primary HPV with cytology triage 35 - 59 12 3 344 4,877,601 48,674
Primary HPV with cytology triage 35 - 71 12 4 355 5,477,508 52,364
Primary HPV with cytology triage 35 - 65 10 4 364 5,984,606 53,712
Primary HPV with cytology triage 35 - 71 9 5 378 6,872,248 67,009
Primary HPV with cytology triage 35 - 75 8 6 384 7,816,679 156,284
Primary cytology with HPV triage 30 - 78 6 9 395 13,392,036 480,256
Primary cytology with HPV triage 30 - 75 5 10 395 15,537,380 37,371,197
QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio; HPV = human papillomavirus.
a Costs and QALYs were discounted at an annual rate of 3%.
Appendix Table 7. Cost-effective strategies for a vaccinated cohort when vaccine efficacy is indirectly 
based on the PATRICIA trial.
Strategy Cost-effectivenessa
Policy Age 
range
Interval No. of 
screens
QALYs 
gained
Costs (€) ICER (€)
Primary HPV with cytology triage 45 - 1 129 1,515,666 -
Primary HPV with cytology triage 40 - 1 152 1,908,685 17,332
Primary HPV with cytology triage 40 - 57 17 2 196 2,904,752 22,669
Primary HPV with cytology triage 40 - 55 15 2 198 2,990,397 49,102
Primary HPV with cytology triage 35 - 59 12 3 237 4,931,273 49,180
Primary HPV with cytology triage 35 - 55 10 3 243 5,243,447 56,753
Primary HPV with cytology triage 35 - 65 10 4 255 6,030,039 66,648
Primary HPV with cytology triage 35 - 75 10 5 259 6,543,607 131,391
Primary HPV with cytology triage 35 - 75 8 6 264 7,863,497 259,251
Primary cytology with HPV triage 30 - 78 6 9 269 13,401,036 1,028,756
QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio; HPV = human papillomavirus.
a Costs and QALYs were discounted at an annual rate of 3%.
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This chapter starts with a summary of the main findings from the studies that are presented 
in this thesis. We will then interpret those findings, and elaborate on their implications for 
cervical cancer and colorectal cancer screening. The chapter ends with conclusions and 
recommendations.
main findings
This section provides answers to the research questions that were raised in the introduction 
of this thesis.
methodological issues in cost-effectiveness analyses
In general, cost-effectiveness analyses (CEAs) are used to compare the effectiveness and 
cost effectiveness of different screening strategies. The incremental cost-effectiveness ratio 
(ICER) is a commonly used measure to judge the cost-effectiveness of cancer screening 
strategies. For all efficient strategies, the ICER equals the additional amount of money that 
needs to be paid to save one additional (healthy) life year, compared to the next less effec-
tive strategy. The estimated ICER of one strategy therefore depends on the estimated costs 
and health benefits of other included strategies. The strategy with the highest ICER within 
the willingness-to-pay threshold is deemed optimal.
To what extent do cost-effectiveness analyses of cervical cancer screening omit relevant 
strategies, and how does this affect their conclusions?
In the review presented in Chapter 2, we identified 30 CEAs of cervical cancer screening 
using HPV testing that were published between January 1995 and September 2013. We 
compared the set of included strategies and their estimated ICERs. Eighteen studies were 
likely to have omitted one or more strategies in the CEA-relevant portion of the efficiency 
frontier, i.e. with ICERs around the willingness-to-pay threshold. In all but three of those 
studies, a longer interval than the one found to be optimal was not included. It should be 
acknowledged that even though strategies with a longer interval may not be considered 
by policy makers, their inclusion is necessary to reliably estimate ICERs of strategies that are 
considered. The underestimation of ICERs can lead to the acceptance and implementation 
of strategies that are not cost-effective. Readers of CEAs can recognize this type of method-
ological flaw by the apparent ‘kinks’ in efficiency frontiers.
reducing harms
Although cancer screening programs aim to reduce morbidity and mortality, they always 
come with burden and harm for some of its participants. In general, for screening tests, 
there is a trade-off between high sensitivity and high specificity. As many cervical lesions 
tend to regress naturally, cytology screening is characterized by a relatively low specificity. 
Unnecessary follow-up testing and potential treatment of regressive cervical intraepithelial 
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neoplasia (CIN) may involve substantial harms, which are likely to increase when cytology is 
replaced with HPV-based screening.
What are the potential harms of primary HPV screening in over-screened women?
As HPV-based screening offers better protection against (precursors of ) cervical cancer than 
cytology screening,1 it is implemented in both Australia and the Netherlands in 2017,2,3 and 
is considered by several other developed countries. The disadvantage of HPV-based screen-
ing, however, is that most HPV infections clear naturally and are therefore preferably not 
detected by screening. Especially at young age, a lot of women who are infected with HPV 
will never develop neoplasia, let alone cancer.
In Chapter 3, we estimated the potential harms of HPV-based screening for over-screened 
women, who are screened more frequently and from a younger age than recommended by 
international guidelines. We found that for women screened every 5 years from age 30, 
switching to HPV-based screening resulted in 32 fewer cervical cancer deaths at a cost of 
~9,000 more positive primary tests. For those screened annually from age 20, this ratio was 
much worse, with only 6-7 fewer deaths at a cost of almost 77,000 more positive primary 
tests. Since with annual or biennial cytology-based screening, clinically relevant lesions are 
rarely missed, a switch to HPV-based testing will merely reduce cancer incidence and mor-
tality in women who are screened this frequently. However, HPV testing will lead to many 
more positive tests and (false-positive) referrals to colposcopy. Altogether, for over-screened 
women, switching to HPV-based screening was found to be associated with a net loss in 
health.
What is the impact of cervical screening on preterm birth? Is it of such importance that 
cervical screening at reproductive age should depend on a woman’s childwish?
Loop electrosurgical excision procedure (LEEP) is the most commonly used method to 
remove CIN.4 Although the procedure is effective in removing CIN, women treated with 
LEEP have a 39% higher risk of subsequent preterm birth than women with untreated CIN.5 
Besides reduced survival probabilities and potential disabilities for the child itself, a preterm 
birth results in substantial costs and emotional distress for parents.6 To our knowledge, this 
harm has not been taken into account in (cost-)effectiveness analyses of cervical cancer 
screening. Therefore, Chapter 4 of this thesis provided insight into the impact of cervical 
cancer screening on preterm birth risk and subsequent infant morbidity and mortality.
Using US birth rates and baseline risk of preterm birth, we showed that initiating 3-yearly 
screening at age 21 instead of age 30 yields very limited health gain in women of reproduc-
tive age (i.e. ~300 life years gained per 100,000 screened women). Moreover, even without 
considering the negative impact of increased preterm birth risk, it resulted in a net loss in 
quality-adjusted life years. Lowering the start age of 3-yearly screening from 30 to 21 years 
did significantly increase preterm birth rates with 223 per 100,000 screened women, leading 
to 20 more infants with (severe) morbidity and 6 more stillborn infants.
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Given that health benefits of cervical cancer screening below age 30 are limited (or even 
negative), but preterm birth risk increases substantially, delaying the start age of screening 
to age 30 should be considered, especially in women with a (future) childwish.
increasing benefits
Benefits of screening can be enhanced by switching to a screening test that provides better 
protection against invasive cancer. Given that incidence and mortality is overrepresented in 
non-attendees, perhaps the most effective way of increasing benefits is by increasing the 
adherence with screening. Introducing an alternative screening test, like the self-sampling 
HPV test for cervical cancer screening and the multitarget stool DNA test for colorectal 
cancer screening, can entice individuals who would otherwise not have participated in 
screening, to participate in screening.
Does cervical cancer incidence after a normal cytological sample differ between SurePath, 
ThinPrep and conventional cytology?
Over the past decade, liquid-based cytology (LBC) tests SurePath and ThinPrep have 
gradually replaced conventional cytology in many countries with organized cervical 
cancer screening programs, such as the UK, the Netherlands and Denmark. As compared 
to conventional cytology, the advantages of using LBC are that it facilitates co-testing (i.e. 
the LBC sample can also be used for HPV testing) and that it results in fewer samples of 
unsatisfactory quality. Two systematic reviews have shown similar sensitivity for LBC and 
conventional cytology,7,8 but did not make a distinction between SurePath and ThinPrep. 
In an earlier study, we have shown that compared to the use of conventional cytology, 
the use of SurePath results in increased CIN 2+ detection rates, while the use of ThinPrep 
does not.9 The remaining question was whether those additionally detected CIN 2+ lesions 
would all have regressed in the absence of screening, or whether their detection prevented 
development to cervical cancer.
To answer this question, we have calculated the cumulative cancer incidence after a 
normal SurePath, ThinPrep and conventional cytology screening sample taken within the 
Dutch cervical cancer screening program (Chapter 5). Using a Cox regression analysis, we 
showed that the 6-year risk of cervical cancer after a normal screening sample was 19% 
lower for SurePath than for conventional cytology. No significant difference was found 
between ThinPrep and conventional cytology. The assumed similarity of test characteristics 
between LBC and conventional cytology, and between different types of LBC tests, should 
therefore be reconsidered.
When do the harms of offering HPV self-sampling to non-attendees of organized primary HPV 
screening outweigh its benefits?
The aim of offering self-sampling to non-attendees of cervical cancer screening is to entice 
women who would otherwise not be screened, to participate in screening. However, it is 
possible that women who would otherwise be screened by a clinician, will switch from 
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getting the office-based test to using the self-sampling kit. If the test characteristics of the 
self-sampling HPV test are comparable to those of the office-based HPV test, this will not be 
problematic. It will in fact be cost-saving, given that self-sampling does not involve smear-
taking costs by a clinician. However, the use of self-sampled material instead of material 
collected by a clinician could lead to a lower sensitivity and/or specificity of the HPV test.
In Chapter 6, we investigated the conditions under which offering self-sampling to 
non-attendees would be (cost-)effective. We found that self-sampling is expected to gain 
health effects if the relative CIN 2+ sensitivity is at least 0.95, previously unscreened women 
are recruited, and the total attendance increases with at least 6 percentage points. If these 
requirements are not met, women switching from office-based sampling to self-sampling 
may decrease the total effectiveness of the program.
Is colorectal cancer screening with the multitarget stool DNA test a cost-effective alternative 
for the Medicare population, and if not, under what conditions will it be?
The recently developed multitarget stool DNA (mtSDNA) test has been included in the 2016 
colorectal cancer screening guidelines of the United States Preventive Services Task Force 
(USPSTF).10 Three-yearly screening with this test is now covered by the Centers for Medicare 
and Medicaid Services (CMS). In Chapter 7, we have estimated whether this screening 
strategy is a cost-effective alternative to other reimbursed strategies for the Medicare popu-
lation, and if not, at what cost, adherence or frequency it would be.
As compared to no screening, screening with the mtSDNA test reduces the incidence 
and mortality from colorectal cancer. However, at $493 per test, the total costs are much 
higher than for other stool-based tests ($22 per FIT and $4 per FOBT). Therefore, 3-yearly 
mtSDNA testing is not a cost-effective alternative to other reimbursed strategies. Even if 
adherence would increase with 30%, this conclusion did not change. The reimbursement 
rate has to be below $33 for 3-yearly mtSDNA testing to be cost-effective. Although per-test 
reimbursement rates of $58 and $47 could be supported with annual or biennial mtSDNA 
testing, these rates are still way lower than the current reimbursement rate of $493.
reducing harms and increasing benefits: opportunities for risk-based 
screening
Personalized screening provides the opportunity to reduce harms of screening in individu-
als at low risk for the disease, while increasing benefits in those at higher risk. Possibilities 
for personalization include cervical cancer screening based on HPV vaccination status and 
colorectal cancer screening based on genetic risk factors.
At what level of herd immunity can uniform cervical cancer screening be adjusted to the risk 
level in vaccinated women?
It is expected that HPV-vaccinated women will be at lower risk for developing cervical 
cancer than unvaccinated women. Using microsimulation modeling, we determined the 
optimal screening strategy for both a pre-vaccination, and a fully vaccinated cohort (Chap-
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ter 8). Under a willingness-to-pay threshold of €50,000 per quality-adjusted life year, primary 
HPV screening with cytology triage was found to be most cost-effective for both cohorts. 
Whereas for the pre-vaccination cohort, the optimal strategy included 8 lifetime screens, for 
the fully vaccinated cohort, it included only 3.
Due to organizational or ethical matters, it may not be possible to offer screening based 
on HPV vaccination status. If a population will be offered uniform screening, then the 
intensity of such screening is preferably reduced as vaccination coverage, and thereby 
herd immunity, increases. Although it would be most cost-effective to reduce the intensity 
gradually, it may not be feasible to adjust the screening program every few years. When the 
screening program will only be adjusted once, then one might consider doing so when 
herd immunity reaches ~50%, as from then on it is more cost-effective to offer unvaccinated 
women 3 lifetime screens instead of 8. This result merely changed when the background 
cervical cancer risk was increased in unvaccinated women, or when the quadrivalent instead 
of the bivalent vaccine was assumed to be offered. Therefore, if a cervical cancer screening 
program cannot be tailored to HPV-vaccination status, and it can only be adjusted once, 
then one should wait with adjusting the screening frequency to the risk level in vaccinated 
women until unvaccinated women benefit from a herd immunity level of at least 50%.
Should colorectal cancer screening for people with a positive family history vary by age?
It is well-known that individuals with a family history of colorectal cancer are at an increased 
risk for developing the disease themselves. Therefore, several screening guidelines recom-
mend more intensive screening for individuals with one or more affected first-degree 
relatives (FDRs) than for people in the general population.11 Although for a given level of 
family history, the relative risk of developing colorectal cancer as compared to the general 
population decreases with age, the current guidelines do not let the recommended interval 
of screening vary by age. To investigate whether such a refinement would be worthwhile, in 
Chapter 9 we optimized colonoscopy screening for individuals with 1, 2, 3, or ≥4 affected 
FDRs, allowing different screening intervals at different ages.
Just as in an earlier modeling study,12 we found that it is cost-effective to offer more 
intensive screening to individuals with more affected FDRs. In addition, we found that for 
individuals with a constant level of family history, the screening interval can be lengthened 
after several subsequent colonoscopies. For individuals with one affected FDR, comprising 
~92% of those with a positive family history, the optimal screening interval rapidly increased 
from 3 years at age 40 to 7 years at age 55. Individuals with 2 or 3 affected FDRs should start 
screening earlier and lengthen their screening interval more gradually, from 2-3 years at age 
35 to 7 years at age 70. These results show that individuals with a constant level of family 
history can safely lengthen their screening interval, provided that they have had several 
subsequent negative colonoscopies.
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What is the potential benefit of risk-stratified colorectal cancer screening based on common 
genetic variants?
Whereas individuals with well-defined cancer syndromes have one rare genetic mutation 
that increases their cancer risk substantially, the presence of multiple more common genetic 
variants can also increase someone’s cancer risk significantly. Until now, relatively few of 
these so-called single nucleotide polymorphisms (SNPs) associated with colorectal cancer 
risk have been discovered. Consequently, currently available polygenic tests have limited 
discriminative power, with an area under the ROC curve (AUC) of approximately 0.60. In 
Chapter 10, we explored the current and potential future benefit of risk-based screening 
using polygenic information.
We showed that under current discriminatory performance of polygenic testing, the 
health benefits of risk-stratified screening are modest at most. At a current estimated price 
of $200 per polygenic test, risk-stratified screening is not cost-effective compared to uniform 
screening. This could change if the costs of polygenic testing would drop below $141 per 
person, or if the AUC value of polygenic testing would increase beyond 0.65.
interPretation of findings
The studies presented in this thesis all aim at informing policy makers on the possible op-
portunities to improve the harm-benefit ratio of cervical cancer or colorectal cancer screen-
ing. While some results, like those presented in Chapter 5, could be of direct use; others 
come from more exploratory analyses that may not directly result in policy applications but 
rather provide guidance for future developments and research. In the paragraphs below, we 
describe the usefulness of the outcomes for policy makers.
improving adherence with cervical cancer screening guidelines
Although cervical cancer screening is practiced in many countries, the extent to which it 
has been organized differs widely.13 In some countries, women are offered yearly check-
ups when they visit their gynecologist, while in others screening is much more structured 
with an official invitation every 5 years. Especially in settings with non-organized screening, 
the efficiency and effectiveness of screening could largely be increased by minimizing the 
extent to which women are over-screened and under-screened.
Reducing over-screening for cervical cancer
In literature, it has been well-acknowledged that over-screening with primary cytology is 
not beneficial for women. A US modeling study showed that annual cytology screening 
provides similar life years gained as 3-yearly cytology screening, but requires more than 
twice the number of colposcopies.14 Our model outcomes show that annual screening does 
provide marginal health benefits compared with 3-yearly screening, but comes with roughly 
70% more colposcopies (Chapter 3). Although the impact on quality of life of certain events 
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is hard to measure, having a positive cytological test and being referred for colposcopy are 
certainly associated with adverse psychological effects.15,16
Despite the limited or absent benefits, screening at shorter intervals than recommended 
by international guidelines is still current practice for a lot of women worldwide. In the US, 
where 3-yearly cytology is recommended, more than 68% of physicians recommend an-
other cytological test in 1 or 2 years,17 even though more than half of the women are willing 
to have the 3-year interval.18 In electronic health record data, 66% of US women aged 30-65 
had a shorter screening interval than recommended. Such data can be used to identify 
women who are screened more often than recommended, and to approach these women 
and/or their physicians about the ineffectiveness and possible harms of such practice.19
In Europe, over-screening rates are also significant, especially in countries with opportu-
nistic screening.20 Annual cytology is even the official policy in some European countries 
(Germany, Luxembourg, Austria, and Poland).20 In those countries, balanced screening 
guidelines and adherence with those guidelines is needed to improve the harm-benefit 
ratio of screening, and to limit waste of screening resources. As for over-screened women, 
switching to primary HPV screening can be considered harmful, cytology should remain the 
preferred testing method (Chapter 3).
HPV-vaccinated women will likely be at much lower risk for cervical cancer, so their poten-
tial benefit from intensive screening is even smaller.As the oldest HPV-vaccinated cohorts 
are approaching the start age of cervical cancer screening, more attention should be drawn 
to the adverse effects of over-screening. Policy makers, but also physicians and women 
themselves, should make sure that over-screening is kept to a minimum.
Reducing under-screening for cervical cancer
Meanwhile, a large part of cervical cancer incidence and mortality is found in women who 
were never screened. In the Netherlands, where 5-year screening coverage is ~80%, more 
than 50% of cervical cancer cases are found in women who never participated in screen-
ing.21 In countries like the Netherlands, where screening is well-organized and covered by 
health insurance, organizational barriers are of little importance for (non-)adherence to 
guidelines. Most non-attendance was found to be related to women’s beliefs about cervical 
screening.22 Although an informed choice to not participate in screening should be fully 
respected, the beliefs also included a low perceived likelihood of developing the disease 
and the belief that the disease is incurable.22 For those women, awareness campaigns 
could increase their knowledge and could help them to make an informed decision about 
screening participation. Although the aversion of the test procedure was not found to be 
associated with uptake of cervical screening,22 Gök et al. did show that some never-screened 
women do participate when offered a self-sampling kit.23
In Chapter 6 of this thesis, we have evaluated the effectiveness of offering self-sampling 
to non-attendees within the new Dutch cervical cancer screening program, which has 
started in January 2017.. At the time of that study, policy makers considered sending self-
sampling kits to all non-attendees of the screening program. In the program that will be 
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implemented, however, self-sampling kits will only be sent to women who actively request 
one. This change in policy reduces the expected increase in participation by 42%,24 mean-
ing that self-sampling is expected to increase participation with only ~3% of the screening 
eligible population. This implies that, if self-sampling provides less accurate test results than 
office-based sampling, it is very important that women do not switch from office-based 
to self-sampling HPV testing. However, screening will be performed using a polymerase 
chain reaction (PCR)-based testing method, for which it has been shown that self-sampling 
and office-based sampling are likely to have similar test accuracy.25 Nevertheless, switching 
from office-based to self-sampling should be discouraged as long as a worse test accuracy 
cannot be ruled out.
improving adherence with colorectal cancer screening guidelines
For colorectal cancer screening, reducing the percentage of non-attendees is also one of the 
most important ways to increase the effectiveness of screening. The US Preventive Services 
Task Force (USPSTF) recommends a variety of possible screening tests,10 such that everyone 
can be screened according to their preferences, and the overall uptake is as high as possible. 
Indeed, providing a range of screening modalities most likely increases uptake with colorectal 
cancer screening.26 However, the possibility of multiple screening options was also found to 
be associated with higher levels of confusion, and individuals who said to be confused by the 
screening options were less likely to participate in colorectal cancer screening.27
Another drawback of offering multiple screening options is that not every test has the 
same test characteristics, and some tests simply outperform others. Although it is good to 
stimulate adherence via a range of different tests, one should be careful with offering a new 
test of which the characteristics are worse than those of other tests. Individuals who would 
otherwise be screened with a test with a better performance, might switch to the new test, 
and then overall effectiveness of screening may drop. This might sound hypothetical, but 
will be true for any individual who switches to a screening strategy with a slightly reduced 
effectiveness, such as from annual FIT to 3-yearly mtSDNA screening.
New screening tests can only be marketed after approval by the US Food and Drug Adminis-
tration (FDA). The FDA judges the safety and accuracy of the tests, but does not consider their 
suitability for mass screening. This suitability is judged by organizations like the USPSTF. If such 
organizations would not recommend screening tests with worse performance, effectiveness 
of cancer screening would never decline with introduction of new screening methods. In April 
2016, however, the FDA approved the blood test Epi proColon®, a molecular DNA test that 
detects methylated Septin9 DNA in blood, with an estimated sensitivity of 48% for colorectal 
cancer.28 Although the use of such a test would be effective and cost-effective compared to 
no screening, it does not provide a good alternative to currently available testing methods.29 
Nevertheless, the test is one of the currently available options for colorectal cancer screen-
ing in the US, where individuals can choose the screening test with which they want to be 
screened. The choice of test is not solely based on test characteristics and invasiveness, but 
can also be influenced by e.g. (aggressive) marketing campaigns.
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Possibilities of personalizing screening
The benefit-harm ratio of screening can also be improved by increasing the level of person-
alization in existing screening programs. To a certain extent, all cancer screening programs 
are somewhat personalized in that they only target a certain age group in the population. 
Clearer examples of personalized screening are the intensified breast cancer screening that 
is offered to women who carry one of the BRCA mutations, and the intensified colorectal 
cancer screening that is offered to individuals with Lynch Syndrome.
Polygenic testing on the presence of common genetic variants may be used to stratify 
the average risk population into distinct risk groups. For colorectal cancer, the current 
discriminatory performance of such testing is insufficient, but this does not mean there is 
no future for colorectal cancer screening based on polygenic risk. Compared to colorectal 
cancer, more research has been done to identify single nucleotide polymorphisms (SNPs) 
associated with breast cancer risk. The AUC value of polygenic testing using 77 SNPs for 
breast cancer risk is currently ~0.68, and may increase with more GWAS underway, even 
though the discovery of additional SNPs will yield diminishing returns.30 The research on 
SNPs associated with colorectal cancer risk started somewhat later, and might show the 
same increase in discriminative performance. Our analysis has shown that with an increase 
in AUC value, the cost-effectiveness of risk-stratified screening based on common genetic 
variants will rise rapidly (Chapter 10).
In addition to including more SNPs, other risk factors for colorectal cancer, such as those 
related to lifestyle, could be included in risk estimates. A recent study estimated the dif-
ference in AUC value between risk-stratification using only SNPs versus using SNPs plus 
inflammatory bowel disease status and lifestyle risk factors including alcohol consumption, 
BMI, red meat consumption, smoking, fruit and vegetable intake, physical activity and aspi-
rin usage.31 Results of this analysis were disappointing; the addition of these risk factors to 
polygenic risk only led to an increase in the AUC value of 0.01.31 Another study even found 
no impact of adding other risk factors (e.g. having a family history) to SNPs.32 The zero or 
limited increase could be due to lifestyle factors being similar within families, although lit-
erature has shown that family history and lifestyle do independently affect colorectal cancer 
risk.33 More research in this field might therefore increase the AUC value of risk-stratification 
strategies incorporating both polygenic risk, family history, and lifestyle and environmental 
factors.
Prior to implementation of promising methods to individualize screening, it is important 
to estimate their effect on the adherence with screening guidelines. The increase in effec-
tiveness of using more individualized screening might easily be offset by a loss in overall ad-
herence with screening. Individualized screening often complicates the process of informed 
decision making, and this may lead to less intensive screening.34 On the contrary, three trials 
have shown that including personalized risk estimates in communication interventions for 
screening programs enhances informed decision making.35 There is weak evidence that 
personalized screening results in higher uptake of screening.35
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Avoidance of more complicated guidelines could well be a reason for not adopting 
the suggested colorectal cancer screening based on someone’s family history (Chapter 
9). However, we feel that the increased complexity will be accepted more easily by those 
with a positive family history. These individuals have seen their family member(s) being 
diagnosed with the disease, and are often highly motivated to prevent themselves from 
getting colorectal cancer. For these individuals, too intensive screening may be a larger 
problem than non-adherence. These people should be made aware that colonoscopies 
are not just burdensome, but can also result in (fatal) complications. As individuals with a 
genetic predisposition (which could be indicated by affected family members) generally 
develop the disease earlier in life, it is important to initiate screening at a younger age, but 
if no adenomas develop, then the screening interval should be lengthened to minimize 
unnecessary harm from screening.
future research
Although the work described in this thesis enabled us to answer multiple research ques-
tions, more questions keep arising in a dynamic field of research like cancer screening. Some 
areas for further research are described below.
Possibilities for personalized screening for colorectal cancer
In Chapter 9 and 10, we have optimized colorectal cancer screening based on family 
history and polygenic risk, respectively. Ideally, screening is based on someone’s risk of de-
veloping the disease within the coming years. For most diseases, this risk is dependent on 
multiple factors. For colorectal cancer, a family history of the disease and the presence of 
common genetic variants are just two of those factors. Both are indicators of someone’s 
genetic predisposition to colorectal cancer. Whether someone will develop colorectal 
cancer, also depends on his/her lifestyle, environment, the unexplainable ‘bad luck’ factor, 
and someone’s screening history. Future research should aim at identifying full risk profiles 
of individuals, including as much relevant information as possible.
The expected benefit of cancer screening not only depends on the probability that a 
cancer diagnosis or death is averted, but also on the expected gain in (healthy) life years. The 
expected harm-benefit ratio of screening is therefore dependent on someone’s (healthy) life 
expectancy. There is general acceptance that for individuals with limited life expectancy, the 
net benefit of screening is either small or negative.36 Current co-morbidity status and risk for 
other diseases are therefore important to incorporate in personalized screening.
Earlier simulation modeling showed that the optimal end age of colonoscopy screening 
varies widely with screening history, background colorectal cancer risk and co-morbidity 
status.37 It would be interesting to expand this work, by optimizing the optimal start age and 
interval of screening, and by including also other screening modalities than colonoscopy. 
By comparing modeling outcomes of such personalized screening with uniform screening, 
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we would get a more precise estimate of the potential usefulness of personalized screening 
for colorectal cancer.
Possibilities for personalized screening for cervical cancer
For cervical cancer, one may consider offering risk-stratified screening based on a woman’s 
risk to acquire a high-risk HPV infection. Although this is unsuitable for unvaccinated co-
horts, in which sexual behavior is the main factor influencing the risk of acquiring HPV, 
it might be fairly straightforward for cohorts that have been offered vaccination. Due to 
large expected differences in cervical cancer risk, tailored screening based on vaccination 
status is likely cost-effective (Chapter 8). Although cigarette smoking38,39, long-term oral 
contraceptive use39,40, and multiparity39 were found to be associated with progression to CIN 
3, their correlation with progression to cervical cancer is uncertain. More research is needed 
to identify factors that are associated with an increased (or decreased) cervical cancer risk.
Just as with colorectal cancer screening, it is also possible to personalize screening based 
on co-morbidity status. Although cervical cancer screening is offered at younger ages than 
colorectal cancer screening, comorbid conditions may still influence the expected (cost-)
effectiveness of screening, especially at ages 60-70.
issues with personalization of screening
As said, in future cohorts, the most obvious direction for risk-stratified cervical cancer screen-
ing would be screening based on HPV-vaccination status. Although this has shown to be 
cost-effective, it is uncertain whether vaccinated women will agree with being offered less 
intensive screening, just because they adhered to vaccination guidelines. Such a reduction 
in screening frequency will be difficult to implement for any type of screening, and for any 
type of reason. To increase the acceptability of the population, the reasoning behind the 
risk-stratification should be explained very clearly.
Although in theory, risk-stratified screening is always beneficial because it involves a 
more efficient way of allocating screening resources, this does not have to hold in practice. 
If risk-stratified screening only leads to individuals at increased risk being screened more 
often and not to those at decreased risk being screened less often, it is uncertain whether 
projected benefits will be achieved. Therefore, and because cancer risk is overrepresented 
in individuals who do not attend screening, attempts to increase adherence with current 
screening guidelines by e.g. offering self-sampling to non-attendees, are likely more effec-
tive than currently available possibilities for risk-stratified screening.
attempts to increase adherence
Cervical and colorectal cancer screening are effective, but could be enhanced by an in-
creased adherence with screening guidelines. In 2013, 81% of screening eligible US women 
reported to have had a cytological test in the past three years.48 At 59%, adherence with 
either endoscopy or FOBT for colorectal cancer screening was much lower.48 For both 
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cervical and colorectal cancer screening, uptake increases with level of education, varies by 
ethnicity and is significantly higher in individuals with health insurance.48
Lower participation with colorectal cancer screening than with cervical cancer screening 
can partly be explained by differences in target population. Men are less likely to adhere 
with colorectal cancer screening guidelines than women.49 Women tend to be more 
knowledgeable about screening, and are therefore better at making informed decisions 
about screening.49 If women delay or refuse screening, it is mostly because of aversion to the 
testing procedure or perceived distress from screening. Men tend to procrastinate making 
an informed decision about screening, and often deny its possible importance.49 Adher-
ence with screening could therefore be increased by supporting men in making definitive 
decisions about screening, and by taking away women’s anxiety around colorectal cancer 
screening.49
Although colorectal cancer screening uptake is ~5% higher in women than in men, this 
finding cannot explain the 22 percent point difference in uptake between cervical and 
colorectal cancer screening. A study among UK women who were eligible for both types of 
screening revealed that dislike of the test seems to be a larger barrier to colorectal cancer 
screening than to breast and cervical cancer screening.50 However, even with the wide range 
of screening tests available in the US, uptake with colorectal cancer screening is relatively 
low. More research is needed to identify perceived barriers to this type of screening.
For cervical cancer screening, self-sampling tests require less time than office-based tests 
and eliminate the involvement of a clinician, and are therefore expected to increase screen-
ing participation.23 However, also self-sampling requires taking a cervical smear, which can 
be considered as an invasive procedure. Recent studies have shown that HPV testing in 
urine also has good accuracy for the detection of HPV and cervical lesions.51,52 More research 
on such testing methods is needed to determine whether it also provides sufficient protec-
tion against invasive cancer.
Personalized treatment
While cancer treatment is getting more personalized, treatment of pre-invasive lesions is 
often still regarded as general practice. Guidelines generally recommend that CIN 1 should 
not be treated directly. Given the long preclinical phase of progressive disease, the lesion 
can still be treated if it does not regress within e.g. 1-3 years. Some local guidelines also 
acknowledge that direct treatment of CIN 2 may not be the best option for all women. 
WHO guidelines do recommend treatment of CIN 2+ for all women, regardless of age and 
potential childwish.41 However, with a regression rate of ~70% at 3 years after diagnosis, 
regression of CIN 2 is also common.42 This means that active surveillance may also be ap-
propriate for women with CIN 2, especially for those with a (future) childwish, given that 
treatment increases their risk of having subsequent preterm labor. However, the probability 
of preterm birth significantly increases with the invasiveness of the treatment.5 This means 
that if the size of the lesion increases instead of reduces, active surveillance instead of direct 
treatment may result in the need for a larger cone depth, which could result in an increased 
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potential harm from treatment. It would be interesting to model the effect of delaying the 
treatment of <CIN 2 and <CIN 3 in terms of preterm births and averted cervical cancer 
diagnoses and deaths.
As evidence for regression of colorectal adenomas is limited, guidelines state that any de-
tected adenoma should be removed. However, the average preclinical duration from a small 
adenoma to clinical cancer is >10 years,43 and treatment is associated with risk of serious 
complications, i.e. gastrointestinal and cardiovascular events, which increases exponentially 
with age.44 Therefore, the expected net benefit of removing a small adenoma in individuals 
with limited life expectancy is probably small and might even be negative. Future modeling 
studies may estimate the potential benefit of more restrained treatment policies for small 
adenomas.
For both cervical lesions and colorectal adenomas, one would ideally be able to identify 
which precursor lesions will develop into clinical cancer, and within what timeframe. If such 
identification would be possible, then only those CIN and adenomas would require treat-
ment, and overtreatment could largely be reduced. For cervical cancer, multiple studies have 
shown that p16 and L1 may be promising markers of progression of low-grade cytological 
abnormalities.45,46 For colorectal cancer, several candidate biomarkers for adenoma-to-carci-
noma progression have been identified.47 More research is needed to improve prediction of 
which lesions are likely to progress and should therefore be treated.
conclusions
From the results of the studies that are presented in this thesis, the following conclusions 
can be drawn:
– Many published cost-effectiveness analyses on cervical cancer screening are likely to 
have omitted relevant comparator strategies, thereby possibly identifying an inefficient 
screening strategy as optimal.
– For over-screened women, switching from primary cytology to primary HPV screening 
slightly reduces cervical cancer risk but comes with a large increase in the number of 
(false-)positive tests, and can therefore be considered as harmful.
– Cervical cancer screening from age 21 instead of age 30 only slightly reduces cervical 
cancer risk, while it substantially increases the risk of preterm birth.
– Data from the Dutch cervical cancer screening program suggest that SurePath detects 
more progressive lesions than conventional cytology, while ThinPrep might detect 
fewer.
– Offering a self-sample test to non-attendees in a cervical cancer screening program is 
likely a cost-effective intervention, but its impact does depend on parameters like the 
relative sensitivity of the self-sample test (as compared to the regular test), the extent 
to which it generates extra attendance, and the extent to which attendees of regular 
screening switch to using the self-sample test.
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– Although screening with the multitarget stool DNA test is an effective way to reduce 
colorectal cancer incidence and mortality, the current price of the test makes it a cost-
ineffective alternative to other stool-based tests.
– When herd immunity reaches beyond 50%, offering unvaccinated women cervical 
cancer screening based on the pre-vaccination risk level is no longer cost-effective, and 
reducing the intensity of uniform screening may be considered.
– It is cost-effective to offer individuals with a family history of colorectal cancer intensive 
colonoscopy screening from a young age onwards. However, if individuals do not de-
velop any adenomas, it is unlikely that they have a genetic predisposition to colorectal 
cancer, so continuing intensive screening would provide little or no additional benefit.
– At the discriminatory performance and cost of current polygenic tests, colonoscopy 
screening based on polygenic risk is not cost-effective compared to uniform screening. 
This may change with a reduction in the price per polygenic test and with the discovery 
of more common genetic variants that are associated with colorectal cancer risk.
recommendations
The conclusions derived in this thesis support the following recommendations:
– In a cancer screening cost-effectiveness analysis, one should include all relevant com-
parator strategies to obtain reliable cost-effectiveness estimates.
– In screening situations that are characterized by a substantial amount of over-screening, 
primary cytology screening should not be replaced by primary HPV screening. Reducing 
the amount of over-screening should be prioritized.
– Cervical cancer screening below age 30 should only be offered after careful evaluation 
of a woman’s expected benefits and harms, taking into account her (future) childwish.
– Since 2017, primary LBC screening is longer performed in the Netherlands, but the 
fact that the use of SurePath resulted in different screening outcomes than the use of 
ThinPrep should raise international awareness that the assumed similarity in test charac-
teristics may not be true.
– Although offering an alternative test could increase effectiveness of screening through 
increasing the uptake among individuals willing to undergo screening, one should be 
careful with offering alternative tests with inferior characteristics compared to already 
offered tests because of the potential substitution effect.
– If cervical cancer screening cannot be tailored to HPV-vaccination status, one should 
wait with adjusting the screening frequency to the risk level in vaccinated women until 
unvaccinated women benefit from a herd immunity level of at least 50%, i.e. until the 
reduction in HPV prevalence in unvaccinated women is at least half of that in vaccinated 
women.
– As screening intensity preferably depends on the disease risk in the target population, 
herd immunity should be closely monitored in partly vaccinated cohorts.
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– Individuals with a constant level of family history of colorectal cancer should consider 
lengthening their screening interval after several subsequent negative colonoscopies, 
as this suggests that they are unlikely to have a genetic predisposition for colorectal 
cancer.
– In addition to discovering more common genetic variants that are associated with 
colorectal cancer risk, research should aim at identifying comprehensive colorectal 
cancer risk profiles, including both genetic and environmental risk factors.
– Given high regression rates of CIN 1 and CIN 2, and the potential adverse effects of CIN 
treatment, future research is needed to estimate the impact of delaying treatment in 
women with CIN 1 and CIN 2.
– Much of the harm related to cervical and colorectal cancer screening comes from the 
detection and treatment of non-progressive lesions. Literature suggests the existence 
of biomarkers that are able to distinguish between progressive and non-progressive le-
sions. As this may largely reduce the amount of overdiagnosis and overtreatment, more 
research is needed to identify those biomarkers.
264 | Chapter 11
references
 1. Ronco G, Dillner J, Elfstrm KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical 
cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-32.
 2. Australian Government: Department of Public Health. National Cervical Screening Program: Future 
changes to cervical screening.
 3. National Institute for Public Health and the Environment. [Screening program will change] Bevolking-
sonderzoek gaat veranderen.
 4. Kyrgiou M, Tsoumpou I, Vrekoussis T, et al. The up-to-date evidence on colposcopy practice and 
treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy & cervical cytopathology 
collaborative group (C5 group) approach. Cancer Treat Rev 2006;32:516-23.
 5. Danhof NA, Kamphuis EI, Limpens J, van Lonkhuijzen LRCW, Pajkrt E, Mol BWJ. The risk of preterm 
birth of treated versus untreated cervical intraepithelial neoplasia (CIN): a systematic review and 
meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2015 May;188:24-33.
 6. Hodek JM, von der Schulenburg JM, Mittendorf T. Measuring economic consequences of preterm 
birth - Methodological recommendations for the evaluation of personal burden on children and their 
caregivers. Health Econ Rev 2011;1:6.
 7. Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology: a 
systematic review and meta-analysis. Obstet Gynecol 2008;111:167-77.
 8. Whitlock EP, Vesco KK, Eder M, et al. Liquid-based cytology and human papillomavirus testing to 
screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern 
Med 2011;155:687-97, W214-5.
 9. Rozemeijer K, Penning C, Siebers AG, et al. Comparing SurePath, ThinPrep, and conventional cytology 
as primary test method: SurePath is associated with increased CIN II(+) detection rates. Cancer Causes 
Control 2016;27:15-25.
 10. U. S. Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for Colorectal 
Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2016;315:2564-75.
 11. Ramsey SD, Wilschut J, Boer R, et al. A decision-analytic evaluation of the cost-effectiveness of family 
history-based colorectal cancer screening programs. Am J Gastroenterol 2010;105:1861-9.
 12. Wilschut JA, Steyerberg EW, van Leerdam ME, et al. How much colonoscopy screening should be 
recommended to individuals with various degrees of family history of colorectal cancer? Cancer 
2011;117:4166-74.
 13. Elfström KM, Arnheim-Dahlström L, von Karsa L, et al. Cervical cancer screening in Europe: Quality 
assurance and organisation of programmes. Eur J Cancer 2015;51:950-68.
 14. Kulasingam SL, Havrilesky L, Ghebre R, et al. Screening for Cervical Cancer: A Decision Analysis for the 
U.S. Preventive Services Task Force. 2011.
 15. O’Connor M, Gallagher P, Waller J, et al. Adverse psychological outcomes following colposcopy and 
related procedures: a systematic review. BJOG 2016;123:24-38.
 16. Lerman C, Miller SM, Scarborough R, et al. Adverse psychologic consequences of positive cytologic 
cervical screening. Am J Obstet Gynecol 1991;165:658-62.
 17. Saraiya M, Berkowitz Z, Yabroff KR, et al. Cervical cancer screening with both human papillomavirus 
and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians 
recommending? Arch Intern Med 2010;170:977-85.
 18. Meissner HI, Tiro JA, Yabroff KR, et al. Too much of a good thing? Physician practices and patient 
willingness for less frequent pap test screening intervals. Med Care 2010;48:249-59.
General discussion | 265
11
 19. Mathias JS, Gossett D, Baker DW. Use of electronic health record data to evaluate overuse of cervical 
cancer screening. Journal of the American Medical Informatics Association 2012;19:E96-E101.
 20. Arbyn M, Rebolj M, De Kok IM, et al. The challenges of organising cervical screening programmes in 
the 15 old member states of the European Union. Eur J Cancer 2009;45:2671-8.
 21. Bos AB, Rebolj M, Habbema JD, et al. Nonattendance is still the main limitation for the effectiveness of 
screening for cervical cancer in the Netherlands. Int J Cancer 2006;119:2372-5.
 22. Tacken MA, Braspenning JC, Hermens RP, et al. Uptake of cervical cancer screening in The Netherlands 
is mainly influenced by women’s beliefs about the screening and by the inviting organization. Eur J 
Public Health 2007;17:178-85.
 23. Gök M, Heideman DA, van Kemenade FJ, et al. Offering self-sampling for human papillomavirus test-
ing to non-attendees of the cervical screening programme: Characteristics of the responders. Eur J 
Cancer 2012;48:1799-808.
 24. Verdoodt F, Jentschke M, Hillemanns P, et al. Reaching women who do not participate in the regular 
cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-
analysis of randomised trials. Eur J Cancer 2015;51:2375-85.
 25. Arbyn M, Snijders PJ, Meijer CJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical 
cancer screening? Clin Microbiol Infect 2015;21:817-26.
 26. Marshall DA, Johnson FR, Phillips KA, et al. Measuring patient preferences for colorectal cancer screen-
ing using a choice-format survey. Value Health 2007;10:415-30.
 27. Jones RM, Vernon SW, Woolf SH. Is discussion of colorectal cancer screening options associated with 
heightened patient confusion? Cancer Epidemiol Biomarkers Prev 2010;19:2821-5.
 28. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for 
detection of asymptomatic colorectal cancer. Gut 2014;63:317-25.
 29. Ladabaum U, Allen J, Wandell M, et al. Colorectal cancer screening with blood-based biomarkers: 
cost-effectiveness of methylated septin 9 DNA versus current strategies. Cancer Epidemiol Biomark-
ers Prev 2013;22:1567-76.
 30. Wu Y, Abbey CK, Liu J, et al. Discriminatory power of common genetic variants in personalized breast 
cancer diagnosis. Proc SPIE Int Soc Opt Eng 2016;9787.
 31. Frampton M, Houlston RS. Modeling the prevention of colorectal cancer from the combined impact 
of host and behavioral risk factors. Genet Med 2016.
 32. Hsu L, Jeon J, Brenner H, et al. A model to determine colorectal cancer risk using common genetic 
susceptibility loci. Gastroenterology 2015;148:1330-9 e14.
 33. Huang XE, Hirose K, Wakai K, et al. Comparison of lifestyle risk factors by family history for gastric, 
breast, lung and colorectal cancer. Asian Pac J Cancer Prev 2004;5:419-27.
 34. Lieberman D. Progress and challenges in colorectal cancer screening and surveillance. Gastroenterol-
ogy 2010;138:2115-26.
 35. Edwards AG, Naik G, Ahmed H, et al. Personalised risk communication for informed decision making 
about taking screening tests. Cochrane Database Syst Rev 2013:CD001865.
 36. Royce TJ, Hendrix LH, Stokes WA, et al. Cancer screening rates in individuals with different life expec-
tancies. JAMA Intern Med 2014;174:1558-65.
 37. van Hees F, Habbema JD, Meester RG, et al. Should colorectal cancer screening be considered in elderly 
persons without previous screening? A cost-effectiveness analysis. Ann Intern Med 2014;160:750-9.
 38. Roura E, Castellsague X, Pawlita M, et al. Smoking as a major risk factor for cervical cancer and pre-
cancer: results from the EPIC cohort. Int J Cancer 2014;135:453-66.
 39. Luhn P, Walker J, Schiffman M, et al. The role of co-factors in the progression from human papil-
lomavirus infection to cervical cancer. Gynecol Oncol 2013;128:265-70.
266 | Chapter 11
 40. Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, 
and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2013;22:1931-43.
 41. World Health Organization. WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 
and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold 
knife conization. 2014. http://apps.who.int/iris/bitstream/10665/94830/1/9789241548694_eng.pdf 
Accessed February 27, 2017.
 42. Moscicki AB, Ma Y, Wibbelsman C, et al. Rate of and risks for regression of cervical intraepithelial 
neoplasia 2 in adolescents and young women. Obstet Gynecol 2010;116:1373-80.
 43. Morson B. President’s address. The polyp-cancer sequence in the large bowel. Proc R Soc Med 
1974;67:451-7.
 44. van Hees F, Zauber AG, Klabunde CN, et al. The Appropriateness of More Intensive Colonoscopy 
Screening Than Recommended in Medicare Beneficiaries - A Modeling Study. JAMA Intern Med 
2014;174:1568-1576.
 45. Ungureanu C, Socolov D, Anton G, et al. Immunocytochemical expression of p16INK4a and HPV L1 
capsid proteins as predictive markers of the cervical lesions progression risk. Rom J Morphol Embryol 
2010;51:497-503.
 46. Negri G, Bellisano G, Zannoni GF, et al. p16 ink4a and HPV L1 immunohistochemistry is helpful 
for estimating the behavior of low-grade dysplastic lesions of the cervix uteri. Am J Surg Pathol 
2008;32:1715-20.
 47. de Wit M, Jimenez CR, Carvalho B, et al. Cell surface proteomics identifies glucose transporter type 
1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. Gut 
2012;61:855-64.
 48. Smith RA, Andrews K, Brooks D, et al. Cancer screening in the United States, 2016: A review of cur-
rent American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 
2016;66:96-114.
 49. Sinicrope PS, Goode EL, Limburg PJ, et al. A population-based study of prevalence and adherence 
trends in average risk colorectal cancer screening, 1997 to 2008. Cancer Epidemiol Biomarkers Prev 
2012;21:347-50.
 50. Lo SH, Waller J, Wardle J, et al. Comparing barriers to colorectal cancer screening with barriers to 
breast and cervical screening: a population-based survey of screening-age women in Great Britain. J 
Med Screen 2013;20:73-9.
 51. Pathak N, Dodds J, Zamora J, et al. Accuracy of urinary human papillomavirus testing for presence of 
cervical HPV: systematic review and meta-analysis. BMJ 2014;349:g5264.
 52. Piyathilake CJ, Badiga S, Chambers MM, et al. Accuracy of urinary human papillomavirus testing 
for the presence of cervical human papillomaviruses and higher grades of cervical intraepithelial 
neoplasia. Cancer 2016;122:2836-44.


Model appendix

Model appendix | 271
introduction
MISCAN is a stochastic, semi-Markov microsimulation model programmed in Delphi (Bor-
land Software Corporation, Scotts Valley, California, United States). It can be used to explain 
and predict trends in cancer incidence and mortality and to quantify the effects and costs 
of primary prevention, screening, and surveillance. 
The term ‘microsimulation’ implies that individuals are moved through the model one at a 
time, rather than as proportions of a cohort. This allows future state transitions to depend on 
past transitions, giving the model a ‘memory’. Furthermore, unlike most traditional Markov 
models, MISCAN does not use yearly or monthly transition probabilities; instead it generates 
durations in states, thereby increasing model flexibility and computational performance. 
The term ‘stochastic’ implies that the model simulates sequences of events by drawing from 
distributions of probabilities/durations, rather than using fixed values. Hence, the results of 
the model are subject to random variation.
In this thesis, two different types of the MISCAN model have been used, i.e. MISCAN-
Cervix for the evaluation of cervical cancer screening, and MISCAN-Colon for the evaluation 
of colorectal cancer (CRC) screening. Both MISCAN-Cervix and MISCAN-Colon consist of 3 
modules: a demography module, a natural history module, and a screening module (Figure 
1), of which the assumptions are described in the next two sections. 
Figure 1. Structure of the MISCAN model.
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modules in miscan-cervix
demography module
Using birth tables and life tables representative for the female population under consider-
ation, MISCAN-Cervix draws a date of birth and a date of death from other causes for each 
simulated individual. In this thesis, we either simulated a cohort of a specific age (Chapters 
3, 4, and 8) or a population with an age distribution representative for the Dutch female 
population (Chapter 6). Life tables were retrieved from Statistics Netherlands.1 In MISCAN-
Cervix the maximum age a woman can achieve is exactly 100 years.
Women who have had a total hysterectomy (i.e. full removal of both the uterus and the 
cervix) can no longer develop cervical cancer. In MISCAN-Cervix, cohort- and age-specific 
probabilities determine the likelihood of getting such a hysterectomy due to causes other 
than cervical cancer. In this thesis, the probability of getting a hysterectomy was based on 
data from Statistics Netherlands and the Information Centre for Health Care.1,2 
natural history module
During her lifetime, each woman has an age-specific risk of acquiring high-risk HPV infec-
tions (i.e. an infection caused by an HPV type that can cause cancer and that can be detected 
by the HPV test) and CIN lesions without a (detectable) high-risk HPV infection. Most HPV 
infections clear or regress naturally, some HPV infections can progress to CIN 1, CIN 2, CIN 3, 
cervical cancer, and death from cervical cancer.
The age-specific incidence of HPV infections that progress to cervical cancer was 
calibrated to the age-specific incidence of cervical cancer, which was obtained from the 
Netherlands Cancer Registry (Figure 2).3 The age-specific incidence of pre-invasive lesions 
that do not progress to cervical cancer was calibrated so that the simulated detection rates 
of CIN lesions fit the observed detection rates in the Netherlands (Figure 3). The observed 
detection rates were obtained from the nationwide network and registry of histo- and cyto-
pathology in the Netherlands (PALGA) for the period 2000-2007.4 The incidence of high-risk 
HPV infections that do not progress to CIN was calibrated so that the simulated prevalence 
of all high-risk HPV infections fits the observed high-risk HPV prevalence (Figure 4).5,6
In MISCAN-Cervix, 6 disease pathways are distinguished. Each instance of these disease 
pathways represents an HPV infection or a ‘lesion’ (i.e. CIN of a certain grade or a stage of cer-
vical cancer). Each disease pathway starts as either an HPV infection or as an HPV negative 
CIN 1 lesion. The natural history (i.e. in the situation without screening) of these 6 disease 
pathways is shown in Figure 5 and can be described as follows:
A) HPV infections that clear naturally without ever leading to CIN
B) HPV infections that progress to CIN 1 and then regress
C) HPV infections that progress to CIN 1 and CIN 2 and then regress
D) HPV infections that progress to CIN 1, CIN 2, and CIN 3 and then regress
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E) HPV negative CIN 1 lesions that regress naturally or become HPV negative CIN 2 and 
then regress naturally
F) HPV infections that progress to CIN 1, CIN 2, CIN 3, preclinical cervical cancer stage IA 
(micro-invasive), and preclinical cervical cancer stage IB. Preclinical cervical cancer stage 
IB can either become clinically detected cervical cancer stage IB or progress to preclinical 
cervical cancer stage II+ and then to clinical cervical cancer stage II+. Clinically detected 
cervical cancer can progress to death from cervical cancer or remain in that state forever 
(if the woman is cured from cervical cancer).
A woman can acquire multiple lesions and HPV infections during her lifetime, and multiple 
lesions and HPV infections may be present at the same time. In each simulated life history 
(i.e. between ages 0 and 100), the number of lesions of each type follows a Poisson distribu-
tion. The annual probability of acquiring an HPV infection or CIN lesion is age-dependent. 
The transitions and sojourn times of the HPV infections or lesions are simulated based on a 
continuous-time semi-Markov process. The sojourn times of most states in the model have 
either an exponential or a Weibull probability distribution.
In the model, women who do not have cervical cancer have an age-specific probability of 
getting a hysterectomy for reasons other than cervical cancer. A hysterectomy is assumed 
to remove all prevalent HPV infections and CIN lesions. After a hysterectomy, women are 
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Figure 2. Cervical cancer incidence as observed in the Netherlands Cancer Registry in 2000-2010 versus 
simulated by MISCAN-Cervix (cases per 100,000 woman years).
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CIN = cervical intraepithelial neoplasia.
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no longer at risk for HPV infections and CIN lesions, and are therefore no longer invited for 
screening. 
The assumptions for the probability and the duration of survival after a clinically detected 
(i.e. detected because of symptoms) cervical cancer are based on data from the NCR for the 
period 1989-2009. As these data include both adenocarcinoma and squamous cell carci-
noma, the survival we estimated is a weighted average of these two types of cervical cancer. 
We assumed that all cervical cancer mortality occurs in the first 10 years after diagnosis. 
The assumed probability of long-term survival depends on age and stage (IB or II+); in the 
model, cervical cancer stage IA cannot be clinically detected. 
screening module
Screening will alter some of the simulated life histories: Some cancers will be prevented by 
the detection and removal of CIN lesions; other cancers will be detected in an earlier stage 
with a more favorable survival. The simulated screening protocol determines in what situa-
tions women are referred for colposcopy. If a woman is referred to colposcopy, all prevalent 
CIN lesions are assumed to be diagnosed and successfully removed. HPV infections without 
CIN are not treated. For screen-detected cervical cancer, a stage-specific improvement 
(compared to the situation without screening) in the probability of cure is assumed.   
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Figure 4. Percentage of women with a positive HPV test as observed in Bulkmans et al. and Lenselink et 
al. versus simulated by MISCAN-Cervix.
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Figure 5. Schematic representation of the natural history module of MISCAN-Cervix, with disease path-
ways A through F.
HPV = human papillomavirus; CIN = cervical intraepithelial neoplasia; CeCa = cervical cancer.
Note: There are six disease pathways (types A through F) in MISCAN-Cervix. All lesions start as either an HPV infection 
without CIN (disease pathways A, B, C, D, and F) or as a CIN 1 lesion without HPV infection (disease pathway E). Cleared/
regressed denotes the absence of CIN and HPV infection; CIN 0 denotes the absence of CIN and cervical cancer. All cer-
vical cancer states are HPV positive. The arrows between the states show which types of transitions can occur. In every 
state before death, a transition to “death from other causes” can occur, and in every state before cancer, a transition to 
“hysterectomy” can occur (states and connecting arrows not shown); in these cases, the transition applies to all HPV 
infections and CIN lesions of that person simultaneously.
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In the model, detection of cervical cancer by screening prevents death from cervical 
cancer in some but not all cases. However, if death from cervical cancer is not prevented, 
the time of death from cervical cancer is not changed by screening. 
For screen-detected invasive cancers, survival was modeled as a reduction in the risk of 
dying compared with that risk in the situation without screening, when the cancer would 
have become clinical. This improvement of prognosis (89.4%, 50% and 20% for stage IA, IB 
and II+ respectively) was calibrated to reproduce recently observed stage-specific survival 
given observed screening (Netherlands Cancer Registry).3 
modules in miscan-colon
demography module
Using birth tables and life tables representative for the population under consideration, MIS-
CAN-Colon draws a date of birth and a date of death from other causes for each simulated 
individual. In this thesis, we simulated single birth cohorts to evaluate screening decisions at 
certain ages. Life tables were retrieved from the Centers for Disease Control and Prevention.7 
In MISCAN-Colon the maximum age an individual can achieve is exactly 100 years.
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Figure 6. Schematic representation of the natural history module of MISCAN-Colon.
CRC = colorectal cancer.
The arrows between the states show which types of transitions can occur. In every state before death, a transition to 
“death from other causes” can occur (state and connecting arrows are not shown).
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natural history module
As each simulated person ages, one or more adenomas may develop (Figure 6). These ad-
enomas can be either progressive or non-progressive. Both progressive and non-progressive 
adenomas can grow in size from small (≤5 mm), to medium (6-9 mm), to large (≥10 mm); 
however, only progressive adenomas can develop into preclinical cancer. A preclinical can-
cer may progress through stages I to IV; however, during each stage CRC may be diagnosed 
because of symptoms. After clinical diagnosis, CRC survival is simulated using age-, stage-, 
and localization-specific survival estimates for clinically diagnosed CRC obtained from a 
study by Rutter and colleagues.8 For individuals with synchronous CRCs at time of diagnosis, 
the survival of the most advanced cancer is used. The date of death for individuals with 
CRC is set to the earliest simulated death (either due to CRC or due to another cause (see: 
‘Demography module’)). 
An individual’s risk of developing adenomas depends on the individual’s age and a per-
sonal risk index. As a result of the latter most individuals develop no adenomas, whilst some 
develop many. We assumed that the distribution of adenomas over the colon and rectum 
equals the distribution of cancers as observed in SEER before the introduction of screen-
ing.9 The age-specific onset of adenomas and the dispersion of the personal risk index were 
calibrated to data on the prevalence and multiplicity distribution of adenomas as observed 
in autopsy studies (Figure 7).10-19 The age-specific probability of adenoma-progressivity and 
the age- and localization-specific transition probabilities between preclinical cancer stages 
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Figure 7. Adenoma prevalence observed in selected autopsy studies versus simulated by MISCAN-Colon 
(% of individuals with adenomas).*
*  Observed results are only shown for the two largest studies (Arminski et al.10 and Clark et al.13) on which the model 
has been calibrated. MISCAN-Colon has additionally been calibrated to 8 other autopsy studies.9,11,12,14-18
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and between preclinical and clinical cancer stages were simultaneously calibrated to SEER 
data on the age-, stage-, and localization-specific incidence of CRC as observed before the 
introduction of screening (Figure 8).9
The average durations of the preclinical cancer stages were calibrated to the rates of 
screen-detected and interval cancers observed in randomized controlled trials evaluating 
screening using guaiac fecal occult blood tests.20-22 This exercise has been described exten-
sively in a publication by Lansdorp-Vogelaar and colleagues.23 The average duration from 
the emergence of an adenoma until progression into preclinical cancer (i.e. the adenoma 
dwell-time) was calibrated to the rates of interval cancers (including surveillance detected 
cancers) observed in a randomized controlled trial evaluating once-only sigmoidoscopy 
screening (Figure 9).24 We assumed an equal overall dwell-time for adenomas developing 
into CRC from a medium size (30% of all CRCs) and from a large size (70% of all CRCs). 
All durations in the adenoma and preclinical cancer phase were drawn from exponential 
distributions. Durations within the adenoma phase and within the preclinical cancer phase 
were assumed to be perfectly correlated (i.e. if a small adenoma grows into a medium-
sized adenoma rapidly, it will also grow into a large adenoma or develop into CRC rapidly); 
however, durations in the adenoma phase were assumed to be uncorrelated with durations 
in the preclinical cancer phase (i.e. a rapidly growing adenoma does not necessarily develop 
into a rapidly progressing cancer). The proportion of medium sized, non-progressive adeno-
mas growing large and the average duration in the medium size, non-progressive adenoma 
state were calibrated to size-specific adenoma detection rates observed in a Dutch random-
ized controlled trial on colonoscopy screening (data not shown).
screening module
Screening will alter some of the simulated life histories: Some cancers will be prevented by 
the detection and removal of adenomas; other cancers will be detected in an earlier stage 
with a more favorable survival. As the stage-specific survival of screen-detected CRC as 
observed in randomized controlled trials on guaiac fecal occult blood testing was substan-
tially more favorable than that of clinically detected CRC, even after correcting for lead-time 
bias,23 we assigned those screen-detected cancers that would have been clinically detected 
in the same stage the survival corresponding to a one stage less progressive cancer. Hence, 
a cancer screen-detected in stage II, that would also have been clinically diagnosed in stage 
II, is assigned the survival of a clinically diagnosed stage I cancer. The only exceptions were 
screen-detected stage IV cancers. These cancers were always assigned the survival of a clini-
cally diagnosed stage IV cancer. 
Besides modeling positive health effects of screening, we also model colonoscopy-
related complications and overdiagnosis and overtreatment of CRC (i.e. the detection and 
treatment of cancers that would not have been diagnosed without screening).25-27 
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Figure 8. CRC incidence observed before the introduction of screening versus simulated by MISCAN-
Colon (total (A), stage I CRC (B), stage II CRC (C), stage III CRC (D), stage IV CRC (E); cases per 100,000 person 
years).
CRC = colorectal cancer.
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CRC = colorectal cancer.
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integrating modules
The demography module generates a date of birth and a date of death from other causes for 
each individual simulated, creating a life history without any lesions or cancer. In Person A in 
Figure 10, the natural history module generates a pre-invasive lesion (e.g. CIN or adenoma). 
This lesion progresses into preclinical cancer, which is diagnosed because of symptoms and 
results in cancer death before death from other causes would have occurred. In the screen-
ing module a screening examination is simulated, indicated by the blue arrow. During this 
examination the pre-invasive lesion is detected, and as a result both cancer diagnosis and 
cancer death are prevented. Hence, in Person A, screening prolongs life by the amount 
indicated by the green arrow. Person B also develops a pre-invasive lesion, and although 
this lesion does progress into preclinical cancer, Person B would never have been diagnosed 
with cancer in a scenario without screening. However, during the screening examination 
simulated in the screening module, again indicated by the blue arrow, cancer is detected. 
Hence, in this person screening results in overdiagnosis of cancer: It detects a cancer that 
would never have been diagnosed in a scenario without screening. Hence, screening does 
not prolong life, but it does result in additional LYs with cancer care (overtreatment) as 
indicated by the red arrow.  
DEMOGRAPHY MODULE
Life history without disease
Other-cause death
Birth
NATURAL HISTORY MODULE
Cancer death
Birth
SCREENING MODULE
 
Life history with screening
Other-cause death
Birth
Life history with development of 
cancer
Screening (detecting the pre-invasive lesion)
Lesion and cancer free
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PERSON A: BENEFITING FROM SCREENING 
DEMOGRAPHY MODULE
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Other-cause death
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SCREENING MODULE
 
Life history with screening
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Pre-invasive lesion    Preclinical cancer
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LYs with overtreatment of cancer
     Screening (detecting the preclinical cancer)
   Preclinical cancer
PERSON B: OVERDIAGNOSING CANCER 
Figure 10. Integrating Modules: Two example Persons.
LYs = life years.
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Screening is the systematic testing of asymptomatic individuals to identify disease or risk 
factors for disease. This enables the possibility to act earlier, e.g. by starting treatment of the 
disease earlier. Screening is especially valuable for diseases like cancer, where prognosis is 
better in earlier stages. In the Netherlands, screening programs exist for early detection of 
cervical cancer, breast cancer, and colorectal cancer.
Prior to implementation of (either organized or opportunistic) screening, the following 
three criteria should be met:
1. There should be scientific evidence of screening program effectiveness.
2. The overall benefits of screening should outweigh the harm.
3. There should be scientific evidence of screening program cost-effectiveness.
Both cervical and colorectal cancer are extremely suitable for mass screening. Their natural 
history is similar in the sense that a long preclinical phase precedes cancer development. 
During this preclinical phase, benign lesions can be detected by screening. By removing 
these lesions, cancer development can be averted. Additionally, early detection and treat-
ment of cancer can improve survival significantly.
As with any form of screening, cervical and colorectal cancer screening may be experi-
enced as burdensome, and even come with harm for some of its participants. Whenever 
possible, attempts should be made to improve the harm-benefit ratio of screening. In this 
thesis, several opportunities to reduce harms and increase benefits of cervical and colorec-
tal cancer screening were explored. Risk-based screening may be particularly suitable, as in 
theory, it reduces harms and increases benefits simultaneously.
In general, the optimal screening strategy for a population or risk group is determined in 
a cost-effectiveness analysis, in which the costs and health benefits of several strategies are 
compared.
methodological issues in cost-effectiveness analyses
Whether a strategy is deemed optimal in a cost-effectiveness analysis depends on the set 
of included strategies for comparison. Chapter 2 of this thesis has shown that the majority 
of cost-effectiveness analyses on cervical cancer screening were likely to have omitted rel-
evant strategies from the analysis. In most cases, strategies with a longer screening interval 
than the one deemed optimal were not included. This likely led to underestimation of the 
incremental costs per life year gained, and may have led to the identification of suboptimal 
strategies as being optimal.
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reducing harms
Over the past decades, cytology-based screening has shown to be an effective way of 
reducing cervical cancer incidence and mortality. Since the discovery that infection with 
human papillomavirus (HPV) is a necessary cause of cervical cancer, a wide range of HPV 
tests have been developed. As HPV-based screening provides better protection against 
invasive cervical cancer, it has already been implemented in the Netherlands (per 1 January 
2017), and will soon be implemented in Australia (per 1 December 2017). However, the 
higher sensitivity of HPV-based screening comes with a reduced specificity, meaning that 
(false-)positive testing rates will increase. Although for cytology screening, it is known that 
over-screening (i.e. screening more often than recommended by international guidelines) is 
neither necessary nor desired, it is still current practice in many countries.
In Chapter 3 we have estimated the potential harms of switching from cytology to HPV-
based screening for women who are over-screened. As with cytology-based screening at 
an annual or biennial basis it is already unlikely to miss clinically relevant disease, the health 
benefits of switching to the more sensitive HPV test were small. The potential harms due 
to increased numbers of (false-)positive tests and referrals for colposcopy, however, were 
substantial. Altogether, for women who are screened at an annual or biennial basis, switch-
ing to HPV-based testing is likely to result in a net loss in health.
Besides psychological distress of cervical cancer screening, treatment of precursor lesions 
called cervical intraepithelial neoplasia (CIN) may increase risk of subsequent preterm birth. 
Preterm birth significantly increases the risk of infant morbidity and mortality. To our knowl-
edge, this harm has not been taken into account in (cost-)effectiveness analyses of cervical 
cancer screening. Chapter 4 of this thesis provides a first attempt by comparing screening 
strategies in terms of (quality-adjusted) life years gained by women and (quality-adjusted) 
life years lost by their future children. Compared to initiating 3-yearly screening at age 30, 
the benefit of initiating 3-yearly screening at age 21 was limited in terms of life years gained, 
and even negative in terms of quality-adjusted life years gained. The harms, however, were 
significant: 223 more preterm births per 100,000 screened women, resulting in 22 more 
cases of infant morbidity and 6 more infant deaths. In countries like the US, where 3-yearly 
screening from age 21 is recommended, women with a (future) childwish should therefore 
consider delaying the start age of cervical cancer screening to age 30.
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increasing Benefits
The benefits of screening can be enhanced by the introduction of new screening modalities. 
The new screening test could either replace the currently offered test, or could function as an 
alternative to existing screening methods. The latter could eliminate test-specific barriers that 
individuals may experience in relation to existing screening methods, and could therefore entice 
un(der)screened individuals to participate in screening. Whereas replacement of a test requires 
that the new test is more effective (or at least more cost-effective) than the one currently offered, 
the addition of an alternative screening method can also be beneficial if the test is less effective.
Over the past 10-15 years, many countries, including the Netherlands, have replaced the 
use of conventional cytology with that of liquid-based cytology (LBC) tests SurePath and 
ThinPrep. As compared to conventional cytology, the use of LBC results in fewer samples of 
unsatisfactory quality. Another advantage of LBC is that it facilitates co-testing (i.e. samples 
can also be tested on the presence of HPV). Systematic reviews comparing conventional 
cytology with LBC showed comparable test performance, but assumed no differences 
between LBC tests. In an earlier study, however, we have shown that in the Netherlands, 
the use of SurePath was associated with an increased CIN 2+ detection rate compared to 
conventional cytology, while the use of ThinPrep was not. The analysis presented in Chap-
ter 5 showed that screening with SurePath also provided better protection against invasive 
cervical cancer than conventional cytology, while screening with ThinPrep did not.
Since 2017, the program no longer involves primary LBC testing, though. Instead, samples 
are primarily tested on the presence of oncogenic HPV-types. Women who do not attend 
screening within 6 months after invitation, are offered HPV self-sampling. In Chapter 6, we 
have shown that this is expected to be (cost-)effective if the relative CIN 2+ sensitivity with 
a self-collected sample (as opposed to with a clinician-collected sample) is at least 0.95, 
previously unscreened women are recruited, and total participation increases with at least 
6 percentage points. If these requirements are not met, women switching from the regular 
test to self-sampling may decrease the total effectiveness of the program.
Offering an alternative screening method might also increase adherence with colorectal 
cancer screening guidelines in the US. The recently updated US Preventive Services Task 
Force guidelines recommend colorectal cancer screening with one (or two) of six modali-
ties, including also the recently approved multitarget Stool DNA test. Three-yearly screening 
with this test has now been covered by the Centers for Medicare and Medicaid Services 
(CMS). In Chapter 7, we have estimated whether this screening strategy is a cost-effective 
alternative to other reimbursed strategies for the Medicare population (i.e. US individuals 
ages 65 and over), and if not, at what cost, adherence level or frequency of testing it would 
be. Our results showed that even if adherence with 3-yearly multitarget Stool DNA testing 
would be 30% higher than with other screening strategies, it would not be cost-effective 
at its current reimbursement rate of $493. For triennial, biennial or annual multitarget Stool 
DNA testing, per-test reimbursement rate has to be below $33, $47, or $58, respectively, to 
be a cost-effective alternative to other reimbursed strategies.
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reducing harms and increasing Benefits: oPPortunities for risk-
Based screening
Risk-based screening provides the opportunity to reduce harms of screening in individuals 
at low risk for the disease, while increasing benefits in those at higher risk.
Compared to the current screening eligible population, HPV-vaccinated women are 
expected to be at much lower risk for cervical cancer. Using microsimulation modeling, 
we found that whereas 8 lifetime screens is optimal for the current (unvaccinated) target 
population of screening, 3 lifetime screens is optimal for vaccinated women (Chapter 
8). However, screening tailored to HPV vaccination status might not be feasible due to 
organizational or ethical matters. If uniform screening is the only viable option, then the 
intensity of such screening is preferably reduced as vaccination coverage, and thereby 
herd immunity, increases. We found that when the reduction in HPV prevalence among 
unvaccinated women is at least half of that in vaccinated women (i.e. herd immunity >50%), 
then a screening program with 3 lifetime screens becomes more cost-effective for unvac-
cinated women than one with 8 lifetime screens. Uniform screening should therefore not 
be adjusted to the risk level in vaccinated women until unvaccinated women benefit from 
a herd immunity level of at least 50%.
US screening guidelines for colorectal cancer already include more intensive screening 
for individuals with a positive family history than for people in the general population. 
Individuals with ≥1 affected first-degree relative, are recommended to start colonoscopy 
screening earlier (at age 40 instead of age 50) and to repeat screening at shorter intervals (5 
years instead of 10 years). In Chapter 9 we used microsimulation modeling to determine, 
for every number of affected first-degree relatives, the optimal screening strategy by age. 
We found that individuals with a positive family history may benefit from intensive screen-
ing at young age. However, if individuals consistently have negative colonoscopies, it is 
unlikely that they are affected by genetic predisposition for colorectal cancer, so continuing 
intensive colonoscopy screening would provide little or no additional benefit. In such case, 
the interval can gradually be lengthened with age.
Genetic predisposition to colorectal cancer can also be measured by testing for the pres-
ence of common genetic variants that are associated with colorectal cancer risk. With an 
area under the curve (AUC) of 0.60, the discriminatory performance of current polygenic 
tests is limited. In Chapter 10, we estimated the current and potential future benefit of risk-
stratified screening based on polygenic risk, as compared to current uniform screening. We 
found that at an estimated current price per polygenic test of ~$200, risk-stratified screening 
is not cost-effective compared to uniform screening. This changes if either the price of the 
polygenic test drops below $141, or the AUC value of polygenic testing increases beyond 
0.65. As population-wide implementation of polygenic testing will likely decrease the price 
per test, and the expected discovery of more common genetic variants will increase the 
AUC value of polygenic testing, risk-stratified screening based on polygenic risk may well 
become cost-effective in the future.
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conclusions and recommendations
Based on the results found in this thesis, we derived the following conclusions:
– Many published cost-effectiveness analyses on cervical cancer screening are likely to 
have omitted relevant comparator strategies, thereby possibly identifying an inefficient 
screening strategy as optimal.
– For over-screened women, switching from primary cytology to primary HPV screening 
slightly reduces cervical cancer risk but comes with a large increase in the number of 
(false-)positive tests, and can therefore be considered as harmful.
– Cervical cancer screening from age 21 instead of age 30 only slightly reduces cervical 
cancer risk, while it substantially increases the risk of preterm birth.
– Data from the Dutch cervical cancer screening program suggest that SurePath detects 
more progressive lesions than conventional cytology, while ThinPrep might detect 
fewer.
– Offering a self-sample test to non-attendees in a cervical cancer screening program is 
likely a cost-effective intervention, but its impact does depend on parameters like the 
relative sensitivity of the self-sample test (as compared to the regular test), the extent 
to which it generates extra attendance, and the extent to which attendees of regular 
screening switch to using the self-sample test.
– Although screening with the multitarget stool DNA test is an effective way to reduce 
colorectal cancer incidence and mortality, the current price of the test makes it a cost-
ineffective alternative to other stool-based tests.
– When herd immunity reaches beyond 50%, offering unvaccinated women cervical 
cancer screening based on the pre-vaccination risk level is no longer cost-effective, and 
reducing the intensity of uniform screening may be considered.
– It is cost-effective to offer individuals with a family history of colorectal cancer intensive 
colonoscopy screening from a young age onwards. However, if individuals do not de-
velop any adenomas, it is unlikely that they have a genetic predisposition to colorectal 
cancer, so continuing intensive screening would provide little or no additional benefit.
– At the discriminatory performance and cost of current polygenic tests, colonoscopy 
screening based on polygenic risk is not cost-effective compared to uniform screening. 
This may change with a reduction in the price per polygenic test and with the discovery 
of more common genetic variants that are associated with colorectal cancer risk.
Based on these conclusions, we formulated the following recommendations:
– In a cancer screening cost-effectiveness analysis, one should include all relevant com-
parator strategies to obtain reliable cost-effectiveness estimates.
– In screening situations that are characterized by a substantial amount of over-screening, 
primary cytology screening should not be replaced by primary HPV screening. Reducing 
the amount of over-screening should be prioritized.
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– Cervical cancer screening below age 30 should only be offered after careful evaluation 
of a woman’s expected benefits and harms, taking into account her (future) childwish.
– Since 2017, primary LBC screening is longer performed in the Netherlands, but the 
fact that the use of SurePath resulted in different screening outcomes than the use of 
ThinPrep should raise international awareness that the assumed similarity in test charac-
teristics may not be true.
– Although offering an alternative test could increase effectiveness of screening through 
increasing the uptake among individuals willing to undergo screening, one should be 
careful with offering alternative tests with inferior characteristics compared to already 
offered tests because of the potential substitution effect.
– If cervical cancer screening cannot be tailored to HPV-vaccination status, one should 
wait with adjusting the screening frequency to the risk level in vaccinated women until 
unvaccinated women benefit from a herd immunity level of at least 50%, i.e. until the 
reduction in HPV prevalence in unvaccinated women is at least half of that in vaccinated 
women.
– As screening intensity preferably depends on the disease risk in the target population, 
herd immunity should be closely monitored in partly vaccinated cohorts.
– Individuals with a constant level of family history of colorectal cancer should consider 
lengthening their screening interval after several subsequent negative colonoscopies, 
as this suggests that they are unlikely to have a genetic predisposition for colorectal 
cancer.
– In addition to discovering more common genetic variants that are associated with 
colorectal cancer risk, research should aim at identifying comprehensive colorectal 
cancer risk profiles, including both genetic and environmental risk factors.
– Given high regression rates of CIN 1 and CIN 2, and the potential adverse effects of CIN 
treatment, future research is needed to estimate the impact of delaying treatment in 
women with CIN 1 and CIN 2.
– Much of the harm related to cervical and colorectal cancer screening comes from the 
detection and treatment of non-progressive lesions. Literature suggests the existence 
of biomarkers that are able to distinguish between progressive and non-progressive le-
sions. As this may largely reduce the amount of overdiagnosis and overtreatment, more 
research is needed to identify those biomarkers.
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Screening is het systematisch testen van asymptomatische personen op de aanwezigheid 
van ziekte of risicofactoren voor ziekte. Dit biedt de mogelijkheid om eerder in te grijpen, 
door bijvoorbeeld het eerder starten van een behandeling. Screening is bijzonder waarde-
vol voor ziektes als kanker, waarbij de prognose beter is in vroegere stadia. In Nederland 
bestaan bevolkingsonderzoeken voor de vroege opsporing van baarmoederhalskanker, 
borstkanker, en darmkanker.
Voorafgaand aan de implementatie van (ofwel georganiseerde, ofwel opportunistische) 
screening moet worden voldaan aan de volgende drie criteria:
1. Er moet wetenschappelijk bewijs zijn voor de effectiviteit van het screenprogramma.
2. De algehele voordelen moeten groter zijn dan de algehele nadelen.
3. Er moet wetenschappelijk bewijs zijn voor de kosteneffectiviteit van het screenpro-
gramma.
Zowel baarmoederhalskanker als darmkanker zijn uitermate geschikt voor massascreening. 
Hun natuurlijk beloop is vergelijkbaar in die zin dat een lange preklinische duur voorafgaat 
aan de ontwikkeling van kanker. Gedurende deze preklinische fase kunnen goedaardige 
laesies gedetecteerd worden door screening. Door het verwijderen van deze laesies kan de 
ontwikkeling van kanker worden voorkomen. Daarnaast kan vroege opsporing en behande-
ling van kanker tot een significante verbetering in overleving leiden.
Zoals bij elke vorm van screening, kan ook screening op baarmoederhalskanker en darm-
kanker als belastend worden ervaren, en kan het zelfs schadelijk zijn voor sommige deelne-
mers. Waar mogelijk, zullen pogingen gedaan moeten worden om de voordelen:nadelen 
ratio te verhogen. In dit proefschrift zijn meerdere mogelijkheden onderzocht om de ne-
gatieve effecten van screening op baarmoederhalskanker en darmkanker te verkleinen en 
de positieve effecten ervan te vergroten. Risicogebaseerde screening kan hierbij uitkomst 
bieden, aangezien dit in theorie zowel de nadelen verkleint als de voordelen vergroot.
Over het algemeen wordt de optimale screenstrategie voor een bevolking of risicogroep 
bepaald in een kosteneffectiviteitsanalyse, waarin de kosten en gezondheidseffecten van 
meerdere strategieën met elkaar worden vergeleken.
methodologische kWesties in kosteneffectiviteitsanalyses
Of een strategie optimaal wordt bevonden in een kosteneffectiviteitsanalyse hangt af 
van de set van geïncludeerde strategieën. Hoofdstuk 2 van dit proefschrift liet zien dat 
in de meeste kosteneffectiviteitsanalyses van baarmoederhalskankerscreening, relevante 
strategieën zijn weggelaten uit de analyse. In de meeste gevallen waren er geen strategieën 
meegenomen met een langer interval dan degene die optimaal werd bevonden. Dit heeft 
waarschijnlijk geleid tot een onderschatting van de incrementele kosten per gewonnen 
levensjaar, en zou ertoe geleid kunnen hebben dat suboptimale strategieën als optimaal 
zijn aangeduid.
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verkleinen van schadelijke effecten
Over de afgelopen decennia heeft cytologie screening laten zien een effectief middel te 
zijn voor het verlagen van baarmoederhalskankerincidentie en -sterfte. Sinds de ontdekking 
dat een infectie met het humaan papillomavirus (HPV) een voorwaarde is voor het ontwik-
kelen van baarmoederhalskanker, is er een veelvoud aan HPV-testen ontwikkeld. Omdat 
screening op HPV een betere bescherming biedt tegen invasieve baarmoederhalskanker, is 
dit onlangs in Nederland ingevoerd (per 1 januari 2017) en zal het binnenkort in Australië 
worden ingevoerd (per 1 december 2017). De hogere sensitiviteit van screening op HPV 
gaat echter gepaard met een lagere specificiteit, hetgeen betekent dat het aantal (vals-)
positieve testuitslagen zal toenemen. Hoewel het voor cytologie screening bekend is dat 
over-screening (d.w.z. frequenter screenen dan wordt aanbevolen in internationale richtlij-
nen) zowel onnodig als ongewenst is, komt het in veel landen nog regelmatig voor.
In Hoofdstuk 3 hebben we de mogelijke schade van het overgaan van cytologie op 
HPV screening geschat voor vrouwen die over-screened zijn. Aangezien het bij jaarlijkse of 
tweejaarlijkse cytologie al onwaarschijnlijk is dat een klinisch relevante laesie gemist wordt, 
was er slechts een kleine gezondheidswinst bij het overgaan op de sensitievere HPV-test. 
De mogelijke schade ten aanzien van toegenomen aantallen (vals-)positieve uitslagen en 
colposcopie verwijzingen was echter aanzienlijk. Alles bij elkaar genomen leidt een over-
stap van cytologie op HPV screening voor vrouwen die jaarlijks of tweejaarlijks gescreend 
worden tot een netto verlies in gezondheid.
Naast de psychologische stress van baarmoederhalskankerscreening, kan de behandeling 
van cervicale intra-epitheliale neoplasie (CIN) tot een verhoogd risico op vroeggeboorte 
leiden. Vroeggeboorte verhoogt het risico op neonatale morbiditeit en mortaliteit aan-
zienlijk. Voor zover wij weten zijn er tot op heden geen (kosten)effectiviteitsanalyses van 
baarmoederhalskankerscreening verricht waarin dit schadelijke effect wordt meegenomen. 
Hoofdstuk 4 van dit proefschrift biedt hiertoe een eerste poging, met een vergelijking 
van screenstrategieën op basis van de (voor kwaliteit van leven gecorrigeerde) gewonnen 
levensjaren bij vrouwen en de (voor kwaliteit van leven gecorrigeerde) verloren levensjaren 
bij hun toekomstige kinderen. Vergeleken met het starten van 3-jaarlijkse screening op 
leeftijd 30, was de opbrengst van het verlagen van de startleeftijd naar 21 jaar beperkt 
in gewonnen levensjaren, en zelfs negatief in de voor kwaliteit van leven gecorrigeerde 
levensjaren. De schadelijke effecten waren echter significant: 223 meer vroeggeboortes per 
100.000 gescreende vrouwen, resulterend in 22 meer gevallen van neonatale morbiditeit en 
6 meer gevallen van neonatale mortaliteit. In landen zoals de VS, waar 3-jaarlijkse screening 
vanaf leeftijd 21 wordt aanbevolen, zouden vrouwen met een (toekomstige) kinderwens 
daarom moeten overwegen om baarmoederhalskankerscreening uit te stellen tot leeftijd 
30.
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vergroten van gunstige effecten
De gunstige effecten van screening kunnen vergroot worden door de invoering van nieuwe 
testmethoden. De nieuwe screentest kan ofwel de bestaande test vervangen, ofwel als een 
alternatief voor huidige screentesten fungeren. Dit laatste zou ervoor kunnen zorgen dat 
personen die (onlangs) niet hebben deelgenomen aan screening vanwege een aversie 
tegen bestaande testmethoden, dan wel besluiten zich te laten screenen. Hoewel het bij 
vervanging van een screentest een vereiste is dat de nieuwe test effectiever (of tenminste 
kosteneffectiever) is dan de tot dan toe aangeboden test, kan het toevoegen van een test 
die minder (kosten)effectief is wel voordelen bieden.
Over de laatste 10-15 jaar hebben veel landen, waaronder Nederland, het gebruik van 
conventionele cytologie vervangen door dat van dunnelaag cytologie (DLC) testen Sure-
Path en ThinPrep. Het gebruik van deze DLC testen resulteert in minder uitstrijkjes van on-
voldoende kwaliteit. Een ander voordeel van DLC is dat het zgn. co-testing mogelijk maakt 
(d.w.z. uitstrijkjes kunnen ook getest worden op de aanwezigheid van HPV). Systematische 
reviews waarin conventionele cytologie vergeleken is met DLC lieten vergelijkbare testei-
genschappen zien, maar veronderstelden geen verschil tussen DLC testen onderling. In een 
eerdere studie hebben we echter laten zien dat in het Nederlandse bevolkingsonderzoek, in 
tegenstelling tot het gebruik van ThinPrep, het gebruik van SurePath geassocieerd was met 
een hoger CIN 2+ detectiecijfer dan conventionele cytologie. De analyse in Hoofdstuk 5 liet 
zien dat SurePath ook een betere bescherming bood tegen invasieve baarmoederhalskan-
ker dan conventionele cytologie, terwijl dit niet gold voor ThinPrep.
Sinds 2017 maakt primaire DLC screening echter geen deel meer uit van het bevolkings-
onderzoek. In plaats daarvan worden uitstrijkjes primair getest op de aanwezigheid van 
oncogene HPV-types. Aan vrouwen die niet binnen 6 maanden na uitnodiging deelnemen 
aan screening wordt een zelfafnameset aangeboden. In Hoofdstuk 6 hebben we laten 
zien dat dit naar verwachting (kosten)effectief is als de relatieve CIN 2+ sensitiviteit bij zelf 
afgenomen materiaal (in vergelijking met door een professional afgenomen materiaal) ten-
minste 0.95 is, als tot dusver ongescreende vrouwen er gebruik van maken, en als de totale 
deelname met tenminste 6 procentpunt toeneemt. Als er aan deze voorwaarden niet kan 
worden voldaan, dan kunnen vrouwen die overstappen van de reguliere test op het gebruik 
van de zelfafnameset de totale effectiviteit van het programma verlagen.
Het aanbieden van een alternatieve screentest zou ook kunnen leiden tot een betere 
naleving van de darmkankerscreeningsrichtlijnen in de VS. De recent geüpdatete richtlijnen 
van de US Preventive Services Task Force bevelen darmkankerscreening aan met één (of twee) 
van zes modaliteiten, waaronder ook de recent goedgekeurde multitarget Stool DNA test. 
Driejaarlijkse screening met deze test wordt inmiddels vergoed door de Centers for Medicare 
and Medicaid Services (CMS). In Hoofdstuk 7 hebben we berekend of deze screenstrategie 
een kosteneffectief alternatief is voor andere vergoede screenstrategieën voor de Medicare 
bevolking (d.w.z. 65-plussers in de VS), en zo niet, bij welke kosten, opkomst en screeningsin-
terval het dat wel zou zijn. Uit onze resultaten bleek dat bij de huidige vergoeding van $493 
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per test, driejaarlijkse screening met de multitarget stool DNA test zelfs niet kosteneffectief 
zou zijn als de opkomst 30% hoger zou zijn dan bij andere strategieën. Voor driejaarlijkse, 
tweejaarlijkse en jaarlijkse screening met de multitarget stool DNA test, moet de vergoeding 
per test lager zijn dan respectievelijk $33, $47, of $58, om het een kosteneffectief alternatief 
te laten zijn voor andere vergoede strategieën.
verkleinen van schadelijke effecten en vergroten van gunstige 
effecten: mogelijkheden voor risicogeBaseerde screening
Risicogebaseerde screening biedt de mogelijkheid om de nadelen van screening te verlagen 
in laag-risico individuen, en tegelijkertijd de voordelen ervan te vergroten in hoger-risico 
individuen.
Vergeleken met de bevolking die momenteel in aanmerking komt voor screening, hebben 
HPV-gevaccineerde vrouwen naar verwachting een veel lager risico op baarmoederhalskan-
ker. Met behulp van microsimulatiemodellering vonden we dat waar 8 screenmomenten per 
leven optimaal is voor de huidige doelgroep van screening, 3 screenmomenten optimaal 
is voor gevaccineerde vrouwen (Hoofdstuk 8). Screening gebaseerd op vaccinatiestatus 
zou echter niet uitvoerbaar kunnen zijn vanwege organisatorische of ethische kwesties. 
Als uniforme screening de enige werkbare optie is, dan zal de intensiteit van dergelijke 
screening teruggebracht moeten worden wanneer de vaccinatiegraad, en daarmee ook 
de collectieve immuniteit, toeneemt. We vonden dat als de reductie in HPV-prevalentie in 
ongevaccineerde vrouwen meer dan de helft is van dat in gevaccineerde vrouwen (d.w.z. 
collectieve immuniteit >50%), dat dan een programma met 3 screenmomenten voor on-
gevaccineerde vrouwen kosteneffectiever is dan een programma met 8 screenmomenten. 
Uniforme screening moet daarom niet aangepast worden aan het risiconiveau in gevacci-
neerde vrouwen totdat ongevaccineerde vrouwen van een collectieve immuniteit genieten 
van tenminste 50%.
In de VS screeningsrichtlijnen voor darmkanker is voor personen met een positieve fami-
liegeschiedenis al intensievere screening opgenomen dan voor de algemene bevolking. 
Individuen met ≥1 eerstegraads familielid wordt aanbevolen om eerder te starten met colo-
scopie screening (op leeftijd 40 in plaats van op leeftijd 50) en om screening met kortere in-
tervallen te herhalen (5 jaar in plaats van 10 jaar). In Hoofdstuk 9 hebben we microsimulatie 
modellering gebruikt om, voor elk aantal eerstegraads familieleden, de optimale strategie 
te bepalen naar leeftijd. We vonden dat individuen met een positieve familiegeschiede-
nis baat kunnen hebben bij intensieve screening op jonge leeftijd. Echter, als individuen 
consistent coloscopieën hebben zonder bevindingen, dan is het onwaarschijnlijk dat zij 
een genetische aanleg hebben voor darmkanker, en biedt het continueren van intensieve 
coloscopie screening weinig of geen voordelen. In zo’n geval kan het screeningsinterval 
geleidelijk verlengd worden.
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Genetische aanleg voor darmkanker kan ook gemeten worden door te testen op de 
aanwezigheid van veelvoorkomende genetische varianten die geassocieerd zijn met het 
risico op darmkanker. Met een area under the curve (AUC) van 0.60, is het discriminerend ver-
mogen van huidige polygenetische testen echter beperkt. In Hoofdstuk 10 hebben we de 
huidige en mogelijke toekomstige voordelen van risicogestratificeerde screening op basis 
van polygenetisch risico geschat, ten opzichte van huidige uniforme screening. We vonden 
dat, bij een geschatte huidige prijs per polygenetische test van ~$200, risicogestratificeerde 
screening niet kosteneffectiever is dan uniforme screening. Dit verandert wanneer ofwel de 
prijs van de polygenetische test lager wordt dan $141, ofwel de AUC waarde stijgt tot meer 
dan 0.65. Aangezien het aanbieden van een polygenetische test op populatieniveau de prijs 
per test waarschijnlijk zal drukken, en de verwachte ontdekking van meer veelvoorkomende 
genetische varianten de AUC waarde zal doen stijgen, zou risicogestratificeerde screening 
in de toekomst wel kosteneffectief kunnen worden.
conclusies en aanBevelingen
Op basis van de resultaten in dit proefschrift, kunnen de volgende conclusies worden 
getrokken:
– Bij veel gepubliceerde kosteneffectiviteitsanalyses van baarmoederhalskankerscreening 
is het aannemelijk dat relevante strategieën ontbreken, waardoor mogelijk een inef-
ficiënte strategie is aangeduid als zijnde optimaal.
– Voor over-gescreende vrouwen leidt de overgang van primaire cytologie op primaire 
HPV screening tot een lichte daling in het risico op baarmoederhalskanker, maar dit gaat 
gepaard met een grote stijging in het aantal (vals-)positieve testen, en kan daardoor als 
schadelijk beschouwd worden.
– Baarmoederhalskankerscreening vanaf 21 jaar in plaats van vanaf 30 jaar leidt tot een 
licht verlaagd risico op baarmoederhalskanker, maar verhoogt de kans op vroegge-
boorte aanzienlijk.
– Data van het Nederlandse bevolkingsonderzoek baarmoederhalskanker suggereren 
dat SurePath meer progressieve laesies detecteert dan conventionele cytologie, terwijl 
ThinPrep er wellicht minder detecteert.
– Het aanbieden van een zelfafnameset aan niet-deelnemers van baarmoederhalskanker-
screening is waarschijnlijk kosteneffectief, maar de impact hangt af van parameters als 
de relatieve sensitiviteit van de zelftest (ten opzichte van de reguliere test), de mate 
waarin het extra deelname genereert, en de mate waarin vrouwen overstappen van de 
reguliere test op het gebruik van de zelfafnameset.
– Hoewel screening met de multitarget Stool DNA test een effectieve manier is om darm-
kankerincidentie en –mortaliteit te verlagen, maakt de huidige prijs van de test het een 
kosten-ineffectief alternatief voor andere ontlastingstesten.
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– Wanneer de collectieve immuniteit stijgt tot meer dan 50% is het niet meer kosteneffec-
tief om ongevaccineerde vrouwen baarmoederhalskankerscreening gebaseerd op het 
pre-vaccinatie risico aan te bieden, en kan een verlaging van de intensiteit van uniforme 
screening worden overwogen.
– Het is kosteneffectief om individuen met een familiegeschiedenis van darmkanker 
intensief te screenen vanaf jonge leeftijd. Als zij echter geen adenomen ontwikkelen, 
dan is het onwaarschijnlijk dat zij een genetische aanleg hebben voor darmkanker en 
dan biedt het continueren van intensieve screening weinig tot geen voordelen.
– Bij het discriminerend vermogen en de prijs van huidige polygenetische testen is colo-
scopie screening op basis van polygenetisch risico niet kosteneffectief vergeleken met 
uniforme screening. Dit kan veranderen door een verlaging van de prijs per polygene-
tische test of met de ontdekking van meer veelvoorkomende genetische varianten die 
geassocieerd zijn met het risico op darmkanker.
Op basis van deze conclusies, hebben we de volgende aanbevelingen geformuleerd:
– In een kosteneffectiviteitsanalyse van kankerscreening moeten alle relevante strate-
gieën worden geïncludeerd om een betrouwbare schatting van de kosteneffectiviteit te 
krijgen.
– In screeningssituaties die gekenmerkt worden door een substantiële mate van over-
screening, moet primaire cytologie niet vervangen worden door primaire HPV screening. 
In zo’n geval moet het terugdringen van de hoeveelheid over-screening geprioriteerd 
worden.
– Baarmoederhalskankerscreening onder leeftijd 30 zou alleen aangeboden moeten wor-
den na een zorgvuldige afweging van de verwachte voor- en nadelen voor een vrouw, 
daarbij in acht nemend haar (toekomstige) kinderwens.
– Sinds 2017 wordt primaire DLC screening niet meer uitgevoerd in Nederland, maar het 
feit dat het gebruik van SurePath tot andere uitkomsten heeft geleid dan het gebruik 
van ThinPrep zou moeten leiden tot een internationaal bewustzijn dat het onterecht is 
om geen verschil tussen de testen te veronderstellen.
– Hoewel het aanbieden van een alternatieve test de effectiviteit van screening kan 
verhogen door het genereren van extra opkomst onder individuen die bereid zijn deel 
te nemen aan screening, is voorzichtigheid geboden bij het aanbieden van alternatieve 
testen met inferieure testeigenschappen vergeleken met huidige screentesten vanwege 
het mogelijke substitutie effect.
– Indien baarmoederhalskankerscreening niet kan afhangen van HPV-vaccinatie status, 
dan zal men moeten wachten met het bijstellen van het screenprogramma naar het 
risico in gevaccineerde vrouwen totdat ongevaccineerde vrouwen profiteren van 
tenminste 50% collectieve immuniteit, d.w.z. totdat de reductie in HPV-prevalentie in 
ongevaccineerde vrouwen tenminste half zo groot is als die in gevaccineerde vrouwen.
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– Aangezien de intensiteit van screening bij voorkeur afhangt van het risico in de doel-
groep, moet de collectieve immuniteit nauwkeurig gemonitord worden in gedeeltelijk 
gevaccineerde cohorten.
– Na meerdere coloscopieën zonder bevindingen, zouden individuen met een onveran-
derde familiegeschiedenis van darmkanker moeten overwegen om hun screeninginter-
val te verlengen, aangezien zij waarschijnlijk geen genetische aanleg voor darmkanker 
hebben.
– Naast het ontdekken van meer veelvoorkomende genetische varianten die geassocieerd 
zijn met darmkanker zou meer onderzoek gericht moeten worden op het identificeren 
van volledige risicoprofielen, met daarin zowel omgevings- als genetische risicofactoren.
– Gegeven de hoge mate van CIN 1 en CIN 2 regressie en de mogelijke negatieve effecten 
van CIN behandeling, is verder onderzoek nodig naar de impact van het uitstellen van 
de behandeling van vrouwen met CIN 1 en CIN 2.
– Een groot deel van de schadelijke effecten van baarmoederhals- en darmkankerscreening 
komt voort uit de detectie en behandeling van niet-progressieve laesies. Literatuur sug-
gereert dat er biomarkers bestaan die onderscheid kunnen maken tussen progressieve 
en niet-progressieve laesies. Aangezien dit de hoeveelheid overdiagnose en overbe-
handeling in grote mate zou kunnen terugdringen, is meer onderzoek nodig om deze 
biomarkers te identificeren.
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Het is zover, mijn boekje is af! Zelf dacht ik lange tijd dat er geen beweging in te krijgen was, 
maar in het laatste jaar belandde alles in een stroomversnelling. Ik kan amper geloven dat 
het me dan toch gelukt is. Tijd om iedereen, die (direct of indirect) heeft bijgedragen aan de 
totstandkoming van dit proefschrift, te bedanken!
Allereerst wil ik natuurlijk mijn promotor Harry de Koning en mijn copromotoren Iris 
Lansdorp-Vogelaar en Inge de Kok heel erg bedanken voor hun bijdrage aan dit proefschrift. 
Harry, jij was niet direct betrokken bij het schrijven van de afzonderlijke hoofdstukken, maar 
des te meer bij het samensmelten tot één geheel. Over de samenhang maakte ik mij in het 
begin zeker zorgen; alle andere promovendi binnen onze sectie deden namelijk onderzoek 
naar slechts één type kankerscreening. En hoewel Iris van het begin af aan zei dat het wel 
goed zou komen omdat de kankers “erg op elkaar leken”, zag ik dat toch heel anders. Toen 
we tijdens een voortgangsgesprek na 3,5 jaar tot mijn verbazing niet alleen de gebruikelijke 
afzonderlijke artikelen bespraken, maar jij over een titel en hoofdstukindeling begon, kwam 
daar verandering in. Harry, heel erg bedankt voor je waardevolle bijdrage aan dit proefschrift.
Inge, jij hebt mij van het begin af aan onder je hoede genomen. Dat vergde de nodige 
begeleiding bij het schrijven van mijn eerste artikel. Meerdere malen zorgde jij ervoor dat 
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